<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7697925</article-id><article-id pub-id-type="pmid">33203147</article-id><article-id pub-id-type="doi">10.3390/antibiotics9110812</article-id><article-id pub-id-type="publisher-id">antibiotics-09-00812</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Antifungal Drug Repurposing</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0944-6685</contrib-id><name><surname>Kim</surname><given-names>Jong H.</given-names></name><xref ref-type="aff" rid="af1-antibiotics-09-00812">1</xref><xref rid="c1-antibiotics-09-00812" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Luisa W.</given-names></name><xref ref-type="aff" rid="af1-antibiotics-09-00812">1</xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Kathleen L.</given-names></name><xref ref-type="aff" rid="af1-antibiotics-09-00812">1</xref></contrib><contrib contrib-type="author"><name><surname>Tam</surname><given-names>Christina C.</given-names></name><xref ref-type="aff" rid="af1-antibiotics-09-00812">1</xref></contrib><contrib contrib-type="author"><name><surname>Mahoney</surname><given-names>Noreen</given-names></name><xref ref-type="aff" rid="af1-antibiotics-09-00812">1</xref></contrib><contrib contrib-type="author"><name><surname>Friedman</surname><given-names>Mendel</given-names></name><xref ref-type="aff" rid="af2-antibiotics-09-00812">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2577-2915</contrib-id><name><surname>Shilman</surname><given-names>Mikhail Martchenko</given-names></name><xref ref-type="aff" rid="af3-antibiotics-09-00812">3</xref></contrib><contrib contrib-type="author"><name><surname>Land</surname><given-names>Kirkwood M.</given-names></name><xref ref-type="aff" rid="af4-antibiotics-09-00812">4</xref></contrib></contrib-group><aff id="af1-antibiotics-09-00812"><label>1</label>Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, Agricultural Research Service, United States Department of Agriculture, Albany, CA 94710, USA; <email>luisa.cheng@usda.gov</email> (L.W.C.); <email>kathy.chan@usda.gov</email> (K.L.C.); <email>christina.tam@usda.gov</email> (C.C.T.); <email>noreen.mahoney@usda.gov</email> (N.M.)</aff><aff id="af2-antibiotics-09-00812"><label>2</label>Healthy Processed Foods Research Unit, Western Regional Research Center, Agricultural Research Service, United States Department of Agriculture, Albany, CA 94710, USA; <email>mendel.friedman@usda.gov</email></aff><aff id="af3-antibiotics-09-00812"><label>3</label>Henry E. Riggs School of Applied Life Sciences, Keck Graduate Institute, Claremont, CA 91711, USA; <email>mikhail_shilman@kgi.edu</email></aff><aff id="af4-antibiotics-09-00812"><label>4</label>Department of Biological Sciences, University of the Pacific, Stockton, CA 95211, USA; <email>kland@pacific.edu</email></aff><author-notes><corresp id="c1-antibiotics-09-00812"><label>*</label>Correspondence: <email>jongheon.kim@usda.gov</email>; Tel.: +1-510-559-5841</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2020</year></pub-date><volume>9</volume><issue>11</issue><elocation-id>812</elocation-id><history><date date-type="received"><day>17</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>13</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Control of fungal pathogens is increasingly problematic due to the limited number of effective drugs available for antifungal therapy. Conventional antifungal drugs could also trigger human cytotoxicity associated with the kidneys and liver, including the generation of reactive oxygen species. Moreover, increased incidences of fungal resistance to the classes of azoles, such as fluconazole, itraconazole, voriconazole, or posaconazole, or echinocandins, including caspofungin, anidulafungin, or micafungin, have been documented. Of note, certain azole fungicides such as propiconazole or tebuconazole that are applied to agricultural fields have the same mechanism of antifungal action as clinical azole drugs. Such long-term application of azole fungicides to crop fields provides environmental selection pressure for the emergence of pan-azole-resistant fungal strains such as <italic>Aspergillus fumigatus</italic> having TR34/L98H mutations, specifically, a 34 bp insertion into the cytochrome P450 51A (<italic>CYP51A</italic>) gene promoter region and a leucine-to-histidine substitution at codon 98 of <italic>CYP51A</italic>. Altogether, the emerging resistance of pathogens to currently available antifungal drugs and insufficiency in the discovery of new therapeutics engender the urgent need for the development of new antifungals and/or alternative therapies for effective control of fungal pathogens. We discuss the current needs for the discovery of new clinical antifungal drugs and the recent drug repurposing endeavors as alternative methods for fungal pathogen control.</p></abstract><kwd-group><kwd>antifungal</kwd><kwd><italic>Aspergillus</italic></kwd><kwd><italic>Candida</italic></kwd><kwd><italic>Cryptococcus</italic></kwd><kwd>drug repurposing</kwd><kwd>multidrug resistance</kwd><kwd>pan-azole resistance</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibiotics-09-00812"><title>1. Introduction</title><p>Fungal infections, such as human invasive aspergillosis, candidiasis, or cryptococcosis caused by <italic>Aspergillus</italic>, <italic>Candida</italic>, or <italic>Cryptococcus</italic> species, respectively, are persistent problems since effective antifungal drugs are often limited [<xref rid="B1-antibiotics-09-00812" ref-type="bibr">1</xref>]. In addition to 5-flucytosine (5FC), only three classes of antifungal drugs are currently applied in clinical settings, namely, azoles, polyenes, and echinocandins; azoles and polyenes were introduced before 1980, while the echinocandin drug caspofungin (CAS) was approved for use in clinics after the year 2000 [<xref rid="B2-antibiotics-09-00812" ref-type="bibr">2</xref>]. These are the three drug classes used in clinical routines to treat invasive/systemic fungal infections and, therefore, emerging resistance incidences of fungal pathogens to these drugs make fungal diseases a global human health concern [<xref rid="B3-antibiotics-09-00812" ref-type="bibr">3</xref>]. Immunocompromised people are at risk of developing fungal diseases.</p><p>For instance, the yeast pathogen <italic>Candida</italic> species are the most common causative agents of bloodstream infections, linked to high morbidity and mortality. While <italic>Candida albicans</italic> is the most prevalent species infecting humans, cases of non-<italic>albicans</italic> infections are also continuously growing. Of note, the non-<italic>albicans <italic>C. auris</italic></italic> is an emerging yeast pathogen showing severe human infections and multidrug resistance, with up to 323 United States (US) clinical cases reported in 2018 [<xref rid="B4-antibiotics-09-00812" ref-type="bibr">4</xref>]. <italic>C. auris</italic> spreads easily between hospitalized patients or nursing home residents, and it has been classified as an &#x0201c;urgent threat&#x0201d; pathogen according to the United States Centers for Disease Control and Prevention&#x02019;s (CDC&#x02019;s) 2019 Antibiotic Resistance Threats Report (ARTR) [<xref rid="B4-antibiotics-09-00812" ref-type="bibr">4</xref>]. Numerous other <italic>Candida</italic> species have also been grouped as &#x0201c;serious threat&#x0201d; pathogens because they cause different types of fungal infections including oral and vaginal infections or severe invasive diseases. Many species of this group are resistant to conventional antifungal drugs, with estimated US hospitalization cases in 2017 of 34,800, resulting in 1700 deaths [<xref rid="B4-antibiotics-09-00812" ref-type="bibr">4</xref>].</p><p>In addition, azole-resistant strains of other fungal species, including <italic>Aspergillus fumigatus</italic>, also cause life-threatening infections, especially in high-risk, immunocompromised people. Azoles are broadly used for treating human fungal pathogens, where the mechanism of action is to inhibit cellular lanosterol 14 alpha-demethylases involved in fungal ergosterol biosynthesis. Azoles are also increasingly applied in agricultural fields to prevent or treat phytopathogenic fungal diseases in crops. Currently, more than 25% of total fungicide sales are azoles [<xref rid="B5-antibiotics-09-00812" ref-type="bibr">5</xref>]. This provides environmental selection pressure for the emergence of pan-azole-resistant strains such as <italic>A. fumigatus</italic> having the TR34/L98H mutation [<xref rid="B5-antibiotics-09-00812" ref-type="bibr">5</xref>]. The development of azole resistance due to their increased use in human medicine and agriculture is a public health concern, leading to the placement of azole-resistant <italic>A. fumigatus</italic> on the microorganism watchlist, according to CDC&#x02019;s 2019 ARTR [<xref rid="B4-antibiotics-09-00812" ref-type="bibr">4</xref>].</p><p>The spectrum of activity for the current systemic antifungal drugs, including amphotericin B (AMB), 5FC, fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS), isavuconazole (ISA), CAS, micafungin (MICA), or anidulafungin (ANI), have been documented [<xref rid="B6-antibiotics-09-00812" ref-type="bibr">6</xref>,<xref rid="B7-antibiotics-09-00812" ref-type="bibr">7</xref>,<xref rid="B8-antibiotics-09-00812" ref-type="bibr">8</xref>]. In brief, the antifungal spectrum has been determined as follows: <italic>C. albicans, Candida glabrata, Candida parapsilosis,</italic> and <italic>Candida tropicalis</italic> (AMB, 5FC, FLU, ITR, VOR, POS, ISA, CAS, MICA, and ANI); <italic>Candida krusei</italic> (AMB, 5FC, ITR, VOR, POS, ISA, CAS, MICA, and ANI); <italic>Candida lusitaniae</italic> (5FC, ITR, VOR, POS, ISA, CAS, MICA, and ANI); <italic>A. fumigatus</italic> (AMB, ITR, VOR, POS, ISA, CAS, MICA, and ANI); <italic>Cryptococcus neoformans</italic> (AMB, 5FC, FLU, ITR, VOR, POS, and ISA); <italic>Fusarium</italic> species (AMB, ITR, VOR, POS, and ISA); <italic>Scedosporium</italic> species (AMB, ITR, VOR, POS, and ISA); <italic>Blastomyces dermatitidis, Coccidioides immitis,</italic> and <italic>Histoplasma capsulatum</italic> (AMB, FLU, ITR, VOR, POS, and ISA); Mucorales (AMB, POS, and ISA). Studies indicated that differential susceptibilities of fungal pathogens to the drugs exist depending on the types of fungi or drugs applied. For example, the yeast pathogens <italic>C. albicans, C. glabrata, C. parapsilosis</italic>, and <italic>C. tropicalis</italic> were susceptible to all antifungal drugs described (AMB, 5FC, FLU, ITR, VOR, POS, ISA, CAS, MICA, and ANI), while the other two <italic>Candida</italic> species (<italic>C. krusei</italic> and <italic>C. lusitaniae</italic>) did not show sensitivity to FLU or AMB, respectively. Of note, except for the <italic>Candida</italic> species and <italic>A. fumigatus</italic>, the other fungi mentioned (namely, <italic>C. neoformans, Fusarium</italic> species, <italic>Scedosporium</italic> species, <italic>Blastomyces dermatitidis, Coccidioides immitis,</italic> and <italic>Histoplasma capsulatum</italic>) did not exhibit susceptibility to the echinocandin drugs (CAS, MICA, and ANI), whereas the azoles POS and ISA were effective against all fungal pathogens described above.</p><p>There have also been persistent efforts to improve the efficacy or to reduce the toxicity of conventional antifungal drugs/intervention strategies. For instance, AMB was the first antifungal drug introduced to clinics over five decades ago, for which several types of formulations have been developed with varying toxicity such as infusion-related reactions and nephrotoxicity [<xref rid="B9-antibiotics-09-00812" ref-type="bibr">9</xref>,<xref rid="B10-antibiotics-09-00812" ref-type="bibr">10</xref>]. Three lipid-associated AMB formulations have been developed, which include the AMB lipid complex (AMB-LC), liposomal AMB (L-AMB), and colloidal dispersion of AMB (AMB-CD) with the recommended therapeutic doses of 5, 3&#x02013;6, and 3&#x02013;4 mg/kg/day, respectively [<xref rid="B9-antibiotics-09-00812" ref-type="bibr">9</xref>,<xref rid="B10-antibiotics-09-00812" ref-type="bibr">10</xref>].</p><p>However, the development of entirely new antifungal drugs is a very expensive and time-consuming process. It is estimated that the overall timelines and costs from new antifungal lead discovery to regulatory approval, especially for those overcoming drug-resistant fungal pathogens, are 10 years and USD &#x0003e;300 million, respectively. In addition, marketing is estimated to cost USD 400 million over the lifespan of a product [<xref rid="B11-antibiotics-09-00812" ref-type="bibr">11</xref>]. Recently, there have been alternative approaches termed antifungal &#x02018;drug repurposing&#x0201d; via which the new utility of various types of marketed, non-antifungal drugs are repositioned as novel antifungal agents. Here, we discuss the current clinical needs for the development of new antifungal therapy, and we comment on the recent antifungal drug repurposing efforts as alternative approaches for the control of fungal pathogens.</p></sec><sec id="sec2-antibiotics-09-00812"><title>2. Drug Repurposing Approaches</title><sec id="sec2dot1-antibiotics-09-00812"><title>2.1. Repurposing Approaches for the Human Therapeutic Drugs (Non-Antifungals)</title><p>Drug repurposing for &#x0201c;medical treatments (other than fungal diseases)&#x0201d; is the repositioning platform of already marketed drugs for treating human diseases to cure new, other types of disorders/health problems such as viral infection, lupus nephritis, and neurodegenerative disease. One of the merits of drug repurposing is that the mechanisms of action, cellular targets, toxicity profile, or safety of the commercial drugs have already been identified, which enables expedited regulatory approval [<xref rid="B12-antibiotics-09-00812" ref-type="bibr">12</xref>,<xref rid="B13-antibiotics-09-00812" ref-type="bibr">13</xref>]. The methodical drug repurposing pipeline largely involves two types of approaches, &#x0201c;experimental testing&#x0201d; approaches such as microtiter plate-based high-throughput screenings and &#x0201c;in silico/computational&#x0201d; approaches that utilize currently available data (omics, drug target, and real-world data, such as the data pertaining to individual&#x02019;s health status or to the healthcare routinely provided) for the identification of potential new drugs to cure diseases. Systematic drug repurposing needs the accession to and interpretation of molecular, protein, and real-world data, as well as experimental analysis, where data validation in the multicellular or higher organism is the key for industry implementation [<xref rid="B12-antibiotics-09-00812" ref-type="bibr">12</xref>]. In principle, the &#x0201c;antifungal&#x0201d; drug repurposing processes also apply similar approaches for successful drug/compound repositioning (<xref ref-type="app" rid="app1-antibiotics-09-00812">Table S1, Supplementary Materials</xref>).</p></sec><sec id="sec2dot2-antibiotics-09-00812"><title>2.2. Repurposing Approaches for the New Antifungal Drugs</title><p>We performed a PubMed database search in the National Center for Biotechnology Information (NCBI) [<xref rid="B14-antibiotics-09-00812" ref-type="bibr">14</xref>] (<uri xlink:href="https://www.ncbi.nlm.nih.gov/">https://www.ncbi.nlm.nih.gov/</uri>) by applying the keywords &#x0201c;antifungal drug repurposing&#x0201d;, &#x0201c;repurposing [and] in silico [and] fungi (or antifungal, <italic>Candida</italic>, <italic>Cryptococcus</italic>, <italic>Aspergillus</italic>)&#x0201d; plus &#x0201c;antifungal resistance [and] Food and Drug Administration (FDA) (or FDA-approved drug)&#x0201d;, which retrieved a total of 747 articles (accessed on 14 August and 20 October 2020). Each repurposed drug identified was then searched further in PubMed with the search terms &#x0201c;fungi [and] antifungal [and] repurposed drug name (individual)&#x0201d; to provide a comprehensive antifungal spectrum. Articles relevant to the new antifungal drug development are summarized in <xref ref-type="app" rid="app1-antibiotics-09-00812">Table S1</xref> (<xref ref-type="app" rid="app1-antibiotics-09-00812">Supplementary Materials</xref>) [<xref rid="B15-antibiotics-09-00812" ref-type="bibr">15</xref>,<xref rid="B16-antibiotics-09-00812" ref-type="bibr">16</xref>,<xref rid="B17-antibiotics-09-00812" ref-type="bibr">17</xref>,<xref rid="B18-antibiotics-09-00812" ref-type="bibr">18</xref>,<xref rid="B19-antibiotics-09-00812" ref-type="bibr">19</xref>,<xref rid="B20-antibiotics-09-00812" ref-type="bibr">20</xref>,<xref rid="B21-antibiotics-09-00812" ref-type="bibr">21</xref>,<xref rid="B22-antibiotics-09-00812" ref-type="bibr">22</xref>,<xref rid="B23-antibiotics-09-00812" ref-type="bibr">23</xref>,<xref rid="B24-antibiotics-09-00812" ref-type="bibr">24</xref>,<xref rid="B25-antibiotics-09-00812" ref-type="bibr">25</xref>,<xref rid="B26-antibiotics-09-00812" ref-type="bibr">26</xref>,<xref rid="B27-antibiotics-09-00812" ref-type="bibr">27</xref>,<xref rid="B28-antibiotics-09-00812" ref-type="bibr">28</xref>,<xref rid="B29-antibiotics-09-00812" ref-type="bibr">29</xref>,<xref rid="B30-antibiotics-09-00812" ref-type="bibr">30</xref>,<xref rid="B31-antibiotics-09-00812" ref-type="bibr">31</xref>,<xref rid="B32-antibiotics-09-00812" ref-type="bibr">32</xref>,<xref rid="B33-antibiotics-09-00812" ref-type="bibr">33</xref>,<xref rid="B34-antibiotics-09-00812" ref-type="bibr">34</xref>,<xref rid="B35-antibiotics-09-00812" ref-type="bibr">35</xref>,<xref rid="B36-antibiotics-09-00812" ref-type="bibr">36</xref>,<xref rid="B37-antibiotics-09-00812" ref-type="bibr">37</xref>,<xref rid="B38-antibiotics-09-00812" ref-type="bibr">38</xref>,<xref rid="B39-antibiotics-09-00812" ref-type="bibr">39</xref>,<xref rid="B40-antibiotics-09-00812" ref-type="bibr">40</xref>,<xref rid="B41-antibiotics-09-00812" ref-type="bibr">41</xref>,<xref rid="B42-antibiotics-09-00812" ref-type="bibr">42</xref>,<xref rid="B43-antibiotics-09-00812" ref-type="bibr">43</xref>,<xref rid="B44-antibiotics-09-00812" ref-type="bibr">44</xref>,<xref rid="B45-antibiotics-09-00812" ref-type="bibr">45</xref>,<xref rid="B46-antibiotics-09-00812" ref-type="bibr">46</xref>,<xref rid="B47-antibiotics-09-00812" ref-type="bibr">47</xref>,<xref rid="B48-antibiotics-09-00812" ref-type="bibr">48</xref>,<xref rid="B49-antibiotics-09-00812" ref-type="bibr">49</xref>,<xref rid="B50-antibiotics-09-00812" ref-type="bibr">50</xref>,<xref rid="B51-antibiotics-09-00812" ref-type="bibr">51</xref>,<xref rid="B52-antibiotics-09-00812" ref-type="bibr">52</xref>,<xref rid="B53-antibiotics-09-00812" ref-type="bibr">53</xref>,<xref rid="B54-antibiotics-09-00812" ref-type="bibr">54</xref>,<xref rid="B55-antibiotics-09-00812" ref-type="bibr">55</xref>,<xref rid="B56-antibiotics-09-00812" ref-type="bibr">56</xref>,<xref rid="B57-antibiotics-09-00812" ref-type="bibr">57</xref>,<xref rid="B58-antibiotics-09-00812" ref-type="bibr">58</xref>,<xref rid="B59-antibiotics-09-00812" ref-type="bibr">59</xref>,<xref rid="B60-antibiotics-09-00812" ref-type="bibr">60</xref>,<xref rid="B61-antibiotics-09-00812" ref-type="bibr">61</xref>,<xref rid="B62-antibiotics-09-00812" ref-type="bibr">62</xref>,<xref rid="B63-antibiotics-09-00812" ref-type="bibr">63</xref>,<xref rid="B64-antibiotics-09-00812" ref-type="bibr">64</xref>,<xref rid="B65-antibiotics-09-00812" ref-type="bibr">65</xref>,<xref rid="B66-antibiotics-09-00812" ref-type="bibr">66</xref>,<xref rid="B67-antibiotics-09-00812" ref-type="bibr">67</xref>,<xref rid="B68-antibiotics-09-00812" ref-type="bibr">68</xref>,<xref rid="B69-antibiotics-09-00812" ref-type="bibr">69</xref>,<xref rid="B70-antibiotics-09-00812" ref-type="bibr">70</xref>,<xref rid="B71-antibiotics-09-00812" ref-type="bibr">71</xref>,<xref rid="B72-antibiotics-09-00812" ref-type="bibr">72</xref>,<xref rid="B73-antibiotics-09-00812" ref-type="bibr">73</xref>,<xref rid="B74-antibiotics-09-00812" ref-type="bibr">74</xref>,<xref rid="B75-antibiotics-09-00812" ref-type="bibr">75</xref>,<xref rid="B76-antibiotics-09-00812" ref-type="bibr">76</xref>,<xref rid="B77-antibiotics-09-00812" ref-type="bibr">77</xref>,<xref rid="B78-antibiotics-09-00812" ref-type="bibr">78</xref>,<xref rid="B79-antibiotics-09-00812" ref-type="bibr">79</xref>,<xref rid="B80-antibiotics-09-00812" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-09-00812" ref-type="bibr">81</xref>,<xref rid="B82-antibiotics-09-00812" ref-type="bibr">82</xref>,<xref rid="B83-antibiotics-09-00812" ref-type="bibr">83</xref>,<xref rid="B84-antibiotics-09-00812" ref-type="bibr">84</xref>,<xref rid="B85-antibiotics-09-00812" ref-type="bibr">85</xref>,<xref rid="B86-antibiotics-09-00812" ref-type="bibr">86</xref>,<xref rid="B87-antibiotics-09-00812" ref-type="bibr">87</xref>,<xref rid="B88-antibiotics-09-00812" ref-type="bibr">88</xref>,<xref rid="B89-antibiotics-09-00812" ref-type="bibr">89</xref>,<xref rid="B90-antibiotics-09-00812" ref-type="bibr">90</xref>,<xref rid="B91-antibiotics-09-00812" ref-type="bibr">91</xref>,<xref rid="B92-antibiotics-09-00812" ref-type="bibr">92</xref>,<xref rid="B93-antibiotics-09-00812" ref-type="bibr">93</xref>,<xref rid="B94-antibiotics-09-00812" ref-type="bibr">94</xref>,<xref rid="B95-antibiotics-09-00812" ref-type="bibr">95</xref>,<xref rid="B96-antibiotics-09-00812" ref-type="bibr">96</xref>,<xref rid="B97-antibiotics-09-00812" ref-type="bibr">97</xref>,<xref rid="B98-antibiotics-09-00812" ref-type="bibr">98</xref>,<xref rid="B99-antibiotics-09-00812" ref-type="bibr">99</xref>,<xref rid="B100-antibiotics-09-00812" ref-type="bibr">100</xref>,<xref rid="B101-antibiotics-09-00812" ref-type="bibr">101</xref>,<xref rid="B102-antibiotics-09-00812" ref-type="bibr">102</xref>,<xref rid="B103-antibiotics-09-00812" ref-type="bibr">103</xref>,<xref rid="B104-antibiotics-09-00812" ref-type="bibr">104</xref>,<xref rid="B105-antibiotics-09-00812" ref-type="bibr">105</xref>,<xref rid="B106-antibiotics-09-00812" ref-type="bibr">106</xref>,<xref rid="B107-antibiotics-09-00812" ref-type="bibr">107</xref>,<xref rid="B108-antibiotics-09-00812" ref-type="bibr">108</xref>,<xref rid="B109-antibiotics-09-00812" ref-type="bibr">109</xref>,<xref rid="B110-antibiotics-09-00812" ref-type="bibr">110</xref>,<xref rid="B111-antibiotics-09-00812" ref-type="bibr">111</xref>,<xref rid="B112-antibiotics-09-00812" ref-type="bibr">112</xref>,<xref rid="B113-antibiotics-09-00812" ref-type="bibr">113</xref>,<xref rid="B114-antibiotics-09-00812" ref-type="bibr">114</xref>,<xref rid="B115-antibiotics-09-00812" ref-type="bibr">115</xref>,<xref rid="B116-antibiotics-09-00812" ref-type="bibr">116</xref>,<xref rid="B117-antibiotics-09-00812" ref-type="bibr">117</xref>,<xref rid="B118-antibiotics-09-00812" ref-type="bibr">118</xref>,<xref rid="B119-antibiotics-09-00812" ref-type="bibr">119</xref>,<xref rid="B120-antibiotics-09-00812" ref-type="bibr">120</xref>,<xref rid="B121-antibiotics-09-00812" ref-type="bibr">121</xref>,<xref rid="B122-antibiotics-09-00812" ref-type="bibr">122</xref>,<xref rid="B123-antibiotics-09-00812" ref-type="bibr">123</xref>,<xref rid="B124-antibiotics-09-00812" ref-type="bibr">124</xref>,<xref rid="B125-antibiotics-09-00812" ref-type="bibr">125</xref>,<xref rid="B126-antibiotics-09-00812" ref-type="bibr">126</xref>,<xref rid="B127-antibiotics-09-00812" ref-type="bibr">127</xref>,<xref rid="B128-antibiotics-09-00812" ref-type="bibr">128</xref>,<xref rid="B129-antibiotics-09-00812" ref-type="bibr">129</xref>,<xref rid="B130-antibiotics-09-00812" ref-type="bibr">130</xref>,<xref rid="B131-antibiotics-09-00812" ref-type="bibr">131</xref>,<xref rid="B132-antibiotics-09-00812" ref-type="bibr">132</xref>,<xref rid="B133-antibiotics-09-00812" ref-type="bibr">133</xref>,<xref rid="B134-antibiotics-09-00812" ref-type="bibr">134</xref>,<xref rid="B135-antibiotics-09-00812" ref-type="bibr">135</xref>,<xref rid="B136-antibiotics-09-00812" ref-type="bibr">136</xref>,<xref rid="B137-antibiotics-09-00812" ref-type="bibr">137</xref>,<xref rid="B138-antibiotics-09-00812" ref-type="bibr">138</xref>,<xref rid="B139-antibiotics-09-00812" ref-type="bibr">139</xref>,<xref rid="B140-antibiotics-09-00812" ref-type="bibr">140</xref>,<xref rid="B141-antibiotics-09-00812" ref-type="bibr">141</xref>,<xref rid="B142-antibiotics-09-00812" ref-type="bibr">142</xref>,<xref rid="B143-antibiotics-09-00812" ref-type="bibr">143</xref>,<xref rid="B144-antibiotics-09-00812" ref-type="bibr">144</xref>,<xref rid="B145-antibiotics-09-00812" ref-type="bibr">145</xref>,<xref rid="B146-antibiotics-09-00812" ref-type="bibr">146</xref>,<xref rid="B147-antibiotics-09-00812" ref-type="bibr">147</xref>,<xref rid="B148-antibiotics-09-00812" ref-type="bibr">148</xref>,<xref rid="B149-antibiotics-09-00812" ref-type="bibr">149</xref>,<xref rid="B150-antibiotics-09-00812" ref-type="bibr">150</xref>,<xref rid="B151-antibiotics-09-00812" ref-type="bibr">151</xref>,<xref rid="B152-antibiotics-09-00812" ref-type="bibr">152</xref>,<xref rid="B153-antibiotics-09-00812" ref-type="bibr">153</xref>,<xref rid="B154-antibiotics-09-00812" ref-type="bibr">154</xref>,<xref rid="B155-antibiotics-09-00812" ref-type="bibr">155</xref>,<xref rid="B156-antibiotics-09-00812" ref-type="bibr">156</xref>,<xref rid="B157-antibiotics-09-00812" ref-type="bibr">157</xref>,<xref rid="B158-antibiotics-09-00812" ref-type="bibr">158</xref>,<xref rid="B159-antibiotics-09-00812" ref-type="bibr">159</xref>,<xref rid="B160-antibiotics-09-00812" ref-type="bibr">160</xref>,<xref rid="B161-antibiotics-09-00812" ref-type="bibr">161</xref>,<xref rid="B162-antibiotics-09-00812" ref-type="bibr">162</xref>,<xref rid="B163-antibiotics-09-00812" ref-type="bibr">163</xref>,<xref rid="B164-antibiotics-09-00812" ref-type="bibr">164</xref>,<xref rid="B165-antibiotics-09-00812" ref-type="bibr">165</xref>,<xref rid="B166-antibiotics-09-00812" ref-type="bibr">166</xref>,<xref rid="B167-antibiotics-09-00812" ref-type="bibr">167</xref>,<xref rid="B168-antibiotics-09-00812" ref-type="bibr">168</xref>,<xref rid="B169-antibiotics-09-00812" ref-type="bibr">169</xref>,<xref rid="B170-antibiotics-09-00812" ref-type="bibr">170</xref>]. The remaining articles not selected here mainly described (1) antibacterial, antiviral, or antiprotozoal drug development, (2) anticancer drug development, or (3) drug development for other human diseases/conditions including metabolic diseases such as arachidonic acid metabolism, Parkinson&#x02019;s/neurodegenerative diseases, immune-mediated disease, altered gene expression, and ATP synthase disorder. Six studies adopted &#x0201c;in silico/computational&#x0201d; approaches including experimental validation (Table 1), while the remaining investigations used &#x0201c;experimental testing&#x0201d; approaches, including the utilization of standard antifungal testing protocols such as CLSI M27-A, CLSI M38-A, and EUCAST-AFST E.DEF 7.3 developed by the Clinical and Laboratory Standard Institute (CLSI) [<xref rid="B171-antibiotics-09-00812" ref-type="bibr">171</xref>] or the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [<xref rid="B172-antibiotics-09-00812" ref-type="bibr">172</xref>], respectively, for breakout determination.</p></sec></sec><sec id="sec3-antibiotics-09-00812"><title>3. Antifungal Drug Repurposing: Current Measures</title><sec id="sec3dot1-antibiotics-09-00812"><title>3.1. In Silico/Computational Repurposing Approaches</title><p>In silico/computational repurposing approaches typically use four steps: (1) mining and compilation of pathogen genome data, (2) homology modeling, (3) ligand preparation and molecular docking, and (4) experimental validation in the target pathogens [<xref rid="B173-antibiotics-09-00812" ref-type="bibr">173</xref>]. As described in <xref rid="antibiotics-09-00812-t001" ref-type="table">Table 1</xref>, public or nonprofit research sectors such as NCBI, Broad Institute (USA), and the European Molecular Biology Laboratory&#x02019;s European Bioinformatics Institute (EMBL-EBI) provide updated fungal genome or protein data, which makes the comprehensive mining and compilation of fungal genome/protein data feasible. Protein or chemical databases such as the SWISS-MODEL server, Protein Data Bank (PDB), and PubChem server allow the execution of protein structure homology modeling of drug targets or the computation of 3D structures of candidate compounds. Other online tools, such as the Visual Molecular Dynamics (VMD) program or LigPlot program that automatically plot the protein&#x02013;ligand interactions, are also currently available (<xref rid="antibiotics-09-00812-t001" ref-type="table">Table 1</xref>). The execution of ligand preparation and the molecular docking step rely mainly on the application software, as documented in <xref rid="antibiotics-09-00812-t001" ref-type="table">Table 1</xref>.</p><p>Noteworthy is the repurposing study performed by de Oliveira et al. [<xref rid="B15-antibiotics-09-00812" ref-type="bibr">15</xref>] targeting the saprobic/dimorphic <italic>Paracoccidioides</italic> species, a causative agent of the systemic mycosis paracoccidioidomycosis, which adopted three additional steps: (a) identification of &#x0201c;orthologs&#x0201d; in different isolates of the target pathogen, (b) identification of &#x0201c;homologs&#x0201d; in the drug&#x02013;target databases, and (c) selection of essential targets in the model fungus <italic>Saccharomyces cerevisiae</italic> system. The study compiled proteins of three <italic>Paracoccidioides</italic> species (<italic>P. lutzii</italic>, <italic>P. americana</italic>, and <italic>P. brasiliensis</italic>) via the Broad Institute Fungal Genomics Database, followed by the identification of orthologs in <italic>Paracoccidioides</italic> species. The study by de Oliveira et al. resulted in the selection of two anticancer drug candidates as new, repurposed antifungals, where the mode of action was to inhibit the fungal phosphatidylinositol 3-kinase TOR2 (<underline>T</underline>arget <underline>O</underline>f <underline>R</underline>apamycin 2) [<xref rid="B15-antibiotics-09-00812" ref-type="bibr">15</xref>].</p><p>The validation of antifungal activity of new, repurposed drugs to achieve more than 99.9% fungal death (breakpoints) requires standard testing methods developed by CLSI [<xref rid="B171-antibiotics-09-00812" ref-type="bibr">171</xref>] or EUCAST [<xref rid="B172-antibiotics-09-00812" ref-type="bibr">172</xref>] (<xref ref-type="sec" rid="sec3dot2-antibiotics-09-00812">Section 3.2</xref>). Of the six in silico/computational studies described in <xref rid="antibiotics-09-00812-t001" ref-type="table">Table 1</xref>, two investigations adopted the CLSI protocols while four other studies applied various agar- or liquid-based antifungal assays. It is expected that the number of in silico/computational investigations will increase in the coming years, especially with the increasing numbers of omics, drug target, and chemical structural data being generated. The adoption of standard methods, such as CLSI or EUCAST, is highly desired for the unbiased/repeatable determination of the breakpoints (and, thus, the efficacy) of repurposed antifungal drugs.</p></sec><sec id="sec3dot2-antibiotics-09-00812"><title>3.2. Experimental Repurposing Approaches</title><sec id="sec3dot2dot1-antibiotics-09-00812"><title>3.2.1. Standard Dilution Methods: CLSI and EUCAST</title><p>The majority of articles (<xref ref-type="app" rid="app1-antibiotics-09-00812">Table S1, Supplementary Materials</xref>) performed drug repurposing via experimental testing approaches. These include CLSI, EUCAST, or other microdilution/agar assays such as biofilm bioassay, high-throughput ATP content assay, microdilution, and fluorescent microscopic analysis, metabolism and hyphal inhibitory assays, drug diffusion susceptibility testing, human neutrophils, epithelial cell adhesion and invasion assays, murine model, and macrophage assay, among others.</p><p>The standard dilution methods developed by the CLSI and EUCAST quantitatively determine (1) minimum inhibitory concentrations (MICs) and minimum fungicidal concentrations (MFC) of drugs/compounds via the microdilution assay settings, as well as whether the antifungal efficacy of drugs/compounds is fungicidal or fungistatic, where fungicidal indicates a ratio of MFC/MIC &#x02264;4 [<xref rid="B211-antibiotics-09-00812" ref-type="bibr">211</xref>], and (2) the levels and types of drug/compound interactions when two drugs/compounds are co-applied, thus calculating the fractional inhibitory concentration indices (FICI) using MIC values or the fractional fungicidal concentration indices (FFCI) using MFC values; synergism indicates FICI or FFCI values &#x02264;0.5, while indifference indicates FICI or FFCI values &#x0003e;0.5&#x02013;4 [<xref rid="B212-antibiotics-09-00812" ref-type="bibr">212</xref>].</p><p>The other method termed the &#x0201c;disc diffusion&#x0201d; test is a relatively inexpensive assay compared to the standard dilution method, for which a few standard assay protocols have been documented in CLSI. CLSI M44 was validated only for azoles and echinocandins for the isolates of <italic>Candida</italic> species, while CLSI M51-A and supplement M51-S1 qualitatively analyze the efficacy of CAS, triazoles, AMB, etc. [<xref rid="B213-antibiotics-09-00812" ref-type="bibr">213</xref>]. There is a lower agreement between the disc diffusion test results and that of the standard dilution assays, especially in the values from <italic>Aspergillus flavus</italic> (AMB and VOR) and <italic>A. fumigatus</italic> (AMB), suggesting that the standard dilution assay seems useful to determine the interpretative breakpoints for both <italic>Candida</italic> and <italic>Aspergillus</italic> species.</p></sec><sec id="sec3dot2dot2-antibiotics-09-00812"><title>3.2.2. Biofilm Analysis</title><p>Studies have shown that many fungi can alternate planktonic (freely floating, homogeneous cells) and sessile (surface-aggregated, heterogeneous cells) growth, which significantly affects fungal pathogenesis and human infection [<xref rid="B214-antibiotics-09-00812" ref-type="bibr">214</xref>,<xref rid="B215-antibiotics-09-00812" ref-type="bibr">215</xref>,<xref rid="B216-antibiotics-09-00812" ref-type="bibr">216</xref>]. The sessile, multicellular communities of fungi, also known as biofilms, are highly structured fungal communities, which are either adherent to biological or physical surfaces, such as oral mucosa, denture acrylic substrates, and catheters, or form aggregates within the protective extracellular matrix (ECM). The majority of clinically important fungi can produce biofilms, which include filamentous fungal pathogens (<italic>Aspergillus</italic>, <italic>Fusarium</italic>, and zygomycetes), yeast pathogens (<italic>Blastoschizomyces, Saccharomyces, Malassezia, Trichosporon, Cryptococcus</italic>, and <italic>Candida</italic> species), and <italic>Pneumocysitis</italic> [<xref rid="B214-antibiotics-09-00812" ref-type="bibr">214</xref>,<xref rid="B215-antibiotics-09-00812" ref-type="bibr">215</xref>,<xref rid="B216-antibiotics-09-00812" ref-type="bibr">216</xref>]. There are also variations in biofilm morphology depending on the types of fungi, namely, (1) <italic>C. albicans</italic> forms complex morphology with blastospores, hyphae, and ECM, (2) <italic>C. neoformans</italic> forms an organized structure having yeast cells with a matrix, (3) <italic>A. fumigatus</italic> forms hyphal cells with ECM, (4) <italic>Trichosporon asahii</italic> forms yeast and hyphal cells with ECM, etc. [<xref rid="B216-antibiotics-09-00812" ref-type="bibr">216</xref>]. Therefore, in addition to the standard in vitro testing for the planktonic cells, such as CLSI or EUCAST assays, a highly reproducible microtiter plate-based colorimetric measurement determining metabolic activities of the pathogen&#x02019;s biofilm are also used [<xref rid="B217-antibiotics-09-00812" ref-type="bibr">217</xref>].</p><p>In general, the development cycle of a fungal biofilm consists of initial adhesion, colonization, proliferation with ECM production, biofilm maturation, and dispersion [<xref rid="B214-antibiotics-09-00812" ref-type="bibr">214</xref>,<xref rid="B215-antibiotics-09-00812" ref-type="bibr">215</xref>,<xref rid="B216-antibiotics-09-00812" ref-type="bibr">216</xref>]. Various environmental factors induce surface attachment and biofilm formation of fungi, including the flow of body fluids (urine, blood, saliva, mucus), pH, temperature, and host immune factors, whereby biofilms protect fungi from the harsh environments including antifungal drugs (e.g., ECM shields fungal cells from drugs and reduces drug penetration), chemical and physical stress, etc., or enable a community-coordinated gene regulation or metabolism [<xref rid="B214-antibiotics-09-00812" ref-type="bibr">214</xref>,<xref rid="B215-antibiotics-09-00812" ref-type="bibr">215</xref>,<xref rid="B216-antibiotics-09-00812" ref-type="bibr">216</xref>].</p><p>Biofilm-forming fungal infections are very difficult to treat, which often involve increased drug-resistance phenotypes [<xref rid="B218-antibiotics-09-00812" ref-type="bibr">218</xref>]. In particular, the triazoles and traditional formulations of polyene drugs are considered inactive against fungal biofilms [<xref rid="B219-antibiotics-09-00812" ref-type="bibr">219</xref>]. Differential antifungal activity of drugs has also been documented against biofilms from different fungal pathogens. For instance, echinocandins and AMB lipid formulations exhibited in vitro and in vivo antifungal activities against <italic>C. albicans</italic> biofilms, while other fungal biofilms, such as <italic>A</italic>. <italic>fumigatus</italic> or <italic>C. auris</italic> biofilms, were resistant to echinocandin drugs including CAS [<xref rid="B214-antibiotics-09-00812" ref-type="bibr">214</xref>,<xref rid="B219-antibiotics-09-00812" ref-type="bibr">219</xref>].</p></sec><sec id="sec3dot2dot3-antibiotics-09-00812"><title>3.2.3. Phenotypic Variability of Infecting Fungi: Conidia, Hyphal, Yeast, and Filamentous Growth</title><p>In addition to biofilm formation, the phenotypic variability of fungi could also play an important role in clinical outcomes of therapeutic interventions, including the repurposed drugs/compounds (<xref rid="antibiotics-09-00812-t002" ref-type="table">Table 2</xref>). In <italic>C. albicans</italic>, the morphological switch from yeast cells to hyphae (filamentous forms) serves as a crucial virulence factor, which promotes infection and invasion in hosts. There was also a positive correlation between the level of azole resistance and the capability to form a hyphal structure; under hypha-inducing conditions, only the <italic>C. albicans</italic> resistant to azoles could form hyphae while the susceptible isolates could not [<xref rid="B220-antibiotics-09-00812" ref-type="bibr">220</xref>]. In the antifungal drug screenings, the manganese nitrosyl [Mn(PaPy<sub>3</sub>)(NO)](ClO<sub>4</sub>) ({Mn-NO}), a biocompatible NO-donating reagent that delivers NO under visible light, has been determined more effective against the hyphal form of <italic>C. albicans</italic>, when compared to the yeast cells [<xref rid="B221-antibiotics-09-00812" ref-type="bibr">221</xref>]. Triclosan has also been used in oral hygiene products with a broad-spectrum antimicrobial activity. Of note, in <italic>C. albicans</italic>, triclosan at subinhibitory concentrations antagonized the antifungal activity of the azole drug FLU, which was specific under hypha-inducing conditions [<xref rid="B222-antibiotics-09-00812" ref-type="bibr">222</xref>]. This antagonism could be due to the membranotropic characteristic of triclosan and also the unique composition of hyphal membranes [<xref rid="B222-antibiotics-09-00812" ref-type="bibr">222</xref>]. Meanwhile, in <italic>A. fumigatus</italic>, the conidia and hyphal forms of fungal fragments were equally susceptible to the AMB and azole drugs, while hyphal clumps were only susceptible to the relatively high concentrations of AMB [<xref rid="B223-antibiotics-09-00812" ref-type="bibr">223</xref>].</p></sec><sec id="sec3dot2dot4-antibiotics-09-00812"><title>3.2.4. Animal Model Systems</title><p>Animal model systems (mammalian and nonmammalian models) are important components for antifungal drug development/discovery including the validation of repurposed drugs [<xref rid="B224-antibiotics-09-00812" ref-type="bibr">224</xref>] (<xref rid="antibiotics-09-00812-t003" ref-type="table">Table 3</xref>).</p><p>Mammalian models are represented by murine, rat, guinea pigs, and rabbits, including both na&#x000ef;ve and compromised mice, whereby the antifungal activity of the repurposed drugs can be examined for pharmacokinetics (PK) (e.g., tissue distribution, excretion), pharmacodynamics (PD), immune responses elicited by fungal pathogens, and vaccination attempts [<xref rid="B224-antibiotics-09-00812" ref-type="bibr">224</xref>,<xref rid="B225-antibiotics-09-00812" ref-type="bibr">225</xref>] (see [<xref rid="B138-antibiotics-09-00812" ref-type="bibr">138</xref>] in <xref ref-type="app" rid="app1-antibiotics-09-00812">Table S1, Supplementary Materials</xref>). There are various animal models and infection routes, together with various immune suppression regimens. Examples include, but are not limited to, drug screening murine model, murine neutropenic thigh model for determining PK/PD of antifungal drugs, murine model for testing mucocutaneous candidiasis, diabetic murine model of disseminated mucormycosis, murine pulmonary mucormycosis, cyclophosphamide/cortisone immunocompromised murine model of pulmonary mucormycosis, persistently neutropenic rabbit model for investigating acute, invasive pulmonary aspergillosis (IPA), and persistently granulocytopenic rabbit model for characterizing the efficacy of L-AMB against IPA [<xref rid="B224-antibiotics-09-00812" ref-type="bibr">224</xref>,<xref rid="B225-antibiotics-09-00812" ref-type="bibr">225</xref>]. It is important to note that animal testing should be compliant with animal welfare regulation, including Institutional Animal Care and Use Committee (IACUC) review, for all proposed animal experiments [<xref rid="B226-antibiotics-09-00812" ref-type="bibr">226</xref>].</p><p>Nonmammalian models currently consist of <italic>Drosophila melanogaster</italic> (fruit fly), <italic>Caenorhabditis elegans</italic> (free-living nematode) and <italic>Galleria mellonella</italic> (wax moth). Examples include biofilm formation in <italic>D. melanogaster</italic>, melanization and toxicity testing in <italic>G. mellonela</italic>, and slow and fast killing testing in <italic>C. elegans</italic>, among others. [<xref rid="B227-antibiotics-09-00812" ref-type="bibr">227</xref>]. When compared to the mammalian models, the nonmammalian models are considered affordable and easy to handle (see [<xref rid="B154-antibiotics-09-00812" ref-type="bibr">154</xref>] in <xref ref-type="app" rid="app1-antibiotics-09-00812">Table S1, Supplementary Materials</xref>). While studies have shown that many data from nonmammalian models are in parallel with those obtained from mammalian models, some results did not correlate well. The major drawback of nonmammalian models lies in their unsuitability for microbial vaccination, colonization assessment, challenge research, and immune response. Accordingly, mammalian models are considered to better represent the human condition during the efficacy assessment of the repurposed drugs [<xref rid="B224-antibiotics-09-00812" ref-type="bibr">224</xref>], as also described in <xref ref-type="sec" rid="sec4dot1-antibiotics-09-00812">Section 4.1</xref>.</p><p>There have been several types of candidate drugs used for antifungal repurposing (<xref ref-type="app" rid="app1-antibiotics-09-00812">Table S1, Supplementary Materials</xref>). These include antipsychiatric, estrogen modulator, antidepressant, antiplatelet aggregation, enzyme (serine palmitoyl-transferase) inhibitor, anticardiovascular, antiarthritis, antistroke, antiatherosclerosis, anticancer, and anthelmintic drugs. However, the use of various drug libraries in the antifungal drug repurposing process is also increasing recently; drug libraries have been prepared/preserved by either public or commercial institutes/vendors, as shown in <xref rid="antibiotics-09-00812-t004" ref-type="table">Table 4</xref>.</p></sec></sec><sec id="sec3dot3-antibiotics-09-00812"><title>3.3. Synergism between Repurposed Agents and Conventional Antifungals</title><p>Combination therapy in controlling fungal pathogens is defined as a co-application of two or more antifungal drugs to treat fungal infections [<xref rid="B230-antibiotics-09-00812" ref-type="bibr">230</xref>]. Combination therapy has been developed on the basis that co-administration of antifungal drugs having different cellular/molecular targets could effectively eliminate fungal pathogens, especially those resistant to conventional drugs. However, the efficacy of combination therapies often varies depending upon the types of drugs co-applied. Although many studies determined better results for fungal pathogen control with drug combinations, other data exhibited no added merit of drug co-treatment over the individual application of each drug alone, which may be associated with drug antagonism [<xref rid="B231-antibiotics-09-00812" ref-type="bibr">231</xref>]. Risk factors also exist during combination therapy, such as multidrug interactions and cytotoxicity.</p><p>Studies have shown the synergistic interaction between repurposed agents and conventional antifungal drugs, such as FLU, AMB, or CAS (see <xref rid="antibiotics-09-00812-t005" ref-type="table">Table 5</xref> for a summary). For example, Spitzer et al. determined that the antifungal capacity of chemicals can be systematically enhanced via the combined application of known commercial drugs, such as FLU, with other types of bioactive compounds from drug repurposing [<xref rid="B23-antibiotics-09-00812" ref-type="bibr">23</xref>]. They found that the repurposed compounds did not have to possess potent antifungal activity on their own, but that the compounds potentiated the FLU antifungal activity with considerable species specificity. These synergistic drug combinations were different from the traditional combination therapies mentioned above [<xref rid="B23-antibiotics-09-00812" ref-type="bibr">23</xref>].</p><p>Similarly, the anticholesterol drug lovastatin has been repurposed as a synergistic antifungal modulator to the azole drug ITR against the planktonic cells and biofilms of the yeast pathogen <italic>C. albicans</italic>; the lovastatin regulation of the ergosterol biosynthetic pathway has been the proposed mechanism of antifungal action [<xref rid="B45-antibiotics-09-00812" ref-type="bibr">45</xref>]. The antifungal mechanism of lovastatin in <italic>A. fumigatus</italic> also involved ergosterol biosynthesis, which was controlled further by cellular iron homeostasis [<xref rid="B65-antibiotics-09-00812" ref-type="bibr">65</xref>]. In <italic>A. fumigatus</italic>, iron starvation induces the production of the siderophore triacetylfusarinine C (TAFC), for which mevalonate is the key intermediate for the synthesis of both ergosterol and TAFC, the critical virulence factors [<xref rid="B65-antibiotics-09-00812" ref-type="bibr">65</xref>]. Of note, the expression of the enzyme 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase (Hmg1), responsible for the production of mevalonate, was increased under iron starvation, while the synthesis of TAFC was reduced following the lovastatin-mediated inhibition of Hmg1 [<xref rid="B65-antibiotics-09-00812" ref-type="bibr">65</xref>].</p><p>In our prior study, considerable augmentation of the control of <italic>Cryptococcus</italic> species was achieved by the co-application of repurposed compounds, such as octyl gallate or benzaldehydes, with conventional antifungal agents [<xref rid="B232-antibiotics-09-00812" ref-type="bibr">232</xref>]. The <italic>Cryptococcus</italic> species exhibited higher susceptibility to the inhibition of mitochondrial respiration compared to other yeast pathogens <italic>Candida</italic> species [<xref rid="B232-antibiotics-09-00812" ref-type="bibr">232</xref>]. This &#x0201c;species-specific&#x0201d; enhancement of sensitivity to the co-treatments resulted from the inability of <italic>Cryptococcus</italic> species to produce cellular energy (ATPs) via the fermentation process. Studies by Spitzer et al. mentioned above indicated that the differential susceptibility of pathogens to the newly developed drugs or interventions is triggered by the differences in physiological/genetic settings of test strains, which could result in species-specific antifungal responses.</p><p>Related antifungal &#x0201c;chemosensitization&#x0201d; has been developed recently as a new intervention strategy, where co-application of a repurposed compound (chemosensitizer), such as food additives, with conventional drugs enhanced the antifungal efficacy of the co-applied drugs [<xref rid="B77-antibiotics-09-00812" ref-type="bibr">77</xref>,<xref rid="B233-antibiotics-09-00812" ref-type="bibr">233</xref>]. A chemosensitizer causes the target pathogen to be more susceptible to the co-applied conventional drug via the modulation of the pathogen&#x02019;s defense system, such as the oxidative stress signaling system or cell-wall integrity pathway. Considering that the chemosensitizers could also function as probe-like chemicals by negatively affecting specific cellular targets such as antioxidant systems, types of &#x0201c;drug&#x02013;compound (repurposed) combinations&#x0201d; enable target-specific control of fungal pathogens, including augmentation of the activity of the echinocandin drug CAS by the cell-wall-targeting octyl gallate [<xref rid="B234-antibiotics-09-00812" ref-type="bibr">234</xref>]. The chemosensitization strategy has been applied further to the development of a high-efficiency drug repurposing protocol that could enhance the sensitivity of target pathogens to the drug candidates, thus reducing time/costs for screening new antifungal drugs, as well as overcoming drug/fungicide resistance of fungal pathogens [<xref rid="B104-antibiotics-09-00812" ref-type="bibr">104</xref>].</p></sec></sec><sec id="sec4-antibiotics-09-00812"><title>4. Challenges</title><sec id="sec4dot1-antibiotics-09-00812"><title>4.1. Pioglitazone: Needs for In Vivo Drug Validation</title><p>Pioglitazone (PIO) has been used as an adjuvant of AMB for the treatment of cryptococcosis. AMB causes excessive generation of reactive oxygen species linked to compromised renal function. PIO is an agonist of peroxisome proliferator-activated receptor &#x003b3;, which is used to treat type 2 diabetes and is also used as an adjuvant of many drugs triggering side-effects due to its redox-active and anti-inflammatory characteristics [<xref rid="B235-antibiotics-09-00812" ref-type="bibr">235</xref>]. In a murine model, co-application of PIO and AMB exhibited higher efficacy than AMB alone for the inhibition of yeast pathogens, whereby the combination (PIO + AMB) disrupted yeast transmission from the lungs to the brain, which also eliminated yeasts that reached the central nervous system [<xref rid="B236-antibiotics-09-00812" ref-type="bibr">236</xref>]. PIO did not exhibit in vitro antifungal activity, nor did it affect the AMB-mediated fungicidal activity of macrophages; however, PIO as a therapeutic adjuvant counteracted the oxidative bursts after the reduction of the fungal burden, thus relieving the oxidative stress damages to the host (in vivo) and preventing the establishment of meningoencephalitis [<xref rid="B236-antibiotics-09-00812" ref-type="bibr">236</xref>]. The fact that the in vitro antifungal activity of PIO and AMB co-application was determined as &#x0201c;indifferent&#x0201d; while that of in vivo administration increased the survivability of the animals, compared to AMB alone, strongly suggests the importance of the in vivo validation of drug repurposing. The in vitro CLSI or EUCAST testing alone could miss identifying highly effective antifungal adjuvants such as PIO (also observed in other drug developments, personal communication [<xref rid="B237-antibiotics-09-00812" ref-type="bibr">237</xref>], American Chemical Society National Meeting, 2020).</p></sec><sec id="sec4dot2-antibiotics-09-00812"><title>4.2. Resistance to Repurposed Drugs/Compounds: Cinnamic and Benzoic Derivatives</title><p>The model yeast <italic>Saccharomyces cerevisiae</italic> has been used as a useful screening system for identifying antifungal agents in view that (1) the <italic>S. cerevisiae</italic> genome has been sequenced and well-characterized ([<xref rid="B238-antibiotics-09-00812" ref-type="bibr">238</xref>], accessed 3 September 2020), (2) <italic>S. cerevisiae</italic> gene deletion mutants have been very useful for investigating the mechanisms or target genes of screened leads [<xref rid="B239-antibiotics-09-00812" ref-type="bibr">239</xref>], and (3) many genes in <italic>S. cerevisiae</italic> are homologous to those of fungal pathogens [<xref rid="B240-antibiotics-09-00812" ref-type="bibr">240</xref>]. The antifungal compounds screened via <italic>S. cerevisiae</italic> (wild type or mutants) also exhibited broad-spectrum antifungal activities against pathogenic yeasts (<italic>Candida</italic> and <italic>Cryptococcus</italic> species) and filamentous fungi (<italic>Aspergillus</italic>, <italic>Fusarium</italic>, and <italic>Scedosporium</italic> species) [<xref rid="B2-antibiotics-09-00812" ref-type="bibr">2</xref>].</p><p>Caution should be exercised during the high-throughput repurposing process so as not to overlook the tolerant response of certain mutants. For instance, cinnamic acids are generally recognized as safe (GRAS) compounds, which have been used as food additives [<xref rid="B241-antibiotics-09-00812" ref-type="bibr">241</xref>]. In recent repurposing studies, cinnamic acid derivatives have been investigated as antifungal alternatives which target fungal cell-wall biosynthesis and integrity [<xref rid="B242-antibiotics-09-00812" ref-type="bibr">242</xref>,<xref rid="B243-antibiotics-09-00812" ref-type="bibr">243</xref>,<xref rid="B244-antibiotics-09-00812" ref-type="bibr">244</xref>]. While the wild type and cell-wall integrity mutants of <italic>S. cerevisiae</italic> showed a sensitive response to the selected cinnamic acids, such as 3- or 4-methoxycinnamic acids, the glutathione reductase mutant (<italic>glr1</italic>&#x00394;) was hyper-tolerant to 4-methoxycinnamic acid when compared to other test strains [<xref rid="B243-antibiotics-09-00812" ref-type="bibr">243</xref>] (<xref ref-type="fig" rid="antibiotics-09-00812-f001">Figure 1</xref>). This type of hyper-tolerance was eliminated by 4-methylcinnamic acid, which is the structural derivative of 4-methoxycinnamic acid having a deoxygenated <italic>para</italic> methyl moiety (<xref ref-type="fig" rid="antibiotics-09-00812-f001">Figure 1</xref>). Glutathione reductase is necessary for the reduction of the oxidized glutathione (GSSG) to reduced glutathione (GSH) to maintain cellular redox homeostasis [<xref rid="B245-antibiotics-09-00812" ref-type="bibr">245</xref>]. While the study showed the structure&#x02013;activity relationship of cinnamic derivatives in targeting fungal cell-wall components where the <italic>para</italic> methyl moiety is critical to overcoming the <italic>glr1</italic>&#x00394; hyper-tolerance to 4-methoxycinnamic acid, the investigation also highlighted the importance of comprehensive determination of the &#x0201c;gene&#x02013;compound&#x0201d; interaction/response, thus avoiding unfavorable outcomes including fungal tolerance to the repurposed agents (<xref ref-type="fig" rid="antibiotics-09-00812-f001">Figure 1</xref>; <xref ref-type="fig" rid="antibiotics-09-00812-f002">Figure 2</xref>b for the scheme) during drug repurposing.</p><p>Edible plants including herbs are rich sources of bioactive metabolites that possess various hepatoprotective, antihypertensive, antitumor, or immunomodulatory effects. However, natural ingredients in plant extracts, such as benzoic derivatives, could negatively affect the fungal signaling mutants (for example, <italic>A. fumigatus</italic> antioxidant mitogen-activated protein kinase (MAPK) mutants <italic>sakA</italic>&#x00394; and <italic>mpkC</italic>&#x00394; [<xref rid="B246-antibiotics-09-00812" ref-type="bibr">246</xref>,<xref rid="B247-antibiotics-09-00812" ref-type="bibr">247</xref>]) where fungal MAPK mutants showed tolerance to the benzoic ingredients, while the wild-type strains remain susceptible to the molecules (our unpublished observation; see <xref ref-type="fig" rid="antibiotics-09-00812-f002">Figure 2</xref>a for fungal bioassay and <xref ref-type="fig" rid="antibiotics-09-00812-f002">Figure 2</xref>b for the scheme). Collectively, studies proved the significance of &#x0201c;gene&#x02013;compound&#x0201d; interaction analysis during the preclinical stage of drug repurposing (regardless of the sources of the drugs or compounds whether synthetic, natural, crude extracts, or purified), thus circumventing the unfavorable downside of repurposed drugs.</p></sec></sec><sec id="sec5-antibiotics-09-00812"><title>5. Summary</title><p>Current antifungal intervention strategies often encounter limited efficiency in controlling fungal pathogens. Infections of the bloodstream or lungs by <italic>Candida</italic> species or the airborne <italic>Cryptococcus</italic>/<italic>Aspergillus</italic> species, respectively, that are resistant to conventional drugs cause serious health issues. Resistance to drugs develops via the repeated usage of antifungal agents over time (acquired resistance), while certain fungal species are intrinsically resistant to the conventional drugs (intrinsic resistance); examples of intrinsic resistance include azole resistance (<italic>C. glabrata</italic>, <italic>C. krusei</italic>, and <italic>C. auris</italic>), echinocandin resistance (<italic>Cryptococcus</italic> and <italic>Fusarium</italic> species), and polyene resistance (<italic>C. auris</italic> and <italic>A. terreus</italic>) [<xref rid="B248-antibiotics-09-00812" ref-type="bibr">248</xref>,<xref rid="B249-antibiotics-09-00812" ref-type="bibr">249</xref>].</p><p>Drug repurposing for fungal treatments is an alternative strategy for developing new antifungals. In this paper, two types of drug repurposing approaches were discussed, in silico/computational approaches and experimental approaches. While the majority of drug repurposing studies adopted experimental repurposing platforms, it is expected that the numbers of in silico/computational investigations will be increased in the future considering the increasing numbers of in silico data including omics, drug target, and chemical structural data. The preclinical validation of the efficacy of the repurposed drugs will require the testing of molecules in the model systems with the unbiased determination of breakpoints via the standard microdilution protocols developed by CLSI or EUCAST.</p><p>While repurposed drugs could be applied independently as novel antifungal agents for treating fungal pathogens, they can also function as effective synergists/adjuvants in formulations to conventional antifungal drugs such as FLU [<xref rid="B23-antibiotics-09-00812" ref-type="bibr">23</xref>]. In contrast to traditional combination therapy, co-application with a repurposed drug could avoid drug antagonism, multidrug interactions, and cytotoxicity. The One Health approach acknowledges that human, animal, and environmental health is closely linked [<xref rid="B250-antibiotics-09-00812" ref-type="bibr">250</xref>], for which drug repurposing could provide solutions to eliminate resistant fungi such as pan-azole-resistant <italic>Aspergillus</italic> species [<xref rid="B251-antibiotics-09-00812" ref-type="bibr">251</xref>].</p><p>In summary, drug repurposing could provide promising alternatives to current antifungal practices. Future inclusion of additional resources, in addition to the one described in this paper, such as the DrugCentral database [<xref rid="B252-antibiotics-09-00812" ref-type="bibr">252</xref>] and Aggregate Analysis of ClinicalTrials.gov (AACT) database [<xref rid="B253-antibiotics-09-00812" ref-type="bibr">253</xref>], would improve the antifungal drug repurposing processes that have the potential to benefit agriculture, food security, and animal and human health.</p></sec></body><back><ack><title>Acknowledgments</title><p>This research was conducted under USDA-ARS CRIS Project 5325-42000-039-00D. We thank Siov Sarreal and De Angela Ford, Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, USDA-ARS, for technical assistance.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-antibiotics-09-00812"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/2079-6382/9/11/812/s1">https://www.mdpi.com/2079-6382/9/11/812/s1</uri>, Table S1: Characteristics of repurposed drugs/compounds for control of fungal pathogens.</p><supplementary-material content-type="local-data" id="antibiotics-09-00812-s001"><media xlink:href="antibiotics-09-00812-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, J.H.K. and L.W.C.; methodology, J.H.K. and K.M.L.; formal analysis, J.H.K., C.C.T., M.M.S., and K.M.L.; investigation, J.H.K., K.M.L., and C.C.T.; resources, M.F. and N.M.; data curation, J.H.K. and K.L.C.; writing&#x02014;original draft preparation, J.H.K.; writing&#x02014;review and editing, J.H.K., C.C.T., K.L.C., M.M.S., M.F., N.M., K.M.L., and L.W.C.; visualization, K.L.C. and N.M.; supervision, L.W.C.; project administration, L.W.C. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-antibiotics-09-00812"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perfect</surname><given-names>J.R.</given-names></name></person-group><article-title>The antifungal pipeline: A reality check</article-title><source>Nat. Rev. Drug Discov.</source><year>2017</year><volume>16</volume><fpage>603</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.46</pub-id><?supplied-pmid 28496146?><pub-id pub-id-type="pmid">28496146</pub-id></element-citation></ref><ref id="B2-antibiotics-09-00812"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roemer</surname><given-names>T.</given-names></name><name><surname>Krysan</surname><given-names>D.J.</given-names></name></person-group><article-title>Antifungal drug development: Challenges, unmet clinical needs, and new approaches</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2014</year><volume>4</volume><pub-id pub-id-type="doi">10.1101/cshperspect.a019703</pub-id><?supplied-pmid 24789878?><pub-id pub-id-type="pmid">24789878</pub-id></element-citation></ref><ref id="B3-antibiotics-09-00812"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>M.W.</given-names></name><name><surname>Kontoyiannis</surname><given-names>D.P.</given-names></name><name><surname>Cornely</surname><given-names>O.A.</given-names></name><name><surname>Perfect</surname><given-names>J.R.</given-names></name><name><surname>Walsh</surname><given-names>T.J.</given-names></name></person-group><article-title>Novel agents and drug targets to meet the challenges of resistant Fungi</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>216</volume><fpage>S474</fpage><lpage>S483</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix130</pub-id><?supplied-pmid 28911042?><pub-id pub-id-type="pmid">28911042</pub-id></element-citation></ref><ref id="B4-antibiotics-09-00812"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>CDC</collab></person-group><source>Antibiotic Resistance Threats in the United States</source><publisher-name>U.S. Department of Health and Human Services, CDC</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2019</year><pub-id pub-id-type="doi">10.15620/cdc:82532</pub-id></element-citation></ref><ref id="B5-antibiotics-09-00812"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowyer</surname><given-names>P.</given-names></name><name><surname>Denning</surname><given-names>D.W.</given-names></name></person-group><article-title>Environmental fungicides and triazole resistance in <italic>Aspergillus</italic></article-title><source>Pest. Manag. Sci.</source><year>2014</year><volume>70</volume><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1002/ps.3567</pub-id><?supplied-pmid 23616354?><pub-id pub-id-type="pmid">23616354</pub-id></element-citation></ref><ref id="B6-antibiotics-09-00812"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nett</surname><given-names>J.E.</given-names></name><name><surname>Andes</surname><given-names>D.R.</given-names></name></person-group><article-title>Antifungal agents: Spectrum of activity, pharmacology, and clinical indications</article-title><source>Infect. Dis. Clin. N. Am.</source><year>2016</year><volume>30</volume><fpage>51</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2015.10.012</pub-id><?supplied-pmid 26739608?><pub-id pub-id-type="pmid">26739608</pub-id></element-citation></ref><ref id="B7-antibiotics-09-00812"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nami</surname><given-names>S.</given-names></name><name><surname>Aghebati-Maleki</surname><given-names>A.</given-names></name><name><surname>Morovati</surname><given-names>H.</given-names></name><name><surname>Aghebati-Maleki</surname><given-names>L.</given-names></name></person-group><article-title>Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases</article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>110</volume><fpage>857</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.12.009</pub-id><?supplied-pmid 30557835?><pub-id pub-id-type="pmid">30557835</pub-id></element-citation></ref><ref id="B8-antibiotics-09-00812"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou&#x00161;&#x00165;</surname><given-names>J.</given-names></name><name><surname>Sp&#x000ed;&#x0017e;ek</surname><given-names>J.</given-names></name><name><surname>Havl&#x000ed;&#x0010d;ek</surname><given-names>V.</given-names></name></person-group><article-title>Antifungal drugs</article-title><source>Metabolites</source><year>2020</year><volume>10</volume><elocation-id>106</elocation-id><pub-id pub-id-type="doi">10.3390/metabo10030106</pub-id></element-citation></ref><ref id="B9-antibiotics-09-00812"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marena</surname><given-names>G.D.</given-names></name><name><surname>Ramos</surname><given-names>M.A.D.S.</given-names></name><name><surname>Bauab</surname><given-names>T.M.</given-names></name><name><surname>Chorilli</surname><given-names>M.</given-names></name></person-group><article-title>A critical review of analytical methods for quantification of amphotericin B in biological samples and pharmaceutical formulations</article-title><source>Crit. Rev. Anal. Chem.</source><year>2020</year><pub-id pub-id-type="doi">10.1080/10408347.2020.1811947</pub-id></element-citation></ref><ref id="B10-antibiotics-09-00812"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamill</surname><given-names>R.J.</given-names></name></person-group><article-title>Amphotericin B formulations: A comparative review of efficacy and toxicity</article-title><source>Drugs</source><year>2013</year><volume>73</volume><fpage>919</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1007/s40265-013-0069-4</pub-id><pub-id pub-id-type="pmid">23729001</pub-id></element-citation></ref><ref id="B11-antibiotics-09-00812"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tillotson</surname><given-names>J.</given-names></name><name><surname>Tillotson</surname><given-names>G.S.</given-names></name></person-group><article-title>The regulatory pathway for antifungal drugs: A US perspective</article-title><source>Clin. Infect. Dis.</source><year>2015</year><volume>61</volume><fpage>S678</fpage><lpage>S683</lpage><pub-id pub-id-type="doi">10.1093/cid/civ819</pub-id><pub-id pub-id-type="pmid">26567287</pub-id></element-citation></ref><ref id="B12-antibiotics-09-00812"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>Y.</given-names></name><name><surname>Erez</surname><given-names>T.</given-names></name><name><surname>Reynolds</surname><given-names>I.J.</given-names></name><name><surname>Kumar</surname><given-names>D.</given-names></name><name><surname>Ross</surname><given-names>J.</given-names></name><name><surname>Koytiger</surname><given-names>G.</given-names></name><name><surname>Kusko</surname><given-names>R.</given-names></name><name><surname>Zeskind</surname><given-names>B.</given-names></name><name><surname>Risso</surname><given-names>S.</given-names></name><name><surname>Kagan</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Drug repurposing from the perspective of pharmaceutical companies</article-title><source>Br. J. Pharmacol.</source><year>2018</year><volume>175</volume><fpage>168</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1111/bph.13798</pub-id><?supplied-pmid 28369768?><pub-id pub-id-type="pmid">28369768</pub-id></element-citation></ref><ref id="B13-antibiotics-09-00812"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>J.J.</given-names></name><name><surname>Pryszlak</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>L.</given-names></name><name><surname>Yanchus</surname><given-names>C.</given-names></name><name><surname>Kurji</surname><given-names>N.</given-names></name><name><surname>Shahani</surname><given-names>V.M.</given-names></name><name><surname>Molinski</surname><given-names>S.V.</given-names></name></person-group><article-title>Giving drugs a second chance: Overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics</article-title><source>Front. Oncol.</source><year>2017</year><volume>7</volume><pub-id pub-id-type="doi">10.3389/fonc.2017.00273</pub-id><?supplied-pmid 29184849?><pub-id pub-id-type="pmid">29184849</pub-id></element-citation></ref><ref id="B14-antibiotics-09-00812"><label>14.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>National Center for Biotechnology Information</collab></person-group><article-title>PubMed</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed">https://www.ncbi.nlm.nih.gov/pubmed</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-14">(accessed on 14 August 2020)</date-in-citation></element-citation></ref><ref id="B15-antibiotics-09-00812"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Oliveira</surname><given-names>A.A.</given-names></name><name><surname>Neves</surname><given-names>B.J.</given-names></name><name><surname>Silva</surname><given-names>L.D.C.</given-names></name><name><surname>Soares</surname><given-names>C.M.D.A.</given-names></name><name><surname>Andrade</surname><given-names>C.H.</given-names></name><name><surname>Pereira</surname><given-names>M.</given-names></name></person-group><article-title>Drug repurposing for paracoccidioidomycosis through a computational chemogenomics framework</article-title><source>Front. Microbiol</source><year>2019</year><volume>10</volume><pub-id pub-id-type="doi">10.3389/fmicb.2019.01301</pub-id><?supplied-pmid 31244810?><pub-id pub-id-type="pmid">31244810</pub-id></element-citation></ref><ref id="B16-antibiotics-09-00812"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khedr</surname><given-names>M.A.</given-names></name><name><surname>Massarotti</surname><given-names>A.</given-names></name><name><surname>Mohamed</surname><given-names>M.E.</given-names></name></person-group><article-title>Rational discovery of (+) (S) abscisic acid as a potential antifungal agent: A repurposing approach</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>8565</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-26998-x</pub-id><pub-id pub-id-type="pmid">29867091</pub-id></element-citation></ref><ref id="B17-antibiotics-09-00812"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krajaejun</surname><given-names>T.</given-names></name><name><surname>Lohnoo</surname><given-names>T.</given-names></name><name><surname>Yingyong</surname><given-names>W.</given-names></name><name><surname>Rujirawat</surname><given-names>T.</given-names></name><name><surname>Kumsang</surname><given-names>Y.</given-names></name><name><surname>Jongkhajornpong</surname><given-names>P.</given-names></name><name><surname>Theerawatanasirikul</surname><given-names>S.</given-names></name><name><surname>Kittichotirat</surname><given-names>W.</given-names></name><name><surname>Reamtong</surname><given-names>O.</given-names></name><name><surname>Yolanda</surname><given-names>H.</given-names></name></person-group><article-title>The repurposed drug disulfiram inhibits urease and aldehyde dehydrogenase and prevents In Vitro growth of the oomycete <italic>Pythium insidiosum</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><fpage>e00609</fpage><lpage>e00619</lpage><pub-id pub-id-type="doi">10.1128/AAC.00609-19</pub-id><pub-id pub-id-type="pmid">31138572</pub-id></element-citation></ref><ref id="B18-antibiotics-09-00812"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rana</surname><given-names>R.</given-names></name><name><surname>Sharma</surname><given-names>R.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name></person-group><article-title>Repurposing of fluvastatin against <italic>Candida albicans</italic> CYP450 lanosterol 14 &#x003b1;-demethylase, a target enzyme for antifungal therapy: An In silico and In vitro study</article-title><source>Curr. Mol. Med.</source><year>2019</year><volume>19</volume><fpage>506</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.2174/1566524019666190520094644</pub-id><pub-id pub-id-type="pmid">31109273</pub-id></element-citation></ref><ref id="B19-antibiotics-09-00812"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavakkoli</surname><given-names>A.</given-names></name><name><surname>Johnston</surname><given-names>T.P.</given-names></name><name><surname>Sahebkar</surname><given-names>A.</given-names></name></person-group><article-title>Antifungal effects of statins</article-title><source>Pharmacol. Ther.</source><year>2020</year><volume>208</volume><fpage>107483</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107483</pub-id><pub-id pub-id-type="pmid">31953128</pub-id></element-citation></ref><ref id="B20-antibiotics-09-00812"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capoci</surname><given-names>I.R.G.</given-names></name><name><surname>Faria</surname><given-names>D.R.</given-names></name><name><surname>Sakita</surname><given-names>K.M.</given-names></name><name><surname>Rodrigues-Vendramini</surname><given-names>F.A.V.</given-names></name><name><surname>Bonfim-Mendon&#x000e7;a</surname><given-names>P.D.S.</given-names></name><name><surname>Becker</surname><given-names>T.C.A.</given-names></name><name><surname>Kioshima</surname><given-names>&#x000c9;.S.</given-names></name><name><surname>Svidzinski</surname><given-names>T.I.E.</given-names></name><name><surname>Maigret</surname><given-names>B.</given-names></name></person-group><article-title>Repurposing approach identifies new treatment options for invasive fungal disease</article-title><source>Bioorg. Chem.</source><year>2019</year><volume>84</volume><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2018.11.019</pub-id><pub-id pub-id-type="pmid">30496872</pub-id></element-citation></ref><ref id="B21-antibiotics-09-00812"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gowri</surname><given-names>M.</given-names></name><name><surname>Jayashree</surname><given-names>B.</given-names></name><name><surname>Jeyakanthan</surname><given-names>J.</given-names></name><name><surname>Girija</surname><given-names>E.K.</given-names></name></person-group><article-title>Sertraline as a promising antifungal agent: Inhibition of growth and biofilm of <italic>Candida auris</italic> with special focus on the mechanism of action in vitro</article-title><source>J. Appl. Microbiol.</source><year>2020</year><volume>128</volume><fpage>426</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1111/jam.14490</pub-id><pub-id pub-id-type="pmid">31621139</pub-id></element-citation></ref><ref id="B22-antibiotics-09-00812"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Singhal</surname><given-names>S.</given-names></name><name><surname>Mathur</surname><given-names>T.</given-names></name><name><surname>Upadhyay</surname><given-names>D.J.</given-names></name><name><surname>Rattan</surname><given-names>A.</given-names></name></person-group><article-title>Antifungal potential of disulfiram</article-title><source>Nippon Ishinkin Gakkai Zasshi</source><year>2007</year><volume>48</volume><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.3314/jjmm.48.109</pub-id></element-citation></ref><ref id="B23-antibiotics-09-00812"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spitzer</surname><given-names>M.</given-names></name><name><surname>Griffiths</surname><given-names>E.</given-names></name><name><surname>Blakely</surname><given-names>K.M.</given-names></name><name><surname>Wildenhain</surname><given-names>J.</given-names></name><name><surname>Ejim</surname><given-names>L.</given-names></name><name><surname>Rossi</surname><given-names>L.</given-names></name><name><surname>De Pascale</surname><given-names>G.</given-names></name><name><surname>Curak</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>E.</given-names></name><name><surname>Tyers</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole</article-title><source>Mol. Syst. Biol.</source><year>2011</year><volume>7</volume><fpage>499</fpage><pub-id pub-id-type="doi">10.1038/msb.2011.31</pub-id><?supplied-pmid 21694716?><pub-id pub-id-type="pmid">21694716</pub-id></element-citation></ref><ref id="B24-antibiotics-09-00812"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villanueva-Lozano</surname><given-names>H.</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>G.M.</given-names></name><name><surname>Espinosa-Mora</surname><given-names>J.E.</given-names></name><name><surname>Bodden-Mendoza</surname><given-names>B.A.</given-names></name><name><surname>Andrade</surname><given-names>A.</given-names></name><name><surname>Mart&#x000ed;nez-Res&#x000e9;ndez</surname><given-names>M.F.</given-names></name><name><surname>Trevi&#x000f1;o-Rangel</surname><given-names>R.d.J.</given-names></name></person-group><article-title>Evaluation of the expanding spectrum of sertraline against uncommon fungal pathogens</article-title><source>J. Infect. Chemother.</source><year>2020</year><volume>26</volume><fpage>309</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2019.10.001</pub-id><?supplied-pmid 31678053?><pub-id pub-id-type="pmid">31678053</pub-id></element-citation></ref><ref id="B25-antibiotics-09-00812"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>G.</given-names></name><name><surname>Chaturvedi</surname><given-names>A.K.</given-names></name><name><surname>Wormley</surname><given-names>F.L.</given-names></name><name><surname>Wiederhold</surname><given-names>N.P.</given-names></name><name><surname>Patterson</surname><given-names>H.P.</given-names></name><name><surname>Patterson</surname><given-names>T.F.</given-names></name><name><surname>Lopez-Ribot</surname><given-names>J.L.</given-names></name></person-group><article-title>Screening a repurposing library for inhibitors of multidrug-resistant <italic>Candida auris</italic> identifies ebselen as a repositionable candidate for antifungal drug development</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><fpage>e01084-18</fpage><pub-id pub-id-type="doi">10.1128/AAC.01084-18</pub-id><?supplied-pmid 30104269?><pub-id pub-id-type="pmid">30104269</pub-id></element-citation></ref><ref id="B26-antibiotics-09-00812"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venturini</surname><given-names>T.P.</given-names></name><name><surname>Chassot</surname><given-names>F.</given-names></name><name><surname>Loreto</surname><given-names>&#x000c9;.S.</given-names></name><name><surname>Keller</surname><given-names>J.T.</given-names></name><name><surname>Azevedo</surname><given-names>M.I.</given-names></name><name><surname>Zeni</surname><given-names>G.</given-names></name><name><surname>Santurio</surname><given-names>J.M.</given-names></name><name><surname>Alves</surname><given-names>S.H.</given-names></name></person-group><article-title>Antifungal activities of diphenyl diselenide and ebselen alone and in combination with antifungal agents against Fusarium spp.</article-title><source>Med. Mycol.</source><year>2016</year><volume>54</volume><fpage>550</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1093/mmy/myv120</pub-id><?supplied-pmid 26773133?><pub-id pub-id-type="pmid">26773133</pub-id></element-citation></ref><ref id="B27-antibiotics-09-00812"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giurg</surname><given-names>M.</given-names></name><name><surname>Go&#x00142;&#x00105;b</surname><given-names>A.</given-names></name><name><surname>Suchodolski</surname><given-names>J.</given-names></name><name><surname>Kaleta</surname><given-names>R.</given-names></name><name><surname>Krasowska</surname><given-names>A.</given-names></name><name><surname>Piasecki</surname><given-names>E.</given-names></name><name><surname>Pi&#x00119;tka-Ottlik</surname><given-names>M.</given-names></name></person-group><article-title>Reaction of bis[(2-chlorocarbonyl)phenyl] diselenide with phenols, aminophenols, and other amines towards diphenyl diselenides with antimicrobial and antiviral properties</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>974</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22060974</pub-id><?supplied-pmid 28604620?><pub-id pub-id-type="pmid">28604620</pub-id></element-citation></ref><ref id="B28-antibiotics-09-00812"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felli Kubi&#x000e7;a</surname><given-names>T.</given-names></name><name><surname>Bedin Denardi</surname><given-names>L.</given-names></name><name><surname>de Loreto</surname><given-names>&#x000c9;.S.</given-names></name><name><surname>Zeni</surname><given-names>G.</given-names></name><name><surname>Weiblen</surname><given-names>C.</given-names></name><name><surname>Oliveira</surname><given-names>V.</given-names></name><name><surname>Morais Santurio</surname><given-names>J.</given-names></name><name><surname>Hartz Alves</surname><given-names>S.</given-names></name></person-group><article-title>In vitro activity of diphenyl diselenide and ebselen alone and in combination with antifungal agents against <italic>Trichosporon. Asahii</italic></article-title><source>Mycoses</source><year>2019</year><volume>62</volume><fpage>428</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1111/myc.12906</pub-id><?supplied-pmid 30784136?><pub-id pub-id-type="pmid">30784136</pub-id></element-citation></ref><ref id="B29-antibiotics-09-00812"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>L.</given-names></name><name><surname>Liao</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name></person-group><article-title>In vitro antifungal activity of sertraline and synergistic effects in combination with antifungal drugs against planktonic forms and biofilms of clinical <italic>Trichosporon asahii</italic> isolates</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0167903</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0167903</pub-id><pub-id pub-id-type="pmid">27930704</pub-id></element-citation></ref><ref id="B30-antibiotics-09-00812"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Cremer</surname><given-names>K.</given-names></name><name><surname>Lanckacker</surname><given-names>E.</given-names></name><name><surname>Cools</surname><given-names>T.L.</given-names></name><name><surname>Bax</surname><given-names>M.</given-names></name><name><surname>De Brucker</surname><given-names>K.</given-names></name><name><surname>Cos</surname><given-names>P.</given-names></name><name><surname>Cammue</surname><given-names>B.P.A.</given-names></name><name><surname>Thevissen</surname><given-names>K.</given-names></name></person-group><article-title>Artemisinins, new miconazole potentiators resulting in increased activity against <italic>Candida albicans</italic> biofilms</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1128/AAC.04229-14</pub-id><pub-id pub-id-type="pmid">25367916</pub-id></element-citation></ref><ref id="B31-antibiotics-09-00812"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>C.</given-names></name><name><surname>Zeng</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name></person-group><article-title>Synergy between pyrvinium pamoate and azoles against <italic>Exophiala dermatitidis</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><fpage>e02361-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.02361-17</pub-id><pub-id pub-id-type="pmid">29437619</pub-id></element-citation></ref><ref id="B32-antibiotics-09-00812"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holbrook</surname><given-names>S.Y.L.</given-names></name><name><surname>Garzan</surname><given-names>A.</given-names></name><name><surname>Dennis</surname><given-names>E.K.</given-names></name><name><surname>Shrestha</surname><given-names>S.K.</given-names></name><name><surname>Garneau-Tsodikova</surname><given-names>S.</given-names></name></person-group><article-title>Repurposing antipsychotic drugs into antifungal agents: Synergistic combinations of azoles and bromperidol derivatives in the treatment of various fungal infections</article-title><source>Eur. J. Med. Chem.</source><year>2017</year><volume>139</volume><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.07.030</pub-id><pub-id pub-id-type="pmid">28797882</pub-id></element-citation></ref><ref id="B33-antibiotics-09-00812"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simm</surname><given-names>C.</given-names></name><name><surname>May</surname><given-names>R.C.</given-names></name></person-group><article-title>Zinc and iron homeostasis: Target-based drug screening as new route for antifungal drug development</article-title><source>Front. Cell Infect. Microbiol.</source><year>2019</year><volume>9</volume><pub-id pub-id-type="doi">10.3389/fcimb.2019.00181</pub-id><?supplied-pmid 31192169?><pub-id pub-id-type="pmid">31192169</pub-id></element-citation></ref><ref id="B34-antibiotics-09-00812"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>Q.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>In vitro and in vivo effects of suloctidil on growth and biofilm formation of the opportunistic fungus <italic>Candida albicans</italic></article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>69972</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.19542</pub-id><?supplied-pmid 29050256?><pub-id pub-id-type="pmid">29050256</pub-id></element-citation></ref><ref id="B35-antibiotics-09-00812"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousfi</surname><given-names>H.</given-names></name><name><surname>Ranque</surname><given-names>S.</given-names></name><name><surname>Rolain</surname><given-names>J.-M.</given-names></name><name><surname>Bittar</surname><given-names>F.</given-names></name></person-group><article-title>In vitro polymyxin activity against clinical multidrug-resistant fungi</article-title><source>Antimicrob. Resist. Infect. Control</source><year>2019</year><volume>8</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.1186/s13756-019-0521-7</pub-id><?supplied-pmid 31044071?><pub-id pub-id-type="pmid">31044071</pub-id></element-citation></ref><ref id="B36-antibiotics-09-00812"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voget</surname><given-names>M.</given-names></name><name><surname>Lorenz</surname><given-names>D.</given-names></name><name><surname>Lieber-Tenorio</surname><given-names>E.</given-names></name><name><surname>Hauck</surname><given-names>R.</given-names></name><name><surname>Meyer</surname><given-names>M.</given-names></name><name><surname>Cieslicki</surname><given-names>M.</given-names></name></person-group><article-title>Is transmission electron microscopy (TEM) a promising approach for qualitative and quantitative investigations of polymyxin B and miconazole interactions with cellular and subcellular structures of <italic>Staphylococcus pseudintermedius</italic>, <italic>Escherichia coli</italic>, <italic>Pseudomonas aeruginosa</italic> and <italic>Malassezia pachydermatis</italic>?</article-title><source>Vet. Microbiol.</source><year>2015</year><volume>181</volume><fpage>261</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2015.10.002</pub-id><?supplied-pmid 26527257?><pub-id pub-id-type="pmid">26527257</pub-id></element-citation></ref><ref id="B37-antibiotics-09-00812"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schemuth</surname><given-names>H.</given-names></name><name><surname>Dittmer</surname><given-names>S.</given-names></name><name><surname>Lackner</surname><given-names>M.</given-names></name><name><surname>Sedlacek</surname><given-names>L.</given-names></name><name><surname>Hamprecht</surname><given-names>A.</given-names></name><name><surname>Steinmann</surname><given-names>E.</given-names></name><name><surname>Buer</surname><given-names>J.</given-names></name><name><surname>Rath</surname><given-names>P.-M.</given-names></name><name><surname>Steinmann</surname><given-names>J.</given-names></name></person-group><article-title>In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis</article-title><source>Mycoses</source><year>2013</year><volume>56</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1111/myc.12022</pub-id><?supplied-pmid 23170818?><pub-id pub-id-type="pmid">23170818</pub-id></element-citation></ref><ref id="B38-antibiotics-09-00812"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mashaly</surname><given-names>G.</given-names></name><name><surname>Shrief</surname><given-names>R.</given-names></name></person-group><article-title><italic>Candida glabrata</italic> complex from patients with healthcare-associated infections in Mansoura University Hospitals, Egypt: Distribution, antifungal susceptibility and effect of fluconazole and polymyxin B combination</article-title><source>Germs</source><year>2019</year><volume>9</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.18683/germs.2019.1167</pub-id><?supplied-pmid 31646142?><pub-id pub-id-type="pmid">31646142</pub-id></element-citation></ref><ref id="B39-antibiotics-09-00812"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Ren</surname><given-names>B.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name><name><surname>Dai</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Synergistic combinations of antifungals and anti-virulence agents to fight against <italic>Candida albicans</italic></article-title><source>Virulence</source><year>2015</year><volume>6</volume><fpage>362</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1080/21505594.2015.1039885</pub-id><pub-id pub-id-type="pmid">26048362</pub-id></element-citation></ref><ref id="B40-antibiotics-09-00812"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhoff&#x02009;</surname><given-names>L.</given-names></name><name><surname>Olsowski</surname><given-names>M.</given-names></name><name><surname>Zilmans</surname><given-names>K.</given-names></name><name><surname>Dittmer</surname><given-names>S.</given-names></name><name><surname>Haase</surname><given-names>G.</given-names></name><name><surname>Sedlacek</surname><given-names>L.</given-names></name><name><surname>Steinmann</surname><given-names>E.</given-names></name><name><surname>Buer</surname><given-names>J.</given-names></name><name><surname>Rath</surname><given-names>P.-M.</given-names></name><name><surname>Steinmann</surname><given-names>J.</given-names></name></person-group><article-title>Biofilm formation of the black yeast-like fungus <italic>Exophiala dermatitidis</italic> and its susceptibility to antiinfective agents</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>42886</fpage><pub-id pub-id-type="doi">10.1038/srep42886</pub-id><pub-id pub-id-type="pmid">28211475</pub-id></element-citation></ref><ref id="B41-antibiotics-09-00812"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>L.-H.</given-names></name><name><surname>Wang</surname><given-names>H.-F.</given-names></name><name><surname>Sun</surname><given-names>P.-L.</given-names></name><name><surname>Hu</surname><given-names>F.-R.</given-names></name><name><surname>Chen</surname><given-names>Y.-L.</given-names></name></person-group><article-title>The antibiotic polymyxin B exhibits novel antifungal activity against <italic>Fusarium</italic> species</article-title><source>Int. J. Antimicrob. Agents</source><year>2017</year><volume>49</volume><fpage>740</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.01.029</pub-id><pub-id pub-id-type="pmid">28433743</pub-id></element-citation></ref><ref id="B42-antibiotics-09-00812"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borjihan</surname><given-names>B.</given-names></name><name><surname>Ogita</surname><given-names>A.</given-names></name><name><surname>Fujita</surname><given-names>K.-i.</given-names></name><name><surname>Doe</surname><given-names>M.</given-names></name><name><surname>Tanaka</surname><given-names>T.</given-names></name></person-group><article-title>The cyclic organosulfur compound zwiebelane a from onion (<italic>Allium cepa</italic>) functions as an enhancer of polymyxin b in fungal vacuole disruption</article-title><source>Planta Med.</source><year>2010</year><volume>76</volume><fpage>1864</fpage><lpage>1866</lpage><pub-id pub-id-type="doi">10.1055/s-0030-1249935</pub-id><pub-id pub-id-type="pmid">20486078</pub-id></element-citation></ref><ref id="B43-antibiotics-09-00812"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blooi</surname><given-names>M.</given-names></name><name><surname>Pasmans</surname><given-names>F.</given-names></name><name><surname>Rouffaer</surname><given-names>L.</given-names></name><name><surname>Haesebrouck</surname><given-names>F.</given-names></name><name><surname>Vercammen</surname><given-names>F.</given-names></name><name><surname>Martel</surname><given-names>A.</given-names></name></person-group><article-title>Successful treatment of <italic>Batrachochytrium salamandrivorans</italic> infections in salamanders requires synergy between voriconazole, polymyxin E and temperature</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>11788</fpage><pub-id pub-id-type="doi">10.1038/srep11788</pub-id><?supplied-pmid 26123899?><pub-id pub-id-type="pmid">26123899</pub-id></element-citation></ref><ref id="B44-antibiotics-09-00812"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bidaud</surname><given-names>A.L.</given-names></name><name><surname>Djenontin</surname><given-names>E.</given-names></name><name><surname>Botterel</surname><given-names>F.</given-names></name><name><surname>Chowdhary</surname><given-names>A.</given-names></name><name><surname>Dannaoui</surname><given-names>E.</given-names></name></person-group><article-title>Colistin interacts synergistically with echinocandins against <italic>Candida auris</italic></article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><volume>55</volume><fpage>105901</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105901</pub-id><?supplied-pmid 31954831?><pub-id pub-id-type="pmid">31954831</pub-id></element-citation></ref><ref id="B45-antibiotics-09-00812"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Alterovitz</surname><given-names>G.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Ren</surname><given-names>B.</given-names></name></person-group><article-title>Lovastatin synergizes with itraconazole against planktonic cells and biofilms of <italic>Candida albicans</italic> through the regulation on ergosterol biosynthesis pathway</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>5255</fpage><lpage>5264</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-8959-8</pub-id><?supplied-pmid 29691631?><pub-id pub-id-type="pmid">29691631</pub-id></element-citation></ref><ref id="B46-antibiotics-09-00812"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>Y.</given-names></name><name><surname>Jaiseng</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Furuyashiki</surname><given-names>T.</given-names></name></person-group><article-title>Characterization of tamoxifen as an antifungal agent using the yeast schizosaccharomyces pombe model organism</article-title><source>Kobe J. Med. Sci.</source><year>2015</year><volume>61</volume><fpage>E54</fpage><lpage>E63</lpage><?supplied-pmid 26628015?><pub-id pub-id-type="pmid">26628015</pub-id></element-citation></ref><ref id="B47-antibiotics-09-00812"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthular</surname><given-names>M.</given-names></name><name><surname>B&#x000e1;lsamo</surname><given-names>F.</given-names></name><name><surname>Passero</surname><given-names>P.</given-names></name><name><surname>Jewtuchowicz</surname><given-names>V.</given-names></name><name><surname>Miozza</surname><given-names>V.</given-names></name><name><surname>Villalba</surname><given-names>M.B.</given-names></name><name><surname>Brusca</surname><given-names>M.I.</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>C.</given-names></name></person-group><article-title>Effects of tamoxifen on periodontal disease and <italic>Candida albicans</italic> of patients with breast cancer and other pathologies</article-title><source>Future Microbiol.</source><year>2019</year><volume>14</volume><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.2217/fmb-2018-0272</pub-id><?supplied-pmid 30672328?><pub-id pub-id-type="pmid">30672328</pub-id></element-citation></ref><ref id="B48-antibiotics-09-00812"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hai</surname><given-names>T.P.</given-names></name><name><surname>Van</surname><given-names>A.D.</given-names></name><name><surname>Ngan</surname><given-names>N.T.T.</given-names></name><name><surname>Nhat</surname><given-names>L.T.H.</given-names></name><name><surname>Lan</surname><given-names>N.P.H.</given-names></name><name><surname>Chau</surname><given-names>N.V.V.</given-names></name><name><surname>Thwaites</surname><given-names>G.E.</given-names></name><name><surname>Krysan</surname><given-names>D.</given-names></name><name><surname>Day</surname><given-names>J.N.</given-names></name></person-group><article-title>The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of <italic>Cryptococcus neoformans</italic></article-title><source>Mycoses</source><year>2019</year><volume>62</volume><fpage>818</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1111/myc.12955</pub-id><pub-id pub-id-type="pmid">31173410</pub-id></element-citation></ref><ref id="B49-antibiotics-09-00812"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butts</surname><given-names>A.</given-names></name><name><surname>Koselny</surname><given-names>K.</given-names></name><name><surname>Chabrier-Rosell&#x000f3;</surname><given-names>Y.</given-names></name><name><surname>Semighini</surname><given-names>C.P.</given-names></name><name><surname>Brown</surname><given-names>J.C.S.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Annadurai</surname><given-names>S.</given-names></name><name><surname>DiDone</surname><given-names>L.</given-names></name><name><surname>Tabroff</surname><given-names>J.</given-names></name><name><surname>Childers</surname><given-names>W.E.</given-names></name><etal/></person-group><article-title>Estrogen receptor antagonists are anti-cryptococcal agents that directly bind ef hand proteins and synergize with fluconazole In Vivo</article-title><source>mBio</source><year>2014</year><volume>5</volume><fpage>e00765-13</fpage><pub-id pub-id-type="doi">10.1128/mBio.00765-13</pub-id><pub-id pub-id-type="pmid">24520056</pub-id></element-citation></ref><ref id="B50-antibiotics-09-00812"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naeimi Eshkaleti</surname><given-names>M.</given-names></name><name><surname>Kordbacheh</surname><given-names>P.</given-names></name><name><surname>Hashemi</surname><given-names>S.J.</given-names></name><name><surname>Falahati</surname><given-names>M.</given-names></name><name><surname>Zaini</surname><given-names>F.</given-names></name><name><surname>Mirhendi</surname><given-names>H.</given-names></name><name><surname>Safara</surname><given-names>M.</given-names></name><name><surname>Hosseinpoor</surname><given-names>L.</given-names></name></person-group><article-title>In vitro activity of amphotericin B in combination with statins against clinical and environmental <italic>Rhizopus oryzae</italic> strains</article-title><source>Iran. J. Public Health</source><year>2019</year><volume>48</volume><fpage>943</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.18502/ijph.v48i5.1812</pub-id><pub-id pub-id-type="pmid">31523652</pub-id></element-citation></ref><ref id="B51-antibiotics-09-00812"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyilasi</surname><given-names>I.</given-names></name><name><surname>Kocsub&#x000e9;</surname><given-names>S.</given-names></name><name><surname>Krizs&#x000e1;n</surname><given-names>K.</given-names></name><name><surname>Galg&#x000f3;czy</surname><given-names>L.</given-names></name><name><surname>Papp</surname><given-names>T.</given-names></name><name><surname>Pesti</surname><given-names>M.</given-names></name><name><surname>Nagy</surname><given-names>K.</given-names></name><name><surname>V&#x000e1;gv&#x000f6;lgyi</surname><given-names>C.</given-names></name></person-group><article-title>Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations</article-title><source>Med. Mycol.</source><year>2013</year><volume>52</volume><fpage>140</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.3109/13693786.2013.828160</pub-id></element-citation></ref><ref id="B52-antibiotics-09-00812"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyilasi</surname><given-names>I.</given-names></name><name><surname>Kocsub&#x000e9;</surname><given-names>S.</given-names></name><name><surname>Krizs&#x000e1;n</surname><given-names>K.</given-names></name><name><surname>Galg&#x000f3;czy</surname><given-names>L.</given-names></name><name><surname>Pesti</surname><given-names>M.</given-names></name><name><surname>Papp</surname><given-names>T.</given-names></name><name><surname>V&#x000e1;gv&#x000f6;lgyi</surname><given-names>C.</given-names></name></person-group><article-title>In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi</article-title><source>FEMS Microbiol. Lett.</source><year>2010</year><volume>307</volume><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2010.01972.x</pub-id><pub-id pub-id-type="pmid">20636975</pub-id></element-citation></ref><ref id="B53-antibiotics-09-00812"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>J.</given-names></name><name><surname>Kontoyiannis</surname><given-names>D.P.</given-names></name><name><surname>Wan</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name></person-group><article-title>Antifungal activity of statins against <italic>Aspergillus</italic> species</article-title><source>Med. Mycol.</source><year>2007</year><volume>45</volume><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1080/13693780701397673</pub-id><?supplied-pmid 18033614?><pub-id pub-id-type="pmid">18033614</pub-id></element-citation></ref><ref id="B54-antibiotics-09-00812"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roze</surname><given-names>L.V.</given-names></name><name><surname>Linz</surname><given-names>J.E.</given-names></name></person-group><article-title>Lovastatin triggers an apoptosis-like cell death process in the fungus <italic>Mucor. Racemosus</italic></article-title><source>Fungal. Genet. Biol.</source><year>1998</year><volume>25</volume><fpage>119</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1006/fgbi.1998.1093</pub-id><?supplied-pmid 9974223?><pub-id pub-id-type="pmid">9974223</pub-id></element-citation></ref><ref id="B55-antibiotics-09-00812"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabral</surname><given-names>M.E.</given-names></name><name><surname>Figueroa</surname><given-names>L.I.C.</given-names></name><name><surname>Fari&#x000f1;a</surname><given-names>J.I.</given-names></name></person-group><article-title>Synergistic antifungal activity of statin&#x02013;azole associations as witnessed by <italic>Saccharomyces cerevisiae</italic>- and <italic>Candida utilis</italic>-bioassays and ergosterol quantification</article-title><source>Rev. Iberoam. Micol.</source><year>2013</year><volume>30</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.riam.2012.09.006</pub-id><?supplied-pmid 23069981?><pub-id pub-id-type="pmid">23069981</pub-id></element-citation></ref><ref id="B56-antibiotics-09-00812"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamilos</surname><given-names>G.</given-names></name><name><surname>Lewis</surname><given-names>R.E.</given-names></name><name><surname>Kontoyiannis</surname><given-names>D.P.</given-names></name></person-group><article-title>Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole</article-title><source>Antimicrob. Agents Chemother.</source><year>2006</year><volume>50</volume><fpage>96</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1128/AAC.50.1.96-103.2006</pub-id><?supplied-pmid 16377673?><pub-id pub-id-type="pmid">16377673</pub-id></element-citation></ref><ref id="B57-antibiotics-09-00812"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galg&#x000f3;czy</surname><given-names>L.</given-names></name><name><surname>Papp</surname><given-names>T.</given-names></name><name><surname>Kov&#x000e1;cs</surname><given-names>L.</given-names></name><name><surname>&#x000d6;rd&#x000f6;gh</surname><given-names>L.</given-names></name><name><surname>V&#x000e1;gv&#x000f6;lgyi</surname><given-names>C.</given-names></name></person-group><article-title>In vitro activity of phenothiazines and their combinations with amphotericin B against Zygomycetes causing rhinocerebral zygomycosis</article-title><source>Med. Mycol.</source><year>2009</year><volume>47</volume><fpage>331</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1080/13693780802378853</pub-id><pub-id pub-id-type="pmid">18798117</pub-id></element-citation></ref><ref id="B58-antibiotics-09-00812"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>R.T.</given-names></name><name><surname>Parks</surname><given-names>L.W.</given-names></name></person-group><article-title>Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in <italic>Saccharomyces cerevisiae</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1990</year><volume>34</volume><fpage>1660</fpage><lpage>1665</lpage><pub-id pub-id-type="doi">10.1128/AAC.34.9.1660</pub-id><pub-id pub-id-type="pmid">2285278</pub-id></element-citation></ref><ref id="B59-antibiotics-09-00812"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macreadie</surname><given-names>I.G.</given-names></name><name><surname>Johnson</surname><given-names>G.</given-names></name><name><surname>Schlosser</surname><given-names>T.</given-names></name><name><surname>Macreadie</surname><given-names>P.I.</given-names></name></person-group><article-title>Growth inhibition of <italic>Candida</italic> species and <italic>Aspergillus fumigatus</italic> by statins</article-title><source>FEMS Microbiol. Lett.</source><year>2006</year><volume>262</volume><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2006.00370.x</pub-id><pub-id pub-id-type="pmid">16907733</pub-id></element-citation></ref><ref id="B60-antibiotics-09-00812"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alem</surname><given-names>M.A.S.</given-names></name><name><surname>Douglas</surname><given-names>L.J.</given-names></name></person-group><article-title>Effects of aspirin and other nonsteroidal anti-inflammatory drugs on biofilms and planktonic cells of <italic>Candida albicans</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2004</year><volume>48</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.1.41-47.2004</pub-id><pub-id pub-id-type="pmid">14693516</pub-id></element-citation></ref><ref id="B61-antibiotics-09-00812"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leeuw</surname><given-names>N.J.</given-names></name><name><surname>Swartt</surname><given-names>C.W.</given-names></name><name><surname>Ncango</surname><given-names>D.M.</given-names></name><name><surname>Kriell</surname><given-names>W.M.</given-names></name><name><surname>Pohl</surname><given-names>C.H.</given-names></name><name><surname>van Wyk</surname><given-names>P.W.J.</given-names></name><name><surname>Kock</surname><given-names>J.L.F.</given-names></name></person-group><article-title>Anti-inflammatory drugs selectively target sporangium development in Mucor</article-title><source>Can. J. Microbiol.</source><year>2009</year><volume>55</volume><fpage>1392</fpage><lpage>1396</lpage><pub-id pub-id-type="doi">10.1139/W09-096</pub-id><pub-id pub-id-type="pmid">20029531</pub-id></element-citation></ref><ref id="B62-antibiotics-09-00812"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Liao</surname><given-names>Y.</given-names></name><name><surname>Cong</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name></person-group><article-title>In Vitro interactions between non-steroidal anti-inflammatory drugs and antifungal agents against planktonic and biofilm forms of <italic>Trichosporon asahii</italic></article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0157047</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0157047</pub-id><pub-id pub-id-type="pmid">27275608</pub-id></element-citation></ref><ref id="B63-antibiotics-09-00812"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogundeji</surname><given-names>A.O.</given-names></name><name><surname>Pohl</surname><given-names>C.H.</given-names></name><name><surname>Sebolai</surname><given-names>O.M.</given-names></name></person-group><article-title>Repurposing of aspirin and ibuprofen as candidate anti-<italic>Cryptococcus</italic> drugs</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>4799</fpage><lpage>4808</lpage><pub-id pub-id-type="doi">10.1128/AAC.02810-15</pub-id><?supplied-pmid 27246782?><pub-id pub-id-type="pmid">27246782</pub-id></element-citation></ref><ref id="B64-antibiotics-09-00812"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosato</surname><given-names>A.</given-names></name><name><surname>Catalano</surname><given-names>A.</given-names></name><name><surname>Carocci</surname><given-names>A.</given-names></name><name><surname>Carrieri</surname><given-names>A.</given-names></name><name><surname>Carone</surname><given-names>A.</given-names></name><name><surname>Caggiano</surname><given-names>G.</given-names></name><name><surname>Franchini</surname><given-names>C.</given-names></name><name><surname>Corbo</surname><given-names>F.</given-names></name><name><surname>Montagna</surname><given-names>M.T.</given-names></name></person-group><article-title>In vitro interactions between anidulafungin and nonsteroidal anti-inflammatory drugs on biofilms of <italic>Candida</italic> spp.</article-title><source>Bioorg. Med. Chem.</source><year>2016</year><volume>24</volume><fpage>1002</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2016.01.026</pub-id><?supplied-pmid 26833243?><pub-id pub-id-type="pmid">26833243</pub-id></element-citation></ref><ref id="B65-antibiotics-09-00812"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasmin</surname><given-names>S.</given-names></name><name><surname>Alcazar-Fuoli</surname><given-names>L.</given-names></name><name><surname>Gr&#x000fc;ndlinger</surname><given-names>M.</given-names></name><name><surname>Puempel</surname><given-names>T.</given-names></name><name><surname>Cairns</surname><given-names>T.</given-names></name><name><surname>Blatzer</surname><given-names>M.</given-names></name><name><surname>Lopez</surname><given-names>J.F.</given-names></name><name><surname>Grimalt</surname><given-names>J.O.</given-names></name><name><surname>Bignell</surname><given-names>E.</given-names></name><name><surname>Haas</surname><given-names>H.</given-names></name></person-group><article-title>Mevalonate governs interdependency of ergosterol and siderophore biosyntheses in the fungal pathogen <italic>Aspergillus fumigatus</italic></article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>E497</fpage><lpage>E504</lpage><pub-id pub-id-type="doi">10.1073/pnas.1106399108</pub-id><?supplied-pmid 22106303?><pub-id pub-id-type="pmid">22106303</pub-id></element-citation></ref><ref id="B66-antibiotics-09-00812"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>S.A.</given-names></name><name><surname>de Oliveira</surname><given-names>H.C.</given-names></name><name><surname>Agreda-Mellon</surname><given-names>D.</given-names></name><name><surname>Lucio</surname><given-names>J.</given-names></name><name><surname>Mendes-Giannini</surname><given-names>M.J.S.</given-names></name><name><surname>Garc&#x000ed;a-Cambero</surname><given-names>J.P.</given-names></name><name><surname>Zaragoza</surname><given-names>O.</given-names></name></person-group><article-title>Identification of off-patent drugs that show synergism with amphotericin B or that present antifungal action against <italic>Cryptococcus neoformans</italic> and <italic>Candida</italic> spp.</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e01921-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.01921-19</pub-id><pub-id pub-id-type="pmid">31988099</pub-id></element-citation></ref><ref id="B67-antibiotics-09-00812"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kr&#x000f3;l</surname><given-names>J.</given-names></name><name><surname>Nawrot</surname><given-names>U.</given-names></name><name><surname>Bartoszewicz</surname><given-names>M.</given-names></name></person-group><article-title>Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole</article-title><source>J. Mycol. Med.</source><year>2018</year><volume>28</volume><fpage>327</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.mycmed.2018.03.002</pub-id><pub-id pub-id-type="pmid">29605543</pub-id></element-citation></ref><ref id="B68-antibiotics-09-00812"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delattin</surname><given-names>N.</given-names></name><name><surname>De Brucker</surname><given-names>K.</given-names></name><name><surname>Vandamme</surname><given-names>K.</given-names></name><name><surname>Meert</surname><given-names>E.</given-names></name><name><surname>Marchand</surname><given-names>A.</given-names></name><name><surname>Chaltin</surname><given-names>P.</given-names></name><name><surname>Cammue</surname><given-names>B.P.A.</given-names></name><name><surname>Thevissen</surname><given-names>K.</given-names></name></person-group><article-title>Repurposing as a means to increase the activity of amphotericin B and caspofungin against <italic>Candida albicans</italic> biofilms</article-title><source>J. Antimicrob. Chemother.</source><year>2013</year><volume>69</volume><fpage>1035</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1093/jac/dkt449</pub-id><pub-id pub-id-type="pmid">24284780</pub-id></element-citation></ref><ref id="B69-antibiotics-09-00812"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Janabi</surname><given-names>A.A.H.S.</given-names></name></person-group><article-title>Determination of antidermatophytic effects of non-steroidal anti-inflammatory drugs on <italic>Trichophyton mentagrophytes</italic> and <italic>Epidermophyton floccosum</italic></article-title><source>Mycoses</source><year>2011</year><volume>54</volume><fpage>e443</fpage><lpage>e448</lpage><pub-id pub-id-type="doi">10.1111/j.1439-0507.2010.01945.x</pub-id><pub-id pub-id-type="pmid">21535450</pub-id></element-citation></ref><ref id="B70-antibiotics-09-00812"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Bakri</surname><given-names>A.G.</given-names></name><name><surname>Othman</surname><given-names>G.</given-names></name><name><surname>Bustanji</surname><given-names>Y.</given-names></name></person-group><article-title>The assessment of the antibacterial and antifungal activities of aspirin, EDTA and aspirin-EDTA combination and their effectiveness as antibiofilm agents</article-title><source>J. Appl. Microbiol.</source><year>2009</year><volume>107</volume><fpage>280</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.2009.04205.x</pub-id><pub-id pub-id-type="pmid">19302313</pub-id></element-citation></ref><ref id="B71-antibiotics-09-00812"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roohparvar</surname><given-names>R.</given-names></name><name><surname>Huser</surname><given-names>A.</given-names></name><name><surname>Zwiers</surname><given-names>L.-H.</given-names></name><name><surname>De Waard</surname><given-names>M.A.</given-names></name></person-group><article-title>Control of <italic>Mycosphaerella graminicola</italic> on wheat seedlings by medical drugs known to modulate the activity of ATP-binding cassette transporters</article-title><source>Appl. Environ. Microbiol.</source><year>2007</year><volume>73</volume><fpage>5011</fpage><lpage>5019</lpage><pub-id pub-id-type="doi">10.1128/AEM.00285-07</pub-id><pub-id pub-id-type="pmid">17545327</pub-id></element-citation></ref><ref id="B72-antibiotics-09-00812"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loreto</surname><given-names>E.S.</given-names></name><name><surname>Tondolo</surname><given-names>J.S.M.</given-names></name><name><surname>Santurio</surname><given-names>J.M.</given-names></name><name><surname>Alves</surname><given-names>S.H.</given-names></name></person-group><article-title>Screening of antibacterial drugs for antimicrobial activity against <italic>Pythium insidiosum</italic></article-title><source>Med. Mycol.</source><year>2018</year><volume>57</volume><fpage>523</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1093/mmy/myy056</pub-id></element-citation></ref><ref id="B73-antibiotics-09-00812"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>H.-T.</given-names></name><name><surname>Hsu</surname><given-names>L.-H.</given-names></name><name><surname>Yang</surname><given-names>S.-Y.</given-names></name><name><surname>Chen</surname><given-names>Y.-L.</given-names></name></person-group><article-title>Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent</article-title><source>Med. Mycol.</source><year>2019</year><volume>58</volume><fpage>493</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1093/mmy/myz077</pub-id><?supplied-pmid 31297540?><pub-id pub-id-type="pmid">31297540</pub-id></element-citation></ref><ref id="B74-antibiotics-09-00812"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caldara</surname><given-names>M.</given-names></name><name><surname>Marmiroli</surname><given-names>N.</given-names></name></person-group><article-title>Tricyclic antidepressants inhibit <italic>Candida albicans</italic> growth and biofilm formation</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>52</volume><fpage>500</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.06.023</pub-id><?supplied-pmid 29990546?><pub-id pub-id-type="pmid">29990546</pub-id></element-citation></ref><ref id="B75-antibiotics-09-00812"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butts</surname><given-names>A.</given-names></name><name><surname>DiDone</surname><given-names>L.</given-names></name><name><surname>Koselny</surname><given-names>K.</given-names></name><name><surname>Baxter</surname><given-names>B.K.</given-names></name><name><surname>Chabrier-Rosello</surname><given-names>Y.</given-names></name><name><surname>Wellington</surname><given-names>M.</given-names></name><name><surname>Krysan</surname><given-names>D.J.</given-names></name></person-group><article-title>A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis</article-title><source>Eukaryot. Cell</source><year>2013</year><volume>12</volume><fpage>278</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1128/EC.00314-12</pub-id><?supplied-pmid 23243064?><pub-id pub-id-type="pmid">23243064</pub-id></element-citation></ref><ref id="B76-antibiotics-09-00812"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagar</surname><given-names>T.</given-names></name><name><surname>Ben&#x0010d;ina</surname><given-names>M.</given-names></name></person-group><article-title>Antiarrhythmic drug amiodarone displays antifungal activity, induces irregular calcium response and intracellular acidification of <italic>Aspergillus niger</italic>&#x02014;Amiodarone targets calcium and pH homeostasis of <italic>A. niger</italic></article-title><source>Fungal. Genet. Biol.</source><year>2012</year><volume>49</volume><fpage>779</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/j.fgb.2012.07.007</pub-id><?supplied-pmid 22906851?><pub-id pub-id-type="pmid">22906851</pub-id></element-citation></ref><ref id="B77-antibiotics-09-00812"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eldesouky</surname><given-names>H.E.</given-names></name><name><surname>Salama</surname><given-names>E.A.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Hazbun</surname><given-names>T.R.</given-names></name><name><surname>Mayhoub</surname><given-names>A.S.</given-names></name><name><surname>Seleem</surname><given-names>M.N.</given-names></name></person-group><article-title>Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant <italic>Candida</italic> species</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>7525</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-64571-7</pub-id><pub-id pub-id-type="pmid">32372011</pub-id></element-citation></ref><ref id="B78-antibiotics-09-00812"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Tu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Han</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Sheng</surname><given-names>C.</given-names></name></person-group><article-title>Drug repurposing of haloperidol: Discovery of new benzocyclane derivatives as potent antifungal agents against cryptococcosis and candidiasis</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>768</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00197</pub-id><pub-id pub-id-type="pmid">31550886</pub-id></element-citation></ref><ref id="B79-antibiotics-09-00812"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stylianou</surname><given-names>M.</given-names></name><name><surname>Kulesskiy</surname><given-names>E.</given-names></name><name><surname>Lopes</surname><given-names>J.P.</given-names></name><name><surname>Granlund</surname><given-names>M.</given-names></name><name><surname>Wennerberg</surname><given-names>K.</given-names></name><name><surname>Urban</surname><given-names>C.F.</given-names></name></person-group><article-title>Antifungal application of nonantifungal drugs</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>1055</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1128/AAC.01087-13</pub-id><pub-id pub-id-type="pmid">24277040</pub-id></element-citation></ref><ref id="B80-antibiotics-09-00812"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venturini</surname><given-names>T.P.</given-names></name><name><surname>Al-Hatmi</surname><given-names>A.M.S.</given-names></name><name><surname>Rossato</surname><given-names>L.</given-names></name><name><surname>Azevedo</surname><given-names>M.I.</given-names></name><name><surname>Keller</surname><given-names>J.T.</given-names></name><name><surname>Weiblen</surname><given-names>C.</given-names></name><name><surname>Santurio</surname><given-names>J.M.</given-names></name><name><surname>Alves</surname><given-names>S.H.</given-names></name></person-group><article-title>Do antibacterial and antifungal combinations have better activity against clinically relevant fusarium species? in vitro synergism</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>51</volume><fpage>784</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.10.017</pub-id><pub-id pub-id-type="pmid">29127050</pub-id></element-citation></ref><ref id="B81-antibiotics-09-00812"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aneke</surname><given-names>C.I.</given-names></name><name><surname>Rhimi</surname><given-names>W.</given-names></name><name><surname>Otranto</surname><given-names>D.</given-names></name><name><surname>Cafarchia</surname><given-names>C.</given-names></name></person-group><article-title>Synergistic effects of efflux pump modulators on the azole antifungal susceptibility of <italic>Microsporum canis</italic></article-title><source>Mycopathologia</source><year>2020</year><volume>185</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1007/s11046-019-00419-7</pub-id><pub-id pub-id-type="pmid">31894500</pub-id></element-citation></ref><ref id="B82-antibiotics-09-00812"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iatta</surname><given-names>R.</given-names></name><name><surname>Puttilli</surname><given-names>M.R.</given-names></name><name><surname>Immediato</surname><given-names>D.</given-names></name><name><surname>Otranto</surname><given-names>D.</given-names></name><name><surname>Cafarchia</surname><given-names>C.</given-names></name></person-group><article-title>The role of drug efflux pumps in <italic>Malassezia pachydermatis</italic> and <italic>Malassezia furfur</italic> defence against azoles</article-title><source>Mycoses</source><year>2017</year><volume>60</volume><fpage>178</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1111/myc.12577</pub-id><pub-id pub-id-type="pmid">27774659</pub-id></element-citation></ref><ref id="B83-antibiotics-09-00812"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamouei</surname><given-names>Z.</given-names></name><name><surname>Alqarihi</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Mansour</surname><given-names>M.K.</given-names></name><name><surname>Ibrahim</surname><given-names>A.S.</given-names></name><name><surname>Uppuluri</surname><given-names>P.</given-names></name></person-group><article-title>Alexidine Dihydrochloride Has Broad-Spectrum Activities against Diverse Fungal Pathogens</article-title><source>mSphere</source><year>2018</year><volume>3</volume><pub-id pub-id-type="doi">10.1128/mSphere.00539-18</pub-id><?supplied-pmid 30381356?><pub-id pub-id-type="pmid">30381356</pub-id></element-citation></ref><ref id="B84-antibiotics-09-00812"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shekhar-Guturja</surname><given-names>T.</given-names></name><name><surname>Gunaherath</surname><given-names>G.M.K.B.</given-names></name><name><surname>Wijeratne</surname><given-names>E.M.K.</given-names></name><name><surname>Lambert</surname><given-names>J.-P.</given-names></name><name><surname>Averette</surname><given-names>A.F.</given-names></name><name><surname>Lee</surname><given-names>S.C.</given-names></name><name><surname>Kim</surname><given-names>T.</given-names></name><name><surname>Bahn</surname><given-names>Y.-S.</given-names></name><name><surname>Tripodi</surname><given-names>F.</given-names></name><name><surname>Ammar</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Dual action antifungal small molecule modulates multidrug efflux and TOR signaling</article-title><source>Nat. Chem. Biol.</source><year>2016</year><volume>12</volume><fpage>867</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2165</pub-id><?supplied-pmid 27571477?><pub-id pub-id-type="pmid">27571477</pub-id></element-citation></ref><ref id="B85-antibiotics-09-00812"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>Song</surname><given-names>F.</given-names></name><name><surname>Dai</surname><given-names>H.</given-names></name><name><surname>Ren</surname><given-names>B.</given-names></name><name><surname>Sun</surname><given-names>N.</given-names></name><name><surname>Pei</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Beauvericin counteracted multi-drug resistant <italic>Candida albicans</italic> by blocking ABC transporters</article-title><source>Synth. Syst. Biotechnol.</source><year>2016</year><volume>1</volume><fpage>158</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.synbio.2016.10.001</pub-id><?supplied-pmid 29062940?><pub-id pub-id-type="pmid">29062940</pub-id></element-citation></ref><ref id="B86-antibiotics-09-00812"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>Bian</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>C.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>N.</given-names></name><name><surname>An</surname><given-names>R.</given-names></name><etal/></person-group><article-title>High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>4606</fpage><lpage>4611</lpage><pub-id pub-id-type="doi">10.1073/pnas.0609370104</pub-id><?supplied-pmid 17360571?><pub-id pub-id-type="pmid">17360571</pub-id></element-citation></ref><ref id="B87-antibiotics-09-00812"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shekhar-Guturja</surname><given-names>T.</given-names></name><name><surname>Tebung</surname><given-names>W.A.</given-names></name><name><surname>Mount</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>K&#x000f6;hler</surname><given-names>J.R.</given-names></name><name><surname>Whiteway</surname><given-names>M.</given-names></name><name><surname>Cowen</surname><given-names>L.E.</given-names></name></person-group><article-title>Beauvericin potentiates azole activity via inhibition of multidrug efflux, blocks <italic>Candida albicans</italic> morphogenesis, and is effluxed via Yor1 and circuitry controlled by Zcf29</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>7468</fpage><lpage>7480</lpage><pub-id pub-id-type="doi">10.1128/aac.01959-16</pub-id><pub-id pub-id-type="pmid">27736764</pub-id></element-citation></ref><ref id="B88-antibiotics-09-00812"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>N.N.</given-names></name><name><surname>Ali</surname><given-names>S.</given-names></name><name><surname>Shukla</surname><given-names>P.K.</given-names></name></person-group><article-title>Arachidonic acid affects biofilm formation and PGE2 level in <italic>Candida albicans</italic> and non-<italic>albicans</italic> species in presence of subinhibitory concentration of fluconazole and terbinafine</article-title><source>Braz. J. Infect. Dis.</source><year>2014</year><volume>18</volume><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.bjid.2013.09.006</pub-id><pub-id pub-id-type="pmid">24389279</pub-id></element-citation></ref><ref id="B89-antibiotics-09-00812"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>T.</given-names></name><name><surname>Arai</surname><given-names>M.</given-names></name><name><surname>Yamaguchi</surname><given-names>Y.</given-names></name><name><surname>Masuma</surname><given-names>R.</given-names></name><name><surname>Tomoda</surname><given-names>H.</given-names></name><name><surname>Omura</surname><given-names>S.</given-names></name></person-group><article-title>New beauvericins, potentiators of antifungal miconazole activity, Produced by <italic>Beauveria</italic> sp. FKI-1366. I. Taxonomy, fermentation, isolation and biological properties</article-title><source>J. Antibiot.</source><year>2004</year><volume>57</volume><fpage>110</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.57.110</pub-id></element-citation></ref><ref id="B90-antibiotics-09-00812"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ells</surname><given-names>R.</given-names></name><name><surname>Kock</surname><given-names>J.L.F.</given-names></name><name><surname>Van Wyk</surname><given-names>P.W.J.</given-names></name><name><surname>Botes</surname><given-names>P.J.</given-names></name><name><surname>Pohl</surname><given-names>C.H.</given-names></name></person-group><article-title>Arachidonic acid increases antifungal susceptibility of <italic>Candida albicans</italic> and <italic>Candida dubliniensis</italic></article-title><source>J. Antimicrob. Chemother.</source><year>2008</year><volume>63</volume><fpage>124</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn446</pub-id><pub-id pub-id-type="pmid">18971215</pub-id></element-citation></ref><ref id="B91-antibiotics-09-00812"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname><given-names>R.A.</given-names></name><name><surname>Joffe</surname><given-names>L.S.</given-names></name><name><surname>Alves</surname><given-names>G.M.</given-names></name><name><surname>Figueiredo-Carvalho</surname><given-names>M.H.G.</given-names></name><name><surname>Brito-Santos</surname><given-names>F.</given-names></name><name><surname>Amaral</surname><given-names>A.C.F.</given-names></name><name><surname>Rodrigues</surname><given-names>M.L.</given-names></name><name><surname>Almeida-Paes</surname><given-names>R.</given-names></name></person-group><article-title>A screening of the MMV Pathogen Box&#x000ae; reveals new potential antifungal drugs against the etiologic agents of chromoblastomycosis</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0229630</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0229630</pub-id><pub-id pub-id-type="pmid">32401759</pub-id></element-citation></ref><ref id="B92-antibiotics-09-00812"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thangamani</surname><given-names>S.</given-names></name><name><surname>Maland</surname><given-names>M.</given-names></name><name><surname>Mohammad</surname><given-names>H.</given-names></name><name><surname>Pascuzzi</surname><given-names>P.E.</given-names></name><name><surname>Avramova</surname><given-names>L.</given-names></name><name><surname>Koehler</surname><given-names>C.M.</given-names></name><name><surname>Hazbun</surname><given-names>T.R.</given-names></name><name><surname>Seleem</surname><given-names>M.N.</given-names></name></person-group><article-title>Repurposing approach identifies auranofin with broad spectrum antifungal activity that targets Mia40-Erv1 pathway</article-title><source>Front. Cell Infect. Microbiol.</source><year>2017</year><volume>7</volume><pub-id pub-id-type="doi">10.3389/fcimb.2017.00004</pub-id></element-citation></ref><ref id="B93-antibiotics-09-00812"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiederhold</surname><given-names>N.P.</given-names></name><name><surname>Patterson</surname><given-names>T.F.</given-names></name><name><surname>Srinivasan</surname><given-names>A.</given-names></name><name><surname>Chaturvedi</surname><given-names>A.K.</given-names></name><name><surname>Fothergill</surname><given-names>A.W.</given-names></name><name><surname>Wormley</surname><given-names>F.L.</given-names></name><name><surname>Ramasubramanian</surname><given-names>A.K.</given-names></name><name><surname>Lopez-Ribot</surname><given-names>J.L.</given-names></name></person-group><article-title>Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi</article-title><source>Virulence</source><year>2017</year><volume>8</volume><fpage>138</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1080/21505594.2016.1196301</pub-id><?supplied-pmid 27268469?><pub-id pub-id-type="pmid">27268469</pub-id></element-citation></ref><ref id="B94-antibiotics-09-00812"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousfi</surname><given-names>H.</given-names></name><name><surname>Cassagne</surname><given-names>C.</given-names></name><name><surname>Ranque</surname><given-names>S.</given-names></name><name><surname>Rolain</surname><given-names>J.-M.</given-names></name><name><surname>Bittar</surname><given-names>F.</given-names></name></person-group><article-title>Repurposing of ribavirin as an adjunct therapy against invasive <italic>Candida</italic> strains in an In Vitro study</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><pub-id pub-id-type="doi">10.1128/AAC.00263-19</pub-id><?supplied-pmid 31307986?><pub-id pub-id-type="pmid">31307986</pub-id></element-citation></ref><ref id="B95-antibiotics-09-00812"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name></person-group><article-title>Antifungal activity of ribavirin used alone or in combination with fluconazole against <italic>Candida albicans</italic> is mediated by reduced virulence</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><volume>55</volume><fpage>105804</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2019.09.008</pub-id><?supplied-pmid 31605727?><pub-id pub-id-type="pmid">31605727</pub-id></element-citation></ref><ref id="B96-antibiotics-09-00812"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousfi</surname><given-names>H.</given-names></name><name><surname>Ranque</surname><given-names>S.</given-names></name><name><surname>Cassagne</surname><given-names>C.</given-names></name><name><surname>Rolain</surname><given-names>J.-M.</given-names></name><name><surname>Bittar</surname><given-names>F.</given-names></name></person-group><article-title>Identification of repositionable drugs with novel antimycotic activity by screening the Prestwick Chemical Library against emerging invasive moulds</article-title><source>J. Glob. Antimicrob. Resist.</source><year>2020</year><volume>21</volume><fpage>314</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2020.01.002</pub-id><pub-id pub-id-type="pmid">32004725</pub-id></element-citation></ref><ref id="B97-antibiotics-09-00812"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>C.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Pang</surname><given-names>G.</given-names></name></person-group><article-title>Effects of contact lens solution disinfectants against filamentous fungi</article-title><source>Optom. Vis. Sci.</source><year>2014</year><volume>91</volume><fpage>1440</fpage><lpage>1445</lpage><pub-id pub-id-type="doi">10.1097/OPX.0000000000000407</pub-id><pub-id pub-id-type="pmid">25279782</pub-id></element-citation></ref><ref id="B98-antibiotics-09-00812"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venturini</surname><given-names>T.P.</given-names></name><name><surname>Rossato</surname><given-names>L.</given-names></name><name><surname>Chassot</surname><given-names>F.</given-names></name><name><surname>Keller</surname><given-names>J.T.</given-names></name><name><surname>Piasentin</surname><given-names>F.B.</given-names></name><name><surname>Santurio</surname><given-names>J.M.</given-names></name><name><surname>Alves</surname><given-names>S.H.</given-names></name></person-group><article-title>In vitro synergistic combinations of pentamidine, polymyxin B, tigecycline and tobramycin with antifungal agents against <italic>Fusarium</italic> spp.</article-title><source>J. Med. Microbiol.</source><year>2016</year><volume>65</volume><fpage>770</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.000301</pub-id><pub-id pub-id-type="pmid">27357655</pub-id></element-citation></ref><ref id="B99-antibiotics-09-00812"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>V.A.</given-names></name><name><surname>Viera</surname><given-names>P.V.</given-names></name><name><surname>Oliveira</surname><given-names>A.M.</given-names></name><name><surname>Zanin</surname><given-names>M.H.</given-names></name><name><surname>Borsatti</surname><given-names>M.A.</given-names></name></person-group><article-title>Antifungal effect of electrospun nanofibers containing cetylpyridinium chloride against <italic>Candida albicans</italic></article-title><source>Braz. Oral. Res.</source><year>2014</year><volume>28</volume><pub-id pub-id-type="doi">10.1590/1807-3107BOR-2014.vol28.0049</pub-id></element-citation></ref><ref id="B100-antibiotics-09-00812"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz</surname><given-names>S.C.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Hull</surname><given-names>C.M.</given-names></name></person-group><article-title>Spore germination as a target for antifungal therapeutics</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><pub-id pub-id-type="doi">10.1128/AAC.00994-19</pub-id></element-citation></ref><ref id="B101-antibiotics-09-00812"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Park</surname><given-names>Y.-D.</given-names></name><name><surname>Sugui</surname><given-names>J.A.</given-names></name><name><surname>Fothergill</surname><given-names>A.</given-names></name><name><surname>Southall</surname><given-names>N.</given-names></name><name><surname>Shinn</surname><given-names>P.</given-names></name><name><surname>McKew</surname><given-names>J.C.</given-names></name><name><surname>Kwon-Chung</surname><given-names>K.J.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name><name><surname>Williamson</surname><given-names>P.R.</given-names></name></person-group><article-title>Rapid identification of antifungal compounds against <italic>Exserohilum rostratum</italic> using high throughput drug repurposing screens</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e70506</elocation-id><comment>Erratum in <bold>2013</bold>, <italic>8</italic>, doi:10.1371/annotation/df5a5a46-cf30-4842-bf11-b6cee36c1f9b</comment><pub-id pub-id-type="doi">10.1371/journal.pone.0070506</pub-id><pub-id pub-id-type="pmid">23990907</pub-id></element-citation></ref><ref id="B102-antibiotics-09-00812"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>P.</given-names></name><name><surname>Schwarz</surname><given-names>P.V.</given-names></name><name><surname>Felske-Zech</surname><given-names>H.</given-names></name><name><surname>Dannaoui</surname><given-names>E.</given-names></name></person-group><article-title>In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>1921</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz102</pub-id><pub-id pub-id-type="pmid">30934052</pub-id></element-citation></ref><ref id="B103-antibiotics-09-00812"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>P.</given-names></name><name><surname>Dannaoui</surname><given-names>E.</given-names></name></person-group><article-title>In vitro interaction between isavuconazole and tacrolimus, cyclosporin A, or sirolimus against <italic>Aspergillus</italic> species</article-title><source>J. Fungi</source><year>2020</year><volume>6</volume><elocation-id>103</elocation-id><pub-id pub-id-type="doi">10.3390/jof6030103</pub-id><?supplied-pmid 32650564?><pub-id pub-id-type="pmid">32650564</pub-id></element-citation></ref><ref id="B104-antibiotics-09-00812"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Chan</surname><given-names>K.L.</given-names></name><name><surname>Cheng</surname><given-names>L.W.</given-names></name><name><surname>Tell</surname><given-names>L.A.</given-names></name><name><surname>Byrne</surname><given-names>B.A.</given-names></name><name><surname>Clothier</surname><given-names>K.</given-names></name><name><surname>Land</surname><given-names>K.M.</given-names></name></person-group><article-title>High efficiency drug repurposing design for new antifungal agents</article-title><source>Meth. Protoc.</source><year>2019</year><volume>2</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.3390/mps2020031</pub-id><?supplied-pmid 31164611?><pub-id pub-id-type="pmid">31164611</pub-id></element-citation></ref><ref id="B105-antibiotics-09-00812"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>A.</given-names></name><name><surname>Hemmelgarn</surname><given-names>T.</given-names></name><name><surname>Danziger-Isakov</surname><given-names>L.</given-names></name><name><surname>Teusink</surname><given-names>A.</given-names></name></person-group><article-title>Intravenous pentamidine for Pneumocystis carinii/jiroveci pneumonia prophylaxis in pediatric transplant patients</article-title><source>Pediatr. Transplant.</source><year>2015</year><volume>19</volume><fpage>326</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1111/petr.12441</pub-id><?supplied-pmid 25712369?><pub-id pub-id-type="pmid">25712369</pub-id></element-citation></ref><ref id="B106-antibiotics-09-00812"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Z.-W.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>N.</given-names></name><name><surname>Pi</surname><given-names>X.-X.</given-names></name><name><surname>Fan</surname><given-names>Y.-M.</given-names></name></person-group><article-title>Molecular epidemiology, in vitro susceptibility and exoenzyme screening of <italic>Malassezia</italic> clinical isolates</article-title><source>J. Med. Microbiol.</source><year>2020</year><volume>69</volume><fpage>436</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.001161</pub-id><pub-id pub-id-type="pmid">32068525</pub-id></element-citation></ref><ref id="B107-antibiotics-09-00812"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nixon</surname><given-names>G.L.</given-names></name><name><surname>McEntee</surname><given-names>L.</given-names></name><name><surname>Johnson</surname><given-names>A.</given-names></name><name><surname>Farrington</surname><given-names>N.</given-names></name><name><surname>Whalley</surname><given-names>S.</given-names></name><name><surname>Livermore</surname><given-names>J.</given-names></name><name><surname>Natal</surname><given-names>C.</given-names></name><name><surname>Washbourn</surname><given-names>G.</given-names></name><name><surname>Bibby</surname><given-names>J.</given-names></name><name><surname>Berry</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Repurposing and reformulation of the antiparasitic agent flubendazole for treatment of cryptococcal meningoencephalitis, a neglected fungal disease</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><fpage>e01909</fpage><lpage>e01917</lpage><pub-id pub-id-type="doi">10.1128/AAC.01909-17</pub-id><?supplied-pmid 29311092?><pub-id pub-id-type="pmid">29311092</pub-id></element-citation></ref><ref id="B108-antibiotics-09-00812"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>N.</given-names></name><name><surname>Tripathi</surname><given-names>M.</given-names></name><name><surname>Gupta</surname><given-names>M.K.</given-names></name><name><surname>Tilak</surname><given-names>R.</given-names></name></person-group><article-title>Overexpression of efflux pump transporter genes and mutations in ERG11 pave the way to fluconazole resistance in <italic>Candida tropicalis</italic>: A study from a North India region</article-title><source>J. Glob. Antimicrob. Resist.</source><year>2020</year><volume>22</volume><fpage>374</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2020.02.010</pub-id><?supplied-pmid 32084606?><pub-id pub-id-type="pmid">32084606</pub-id></element-citation></ref><ref id="B109-antibiotics-09-00812"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>Y.-D.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Salas</surname><given-names>A.</given-names></name><name><surname>Antia</surname><given-names>A.</given-names></name><name><surname>Carvajal</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>A.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Meng</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Tawa</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Identification of multiple cryptococcal fungicidal drug targets by combined gene dosing and drug affinity responsive target stability screening</article-title><source>mBio</source><year>2016</year><volume>7</volume><pub-id pub-id-type="doi">10.1128/mBio.01073-16</pub-id></element-citation></ref><ref id="B110-antibiotics-09-00812"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truong</surname><given-names>M.</given-names></name><name><surname>Monahan</surname><given-names>L.G.</given-names></name><name><surname>Carter</surname><given-names>D.A.</given-names></name><name><surname>Charles</surname><given-names>I.G.</given-names></name></person-group><article-title>Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis</article-title><source>PeerJ</source><year>2018</year><volume>6</volume><fpage>e4761</fpage><pub-id pub-id-type="doi">10.7717/peerj.4761</pub-id><pub-id pub-id-type="pmid">29740519</pub-id></element-citation></ref><ref id="B111-antibiotics-09-00812"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afeltra</surname><given-names>J.</given-names></name><name><surname>Vitale</surname><given-names>R.G.</given-names></name><name><surname>Mouton</surname><given-names>J.W.</given-names></name><name><surname>Verweij</surname><given-names>P.E.</given-names></name></person-group><article-title>Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of <italic>Aspergillus fumigatus</italic> resistant to itraconazole</article-title><source>Antimicrob. Agents Chemother.</source><year>2004</year><volume>48</volume><fpage>1335</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.4.1335-1343.2004</pub-id><pub-id pub-id-type="pmid">15047538</pub-id></element-citation></ref><ref id="B112-antibiotics-09-00812"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alnajjar</surname><given-names>L.M.</given-names></name><name><surname>Bulatova</surname><given-names>N.R.</given-names></name><name><surname>Darwish</surname><given-names>R.M.</given-names></name></person-group><article-title>Evaluation of four calcium channel blockers as fluconazole resistance inhibitors in <italic>Candida glabrata</italic></article-title><source>J. Glob. Antimicrob. Resist.</source><year>2018</year><volume>14</volume><fpage>185</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2018.04.004</pub-id><pub-id pub-id-type="pmid">29665423</pub-id></element-citation></ref><ref id="B113-antibiotics-09-00812"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eldesouky</surname><given-names>H.E.</given-names></name><name><surname>Mayhoub</surname><given-names>A.</given-names></name><name><surname>Hazbun</surname><given-names>T.R.</given-names></name><name><surname>Seleem</surname><given-names>M.N.</given-names></name></person-group><article-title>Reversal of azole resistance in <italic>Candida albicans</italic> by sulfa antibacterial drugs</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><fpage>e00701</fpage><lpage>e00717</lpage><pub-id pub-id-type="doi">10.1128/aac.00701-17</pub-id><?supplied-pmid 29263071?><pub-id pub-id-type="pmid">29263071</pub-id></element-citation></ref><ref id="B114-antibiotics-09-00812"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Yue</surname><given-names>L.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name></person-group><article-title>Synergistic effect of fluconazole and calcium channel blockers against resistant <italic>Candida albicans</italic></article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0150859</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0150859</pub-id><?supplied-pmid 26986478?><pub-id pub-id-type="pmid">26986478</pub-id></element-citation></ref><ref id="B115-antibiotics-09-00812"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>A.G.</given-names></name><name><surname>Araujo</surname><given-names>R.</given-names></name><name><surname>Pina-Vaz</surname><given-names>C.</given-names></name></person-group><article-title>Interaction of local anaesthetics with other antifungal agents against pathogenic <italic>Aspergillus</italic></article-title><source>Int. J. Antimicrob. Agents</source><year>2006</year><volume>27</volume><fpage>339</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2005.11.011</pub-id><?supplied-pmid 16527460?><pub-id pub-id-type="pmid">16527460</pub-id></element-citation></ref><ref id="B116-antibiotics-09-00812"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brilhante</surname><given-names>R.S.N.</given-names></name><name><surname>Caetano</surname><given-names>E.P.</given-names></name><name><surname>Lima</surname><given-names>R.A.C.</given-names></name><name><surname>Castelo Branco</surname><given-names>D.S.C.M.</given-names></name><name><surname>Serpa</surname><given-names>R.</given-names></name><name><surname>Oliveira</surname><given-names>J.S.</given-names></name><name><surname>Monteiro</surname><given-names>A.J.</given-names></name><name><surname>Rocha</surname><given-names>M.F.G.</given-names></name><name><surname>Cordeiro</surname><given-names>R.A.</given-names></name><name><surname>Sidrim</surname><given-names>J.J.C.</given-names></name></person-group><article-title>In vitro antifungal activity of miltefosine and levamisole: Their impact on ergosterol biosynthesis and cell permeability of dimorphic fungi</article-title><source>J. Appl. Microbiol.</source><year>2015</year><volume>119</volume><fpage>962</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1111/jam.12891</pub-id><pub-id pub-id-type="pmid">26178247</pub-id></element-citation></ref><ref id="B117-antibiotics-09-00812"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brilhante</surname><given-names>R.S.N.</given-names></name><name><surname>Silva</surname><given-names>M.L.Q.D.</given-names></name><name><surname>Pereira</surname><given-names>V.S.</given-names></name><name><surname>de Oliveira</surname><given-names>J.S.</given-names></name><name><surname>Maciel</surname><given-names>J.M.</given-names></name><name><surname>Silva</surname><given-names>I.N.G.D.</given-names></name><name><surname>Garcia</surname><given-names>L.G.S.</given-names></name><name><surname>Guedes</surname><given-names>G.M.D.M.</given-names></name><name><surname>Cordeiro</surname><given-names>R.D.A.</given-names></name><name><surname>Pereira-Neto</surname><given-names>W.D.A.</given-names></name><etal/></person-group><article-title>Potassium iodide and miltefosine inhibit biofilms of <italic>Sporothrix schenckii</italic> species complex in yeast and filamentous forms</article-title><source>Med. Mycol.</source><year>2018</year><volume>57</volume><fpage>764</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1093/mmy/myy119</pub-id><?supplied-pmid 30462271?><pub-id pub-id-type="pmid">30462271</pub-id></element-citation></ref><ref id="B118-antibiotics-09-00812"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spadari</surname><given-names>C.d.C.</given-names></name><name><surname>Vila</surname><given-names>T.</given-names></name><name><surname>Rozental</surname><given-names>S.</given-names></name><name><surname>Ishida</surname><given-names>K.</given-names></name></person-group><article-title>Miltefosine has a postantifungal effect and induces apoptosis in <italic>Cryptococcus</italic> yeasts</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><fpage>e00312</fpage><lpage>e00318</lpage><pub-id pub-id-type="doi">10.1128/AAC.00312-18</pub-id><pub-id pub-id-type="pmid">29844051</pub-id></element-citation></ref><ref id="B119-antibiotics-09-00812"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>G.</given-names></name><name><surname>Herrera</surname><given-names>N.</given-names></name><name><surname>Lopez-Ribot</surname><given-names>J.L.</given-names></name></person-group><article-title>Repositionable compounds with antifungal activity against multidrug resistant <italic>Candida auris</italic> identified in the medicines for malaria venture&#x02019;s pathogen box</article-title><source>J. Fungi</source><year>2019</year><volume>5</volume><elocation-id>92</elocation-id><pub-id pub-id-type="doi">10.3390/jof5040092</pub-id></element-citation></ref><ref id="B120-antibiotics-09-00812"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Grossman</surname><given-names>N.</given-names></name><name><surname>Totten</surname><given-names>M.</given-names></name><name><surname>Memon</surname><given-names>W.</given-names></name><name><surname>Fitzgerald</surname><given-names>A.</given-names></name><name><surname>Ying</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>S.X.</given-names></name></person-group><article-title>Antifungal susceptibility profiles and drug resistance mechanisms of clinical <italic>Lomentospora prolificans</italic> isolates</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e00318</fpage><lpage>e00320</lpage><pub-id pub-id-type="doi">10.1128/AAC.00318-20</pub-id><pub-id pub-id-type="pmid">32816726</pub-id></element-citation></ref><ref id="B121-antibiotics-09-00812"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulatova</surname><given-names>N.R.</given-names></name><name><surname>Darwish</surname><given-names>R.M.</given-names></name></person-group><article-title>Effect of chemosensitizers on minimum inhibitory concentrations of fluconazole in <italic>Candida albicans</italic></article-title><source>Med. Prince Pract.</source><year>2008</year><volume>17</volume><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1159/000112964</pub-id></element-citation></ref><ref id="B122-antibiotics-09-00812"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>T.S.</given-names></name><name><surname>Griffin</surname><given-names>G.E.</given-names></name><name><surname>Levitz</surname><given-names>S.M.</given-names></name></person-group><article-title>Conditional lethality of the diprotic weak bases chloroquine and quinacrine against <italic>Cryptococcus neoformans</italic></article-title><source>J. Infect. Dis.</source><year>2000</year><volume>182</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1086/315649</pub-id><pub-id pub-id-type="pmid">10882608</pub-id></element-citation></ref><ref id="B123-antibiotics-09-00812"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarny</surname><given-names>V.V.</given-names></name><name><surname>Chavez-Dozal</surname><given-names>A.</given-names></name><name><surname>Rane</surname><given-names>H.S.</given-names></name><name><surname>Jahng</surname><given-names>M.</given-names></name><name><surname>Bernardo</surname><given-names>S.M.</given-names></name><name><surname>Parra</surname><given-names>K.J.</given-names></name><name><surname>Lee</surname><given-names>S.A.</given-names></name></person-group><article-title>Quinacrine inhibits <italic>Candida albicans</italic> growth and filamentation at neutral pH</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>7501</fpage><lpage>7509</lpage><pub-id pub-id-type="doi">10.1128/AAC.03083-14</pub-id><?supplied-pmid 25288082?><pub-id pub-id-type="pmid">25288082</pub-id></element-citation></ref><ref id="B124-antibiotics-09-00812"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siles</surname><given-names>S.A.</given-names></name><name><surname>Srinivasan</surname><given-names>A.</given-names></name><name><surname>Pierce</surname><given-names>C.G.</given-names></name><name><surname>Lopez-Ribot</surname><given-names>J.L.</given-names></name><name><surname>Ramasubramanian</surname><given-names>A.K.</given-names></name></person-group><article-title>High-throughput screening of a collection of known pharmacologically active small compounds for identification of <italic>Candida albicans</italic> biofilm inhibitors</article-title><source>Antimicrob. Agents Chemother.</source><year>2013</year><volume>57</volume><fpage>3681</fpage><lpage>3687</lpage><pub-id pub-id-type="doi">10.1128/AAC.00680-13</pub-id><?supplied-pmid 23689719?><pub-id pub-id-type="pmid">23689719</pub-id></element-citation></ref><ref id="B125-antibiotics-09-00812"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valli&#x000e8;res</surname><given-names>C.</given-names></name><name><surname>Raulo</surname><given-names>R.</given-names></name><name><surname>Dickinson</surname><given-names>M.</given-names></name><name><surname>Avery</surname><given-names>S.V.</given-names></name></person-group><article-title>Novel combinations of agents targeting translation that synergistically inhibit fungal pathogens</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><pub-id pub-id-type="doi">10.3389/fmicb.2018.02355</pub-id><?supplied-pmid 30349511?><pub-id pub-id-type="pmid">30349511</pub-id></element-citation></ref><ref id="B126-antibiotics-09-00812"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zani</surname><given-names>C.</given-names></name><name><surname>Bisceglie</surname><given-names>F.</given-names></name><name><surname>Restivo</surname><given-names>F.M.</given-names></name><name><surname>Feretti</surname><given-names>D.</given-names></name><name><surname>Pioli</surname><given-names>M.</given-names></name><name><surname>Degola</surname><given-names>F.</given-names></name><name><surname>Montalbano</surname><given-names>S.</given-names></name><name><surname>Galati</surname><given-names>S.</given-names></name><name><surname>Pelosi</surname><given-names>G.</given-names></name><name><surname>Viola</surname><given-names>G.V.C.</given-names></name><etal/></person-group><article-title>A battery of assays as an integrated approach to evaluate fungal and mycotoxin inhibition properties and cytotoxic/genotoxic side-effects for the prioritization in the screening of thiosemicarbazone derivatives</article-title><source>Food Chem. Toxicol.</source><year>2017</year><volume>105</volume><fpage>498</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2017.05.008</pub-id><pub-id pub-id-type="pmid">28483535</pub-id></element-citation></ref><ref id="B127-antibiotics-09-00812"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Killeen</surname><given-names>K.</given-names></name><name><surname>Groutas</surname><given-names>W.</given-names></name><name><surname>Calderone</surname><given-names>R.</given-names></name></person-group><article-title>Repurposing an inhibitor of ribosomal biogenesis with broad anti-fungal activity</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>17014</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17147-x</pub-id><pub-id pub-id-type="pmid">29209049</pub-id></element-citation></ref><ref id="B128-antibiotics-09-00812"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogolino</surname><given-names>D.</given-names></name><name><surname>Gatti</surname><given-names>A.</given-names></name><name><surname>Carcelli</surname><given-names>M.</given-names></name><name><surname>Pelosi</surname><given-names>G.</given-names></name><name><surname>Bisceglie</surname><given-names>F.</given-names></name><name><surname>Restivo</surname><given-names>F.M.</given-names></name><name><surname>Degola</surname><given-names>F.</given-names></name><name><surname>Buschini</surname><given-names>A.</given-names></name><name><surname>Montalbano</surname><given-names>S.</given-names></name><name><surname>Feretti</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Thiosemicarbazone scaffold for the design of antifungal and antiaflatoxigenic agents: Evaluation of ligands and related copper complexes</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>11214</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-11716-w</pub-id><pub-id pub-id-type="pmid">28894265</pub-id></element-citation></ref><ref id="B129-antibiotics-09-00812"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degola</surname><given-names>F.</given-names></name><name><surname>Morcia</surname><given-names>C.</given-names></name><name><surname>Bisceglie</surname><given-names>F.</given-names></name><name><surname>Mussi</surname><given-names>F.</given-names></name><name><surname>Tumino</surname><given-names>G.</given-names></name><name><surname>Ghizzoni</surname><given-names>R.</given-names></name><name><surname>Pelosi</surname><given-names>G.</given-names></name><name><surname>Terzi</surname><given-names>V.</given-names></name><name><surname>Buschini</surname><given-names>A.</given-names></name><name><surname>Restivo</surname><given-names>F.M.</given-names></name><etal/></person-group><article-title>In vitro evaluation of the activity of thiosemicarbazone derivatives against mycotoxigenic fungi affecting cereals</article-title><source>Int. J. Food Microbiol.</source><year>2015</year><volume>200</volume><fpage>104</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2015.02.009</pub-id><pub-id pub-id-type="pmid">25702884</pub-id></element-citation></ref><ref id="B130-antibiotics-09-00812"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De S&#x000e1;</surname><given-names>N.P.</given-names></name><name><surname>Cisalpino</surname><given-names>P.S.</given-names></name><name><surname>Bertollo</surname><given-names>C.M.</given-names></name><name><surname>Santos</surname><given-names>P.C.</given-names></name><name><surname>Rosa</surname><given-names>C.A.</given-names></name><name><surname>de Souza</surname><given-names>D.D.G.</given-names></name><name><surname>Barbeira</surname><given-names>P.J.S.</given-names></name><name><surname>Alves</surname><given-names>T.M.D.A.</given-names></name><name><surname>Zani</surname><given-names>C.L.</given-names></name><name><surname>Johann</surname><given-names>S.</given-names></name></person-group><article-title>Thiosemicarbazone of lapachol acts on cell membrane in <italic>Paracoccidioides brasiliensis</italic></article-title><source>Med. Mycol.</source><year>2018</year><volume>57</volume><fpage>332</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1093/mmy/myy045</pub-id></element-citation></ref><ref id="B131-antibiotics-09-00812"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>S.</given-names></name><name><surname>Hogardt</surname><given-names>M.</given-names></name><name><surname>Demir</surname><given-names>A.</given-names></name><name><surname>R&#x000f6;ger</surname><given-names>F.</given-names></name><name><surname>Lehrnbecher</surname><given-names>T.</given-names></name></person-group><article-title>Immunosuppressive compounds affect the fungal growth and viability of defined <italic>Aspergillus</italic> species</article-title><source>Pathogens</source><year>2019</year><volume>8</volume><elocation-id>273</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens8040273</pub-id></element-citation></ref><ref id="B132-antibiotics-09-00812"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noto</surname><given-names>T.</given-names></name><name><surname>Sawada</surname><given-names>M.</given-names></name><name><surname>Ando</surname><given-names>K.</given-names></name><name><surname>Koyama</surname><given-names>K.</given-names></name></person-group><article-title>Some biological properties of mycophenolic acid</article-title><source>J. Antibiot.</source><year>1969</year><volume>22</volume><fpage>165</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.22.165</pub-id></element-citation></ref><ref id="B133-antibiotics-09-00812"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Zilbermintz</surname><given-names>L.</given-names></name><name><surname>Martchenko</surname><given-names>M.</given-names></name></person-group><article-title>Repurposing FDA approved drugs against the human fungal pathogen, <italic>Candida albicans</italic></article-title><source>Ann. Clin. Microbiol. Antimicrob.</source><year>2015</year><volume>14</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s12941-015-0090-4</pub-id><?supplied-pmid 26054754?><pub-id pub-id-type="pmid">26054754</pub-id></element-citation></ref><ref id="B134-antibiotics-09-00812"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoli</surname><given-names>J.</given-names></name><name><surname>Montalbano</surname><given-names>S.</given-names></name><name><surname>Spadola</surname><given-names>G.</given-names></name><name><surname>Rogolino</surname><given-names>D.</given-names></name><name><surname>Pelosi</surname><given-names>G.</given-names></name><name><surname>Bisceglie</surname><given-names>F.</given-names></name><name><surname>Restivo</surname><given-names>F.M.</given-names></name><name><surname>Degola</surname><given-names>F.</given-names></name><name><surname>Serra</surname><given-names>O.</given-names></name><name><surname>Buschini</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Antiaflatoxigenic thiosemicarbazones as crop-protective agents: A cytotoxic and genotoxic study</article-title><source>J. Agric. Food Chem.</source><year>2019</year><volume>67</volume><fpage>10947</fpage><lpage>10953</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.9b01814</pub-id><?supplied-pmid 31498626?><pub-id pub-id-type="pmid">31498626</pub-id></element-citation></ref><ref id="B135-antibiotics-09-00812"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>D.</given-names></name><name><surname>Burkard</surname><given-names>L.</given-names></name><name><surname>Panepinto</surname><given-names>J.C.</given-names></name></person-group><article-title>Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e87246</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0087246</pub-id><?supplied-pmid 24498052?><pub-id pub-id-type="pmid">24498052</pub-id></element-citation></ref><ref id="B136-antibiotics-09-00812"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanette</surname><given-names>R.A.</given-names></name><name><surname>Jesus</surname><given-names>F.P.K.</given-names></name><name><surname>Pilotto</surname><given-names>M.B.</given-names></name><name><surname>Weiblen</surname><given-names>C.</given-names></name><name><surname>P&#x000f6;tter</surname><given-names>L.</given-names></name><name><surname>Ferreiro</surname><given-names>L.</given-names></name><name><surname>Alves</surname><given-names>S.H.</given-names></name><name><surname>Santurio</surname><given-names>J.M.</given-names></name></person-group><article-title>Micafungin alone and in combination therapy with deferasirox against <italic>Pythium insidiosum</italic></article-title><source>J. Mycol. Med.</source><year>2015</year><volume>25</volume><fpage>91</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.mycmed.2014.09.002</pub-id><?supplied-pmid 25459680?><pub-id pub-id-type="pmid">25459680</pub-id></element-citation></ref><ref id="B137-antibiotics-09-00812"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puri</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>R.</given-names></name><name><surname>Rojas</surname><given-names>I.G.</given-names></name><name><surname>Salvatori</surname><given-names>O.</given-names></name><name><surname>Edgerton</surname><given-names>M.</given-names></name></person-group><article-title>Iron chelator deferasirox reduces <italic>Candida albicans</italic> invasion of oral epithelial cells and infection levels in murine oropharyngeal Candidiasis</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><fpage>e02152-18</fpage><pub-id pub-id-type="doi">10.1128/AAC.02152-18</pub-id><?supplied-pmid 30718249?><pub-id pub-id-type="pmid">30718249</pub-id></element-citation></ref><ref id="B138-antibiotics-09-00812"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magalh&#x000e3;es</surname><given-names>T.F.F.</given-names></name><name><surname>Costa</surname><given-names>M.C.</given-names></name><name><surname>Holanda</surname><given-names>R.A.</given-names></name><name><surname>Ferreira</surname><given-names>G.F.</given-names></name><name><surname>Carvalho</surname><given-names>V.S.D.</given-names></name><name><surname>Freitas</surname><given-names>G.J.C.</given-names></name><name><surname>Ribeiro</surname><given-names>N.Q.</given-names></name><name><surname>Em&#x000ed;dio</surname><given-names>E.C.P.</given-names></name><name><surname>Carmo</surname><given-names>P.H.F.</given-names></name><name><surname>de Brito</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>N-acetylcysteine reduces amphotericin B deoxycholate nephrotoxicity and improves the outcome of murine cryptococcosis</article-title><source>Med. Mycol.</source><year>2020</year><volume>58</volume><fpage>835</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1093/mmy/myz129</pub-id><pub-id pub-id-type="pmid">31919505</pub-id></element-citation></ref><ref id="B139-antibiotics-09-00812"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>R.E.</given-names></name><name><surname>Albert</surname><given-names>N.D.</given-names></name><name><surname>Kontoyiannis</surname><given-names>D.P.</given-names></name></person-group><article-title>Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>6767</fpage><lpage>6772</lpage><pub-id pub-id-type="doi">10.1128/AAC.03569-14</pub-id><pub-id pub-id-type="pmid">25182639</pub-id></element-citation></ref><ref id="B140-antibiotics-09-00812"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homa</surname><given-names>M.</given-names></name><name><surname>Galg&#x000f3;czy</surname><given-names>L.</given-names></name><name><surname>T&#x000f3;th</surname><given-names>E.</given-names></name><name><surname>T&#x000f3;th</surname><given-names>L.</given-names></name><name><surname>Papp</surname><given-names>T.</given-names></name><name><surname>Chandrasekaran</surname><given-names>M.</given-names></name><name><surname>Kadaikunnan</surname><given-names>S.</given-names></name><name><surname>Alharbi</surname><given-names>N.S.</given-names></name><name><surname>V&#x000e1;gv&#x000f6;lgyi</surname><given-names>C.</given-names></name></person-group><article-title>In vitro antifungal activity of antipsychotic drugs and their combinations with conventional antifungals against <italic>Scedosporium</italic> and <italic>Pseudallescheria</italic> isolates</article-title><source>Med. Mycol.</source><year>2015</year><volume>53</volume><fpage>890</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1093/mmy/myv064</pub-id><pub-id pub-id-type="pmid">26316212</pub-id></element-citation></ref><ref id="B141-antibiotics-09-00812"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>Z.</given-names></name><name><surname>Ran</surname><given-names>X.</given-names></name><name><surname>Dai</surname><given-names>Y.</given-names></name><name><surname>Ran</surname><given-names>Y.</given-names></name></person-group><article-title>Clioquinol, an alternative antimicrobial agent against common pathogenic microbe</article-title><source>J. Mycol. Med.</source><year>2018</year><volume>28</volume><fpage>492</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.mycmed.2018.03.007</pub-id><pub-id pub-id-type="pmid">29650464</pub-id></element-citation></ref><ref id="B142-antibiotics-09-00812"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thangamani</surname><given-names>S.</given-names></name><name><surname>Eldesouky</surname><given-names>H.E.</given-names></name><name><surname>Mohammad</surname><given-names>H.</given-names></name><name><surname>Pascuzzi</surname><given-names>P.E.</given-names></name><name><surname>Avramova</surname><given-names>L.</given-names></name><name><surname>Hazbun</surname><given-names>T.R.</given-names></name><name><surname>Seleem</surname><given-names>M.N.</given-names></name></person-group><article-title>Ebselen exerts antifungal activity by regulating glutathione (GSH) and reactive oxygen species (ROS) production in fungal cells</article-title><source>Biochim. Biophys. Acta Gen. Subj.</source><year>2017</year><volume>1861</volume><fpage>3002</fpage><lpage>3010</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2016.09.029</pub-id><?supplied-pmid 27712973?><pub-id pub-id-type="pmid">27712973</pub-id></element-citation></ref><ref id="B143-antibiotics-09-00812"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Jia</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name></person-group><article-title>Antifungal activity and potential mechanism of panobinostat in combination with fluconazole against <italic>Candida albicans</italic></article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><pub-id pub-id-type="doi">10.3389/fmicb.2020.01584</pub-id><?supplied-pmid 32765454?><pub-id pub-id-type="pmid">32765454</pub-id></element-citation></ref><ref id="B144-antibiotics-09-00812"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonardelli</surname><given-names>F.</given-names></name><name><surname>Macedo</surname><given-names>D.</given-names></name><name><surname>Dudiuk</surname><given-names>C.</given-names></name><name><surname>Theill</surname><given-names>L.</given-names></name><name><surname>Cabeza</surname><given-names>M.S.</given-names></name><name><surname>Gamarra</surname><given-names>S.</given-names></name><name><surname>Garcia-Effron</surname><given-names>G.</given-names></name></person-group><article-title>In Vitro activity of combinations of zinc chelators with amphotericin b and posaconazole against six mucorales species</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><pub-id pub-id-type="doi">10.1128/AAC.00266-19</pub-id></element-citation></ref><ref id="B145-antibiotics-09-00812"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaromin</surname><given-names>A.</given-names></name><name><surname>Zarnowski</surname><given-names>R.</given-names></name><name><surname>Pi&#x00119;tka-Ottlik</surname><given-names>M.</given-names></name><name><surname>Andes</surname><given-names>D.R.</given-names></name><name><surname>Gubernator</surname><given-names>J.</given-names></name></person-group><article-title>Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: Drug repurposing enhanced antifungal activity</article-title><source>Nanomedicine</source><year>2018</year><volume>13</volume><fpage>1139</fpage><lpage>1155</lpage><pub-id pub-id-type="doi">10.2217/nnm-2017-0337</pub-id><pub-id pub-id-type="pmid">29873597</pub-id></element-citation></ref><ref id="B146-antibiotics-09-00812"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Gigi</surname><given-names>G.</given-names></name><name><surname>Polacheck</surname><given-names>I.</given-names></name><name><surname>Eilam</surname><given-names>Y.</given-names></name></person-group><article-title>In vitro synergistic activity of ketoconazole with trifluoperazine and with chlorpromazine against medically important yeasts</article-title><source>Chemotherapy</source><year>1988</year><volume>34</volume><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1159/000238554</pub-id><pub-id pub-id-type="pmid">3391057</pub-id></element-citation></ref><ref id="B147-antibiotics-09-00812"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butts</surname><given-names>A.</given-names></name><name><surname>Palmer</surname><given-names>G.E.</given-names></name><name><surname>Rogers</surname><given-names>P.D.</given-names></name></person-group><article-title>Antifungal adjuvants: Preserving and extending the antifungal arsenal</article-title><source>Virulence</source><year>2017</year><volume>8</volume><fpage>198</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1080/21505594.2016.1216283</pub-id><?supplied-pmid 27459018?><pub-id pub-id-type="pmid">27459018</pub-id></element-citation></ref><ref id="B148-antibiotics-09-00812"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>E.H.</given-names></name><name><surname>Meyers</surname><given-names>D.J.</given-names></name><name><surname>Bosch</surname><given-names>J.</given-names></name><name><surname>Casadevall</surname><given-names>A.</given-names></name></person-group><article-title>Novel antifungal compounds discovered in medicines for malaria venture&#x02019;s malaria box</article-title><source>mSphere</source><year>2018</year><volume>3</volume><pub-id pub-id-type="doi">10.1128/mSphere.00537-17</pub-id><?supplied-pmid 29564402?><pub-id pub-id-type="pmid">29564402</pub-id></element-citation></ref><ref id="B149-antibiotics-09-00812"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montoya</surname><given-names>M.C.</given-names></name><name><surname>DiDone</surname><given-names>L.</given-names></name><name><surname>Heier</surname><given-names>R.F.</given-names></name><name><surname>Meyers</surname><given-names>M.J.</given-names></name><name><surname>Krysan</surname><given-names>D.J.</given-names></name></person-group><article-title>Antifungal Phenothiazines: Optimization, characterization of mechanism, and modulation of neuroreceptor activity</article-title><source>ACS Infect. Dis.</source><year>2018</year><volume>4</volume><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00157</pub-id><?supplied-pmid 29058407?><pub-id pub-id-type="pmid">29058407</pub-id></element-citation></ref><ref id="B150-antibiotics-09-00812"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siavoshi</surname><given-names>F.</given-names></name><name><surname>Tavakolian</surname><given-names>A.</given-names></name><name><surname>Foroumadi</surname><given-names>A.</given-names></name><name><surname>Hosseini</surname><given-names>N.M.</given-names></name><name><surname>Massarrat</surname><given-names>S.</given-names></name><name><surname>Pedramnia</surname><given-names>S.</given-names></name><name><surname>Saniee</surname><given-names>P.</given-names></name></person-group><article-title>Comparison of the effect of non-antifungal and antifungal agents on <italic>Candida</italic> isolates from the gastrointestinal tract</article-title><source>Arch. Iran. Med.</source><year>2012</year><volume>15</volume><fpage>27</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">22208440</pub-id></element-citation></ref><ref id="B151-antibiotics-09-00812"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Fatima</surname><given-names>Z.</given-names></name><name><surname>Ahmad</surname><given-names>K.</given-names></name><name><surname>Hameed</surname><given-names>S.</given-names></name></person-group><article-title>Repurposing of respiratory drug theophylline against <italic>Candida albicans</italic>: Mechanistic insights unveil alterations in membrane properties and metabolic fitness</article-title><source>J. Appl. Microbiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1111/jam.14669</pub-id></element-citation></ref><ref id="B152-antibiotics-09-00812"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajasekharan</surname><given-names>S.K.</given-names></name><name><surname>Lee</surname><given-names>J.-H.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name></person-group><article-title>Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant <italic>Candida albicans</italic></article-title><source>Int. J. Antimicrob. Agents</source><year>2019</year><volume>54</volume><fpage>518</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2019.05.016</pub-id><pub-id pub-id-type="pmid">31173863</pub-id></element-citation></ref><ref id="B153-antibiotics-09-00812"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pic</surname><given-names>E.</given-names></name><name><surname>Burgain</surname><given-names>A.</given-names></name><name><surname>Sellam</surname><given-names>A.</given-names></name></person-group><article-title>Repurposing the anthelminthic salicylanilide oxyclozanide against susceptible and clinical resistant <italic>Candida albicans</italic> strains</article-title><source>Med. Mycol.</source><year>2018</year><volume>57</volume><fpage>387</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1093/mmy/myy027</pub-id><?supplied-pmid 29762783?><pub-id pub-id-type="pmid">29762783</pub-id></element-citation></ref><ref id="B154-antibiotics-09-00812"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nile</surname><given-names>C.</given-names></name><name><surname>Falleni</surname><given-names>M.</given-names></name><name><surname>Cirasola</surname><given-names>D.</given-names></name><name><surname>Alghamdi</surname><given-names>A.</given-names></name><name><surname>Anderson</surname><given-names>O.F.</given-names></name><name><surname>Delaney</surname><given-names>C.</given-names></name><name><surname>Ramage</surname><given-names>G.</given-names></name><name><surname>Ottaviano</surname><given-names>E.</given-names></name><name><surname>Tosi</surname><given-names>D.</given-names></name><name><surname>Bulfamante</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Repurposing pilocarpine hydrochloride for treatment of <italic>Candida albicans</italic> infections</article-title><source>mSphere</source><year>2019</year><volume>4</volume><pub-id pub-id-type="doi">10.1128/mSphere.00689-18</pub-id><?supplied-pmid 30674648?><pub-id pub-id-type="pmid">30674648</pub-id></element-citation></ref><ref id="B155-antibiotics-09-00812"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montoya</surname><given-names>M.C.</given-names></name><name><surname>Beattie</surname><given-names>S.</given-names></name><name><surname>Alden</surname><given-names>K.M.</given-names></name><name><surname>Krysan</surname><given-names>D.J.</given-names></name></person-group><article-title>Derivatives of the antimalarial drug mefloquine are broad-spectrum antifungal molecules with activity against drug-resistant clinical isolates</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><pub-id pub-id-type="doi">10.1128/AAC.02331-19</pub-id><?supplied-pmid 31907188?><pub-id pub-id-type="pmid">31907188</pub-id></element-citation></ref><ref id="B156-antibiotics-09-00812"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>D.</given-names></name><name><surname>Leal-Pinto</surname><given-names>S.M.</given-names></name><name><surname>Roa-Cordero</surname><given-names>M.V.</given-names></name><name><surname>Vargas</surname><given-names>J.D.</given-names></name><name><surname>Moreno-Moreno</surname><given-names>E.M.</given-names></name><name><surname>Mac&#x000ed;as</surname><given-names>M.A.</given-names></name><name><surname>Suescun</surname><given-names>L.</given-names></name><name><surname>Mu&#x000f1;oz-Castro</surname><given-names>&#x000c1;.</given-names></name><name><surname>Hurtado</surname><given-names>J.J.</given-names></name></person-group><article-title>Inhibition of <italic>C. albicans</italic> dimorphic switch by Cobalt(II) complexes with ligands derived from pyrazoles and dinitrobenzoate: Synthesis, characterization and biological activity</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>3237</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20133237</pub-id></element-citation></ref><ref id="B157-antibiotics-09-00812"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joffe</surname><given-names>L.S.</given-names></name><name><surname>Schneider</surname><given-names>R.</given-names></name><name><surname>Lopes</surname><given-names>W.</given-names></name><name><surname>Azevedo</surname><given-names>R.</given-names></name><name><surname>Staats</surname><given-names>C.C.</given-names></name><name><surname>Kmetzsch</surname><given-names>L.</given-names></name><name><surname>Schrank</surname><given-names>A.</given-names></name><name><surname>Del Poeta</surname><given-names>M.</given-names></name><name><surname>Vainstein</surname><given-names>M.H.</given-names></name><name><surname>Rodrigues</surname><given-names>M.L.</given-names></name></person-group><article-title>The anti-helminthic compound mebendazole has multiple antifungal effects against <italic>Cryptococcus neoformans</italic></article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><pub-id pub-id-type="doi">10.3389/fmicb.2017.00535</pub-id><?supplied-pmid 28400768?><pub-id pub-id-type="pmid">28400768</pub-id></element-citation></ref><ref id="B158-antibiotics-09-00812"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name></person-group><article-title>Development of anti-fungal pesticides from protein kinase inhibitor-based anticancer agents</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>148</volume><fpage>349</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.02.040</pub-id><pub-id pub-id-type="pmid">29475155</pub-id></element-citation></ref><ref id="B159-antibiotics-09-00812"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>H.X.</given-names></name><name><surname>Shrestha</surname><given-names>S.K.</given-names></name><name><surname>Garneau-Tsodikova</surname><given-names>S.</given-names></name></person-group><article-title>Identification of ebsulfur analogues with broad-spectrum antifungal activity</article-title><source>ChemMedChem</source><year>2016</year><volume>11</volume><fpage>1507</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201600236</pub-id><pub-id pub-id-type="pmid">27334363</pub-id></element-citation></ref><ref id="B160-antibiotics-09-00812"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veri</surname><given-names>A.</given-names></name><name><surname>Cowen</surname><given-names>L.E.</given-names></name></person-group><article-title>Progress and prospects for targeting Hsp90 to treat fungal infections</article-title><source>Parasitology</source><year>2014</year><volume>141</volume><fpage>1127</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1017/S0031182013002072</pub-id><pub-id pub-id-type="pmid">24560124</pub-id></element-citation></ref><ref id="B161-antibiotics-09-00812"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>She</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>F.</given-names></name><name><surname>Luo</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Antibiofilm efficacy of the gold compound auranofin on dual species biofilms of <italic>Staphylococcus aureus</italic> and <italic>Candida</italic> sp.</article-title><source>J. Appl. Microbiol.</source><year>2020</year><volume>128</volume><fpage>88</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1111/jam.14443</pub-id><pub-id pub-id-type="pmid">31509623</pub-id></element-citation></ref><ref id="B162-antibiotics-09-00812"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nobile</surname><given-names>C.J.</given-names></name><name><surname>Ennis</surname><given-names>C.L.</given-names></name><name><surname>Hartooni</surname><given-names>N.</given-names></name><name><surname>Johnson</surname><given-names>A.D.</given-names></name><name><surname>Lohse</surname><given-names>M.B.</given-names></name></person-group><article-title>A selective serotonin reuptake inhibitor, a proton pump inhibitor, and two calcium channel blockers inhibit <italic>Candida albicans</italic> biofilms</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>756</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8050756</pub-id></element-citation></ref><ref id="B163-antibiotics-09-00812"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eldesouky</surname><given-names>H.E.</given-names></name><name><surname>Salama</surname><given-names>E.A.</given-names></name><name><surname>Lanman</surname><given-names>N.A.</given-names></name><name><surname>Hazbun</surname><given-names>T.R.</given-names></name><name><surname>Seleem</surname><given-names>M.N.</given-names></name></person-group><article-title>Potent synergistic interactions between lopinavir and azole antifungal drugs against emerging multidrug-resistant <italic>Candida auris</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><pub-id pub-id-type="doi">10.1128/AAC.00684-20</pub-id><?supplied-pmid 33046487?><pub-id pub-id-type="pmid">33046487</pub-id></element-citation></ref><ref id="B164-antibiotics-09-00812"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavez-Dozal</surname><given-names>A.A.</given-names></name><name><surname>Lown</surname><given-names>L.</given-names></name><name><surname>Jahng</surname><given-names>M.</given-names></name><name><surname>Walraven</surname><given-names>C.J.</given-names></name><name><surname>Lee</surname><given-names>S.A.</given-names></name></person-group><article-title>In vitro analysis of finasteride activity against <italic>Candida albicans</italic> urinary biofilm formation and filamentation</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>5855</fpage><lpage>5862</lpage><pub-id pub-id-type="doi">10.1128/AAC.03137-14</pub-id><?supplied-pmid 25049253?><pub-id pub-id-type="pmid">25049253</pub-id></element-citation></ref><ref id="B165-antibiotics-09-00812"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardo</surname><given-names>S.M.</given-names></name><name><surname>Allen</surname><given-names>C.P.</given-names></name><name><surname>Waller</surname><given-names>A.</given-names></name><name><surname>Young</surname><given-names>S.M.</given-names></name><name><surname>Oprea</surname><given-names>T.</given-names></name><name><surname>Sklar</surname><given-names>L.A.</given-names></name><name><surname>Lee</surname><given-names>S.A.</given-names></name></person-group><article-title>An automated high-throughput cell-based multiplexed flow cytometry assay to identify novel compounds to target <italic>Candida albicans</italic> virulence-related proteins</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e110354</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0110354</pub-id><?supplied-pmid 25350399?><pub-id pub-id-type="pmid">25350399</pub-id></element-citation></ref><ref id="B166-antibiotics-09-00812"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>L.-N.</given-names></name><name><surname>Liu</surname><given-names>J.-Y.</given-names></name><name><surname>Wang</surname><given-names>Y.-T.</given-names></name><name><surname>Ni</surname><given-names>S.-S.</given-names></name><name><surname>Xiang</surname><given-names>M.-J.</given-names></name></person-group><article-title>The discovery of potential phosphopantetheinyl transferase Ppt2 inhibitors against drug-resistant <italic>Candida albicans</italic></article-title><source>Braz. J. Microbiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s42770-020-00318-w</pub-id></element-citation></ref><ref id="B167-antibiotics-09-00812"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>T.</given-names></name><name><surname>Zou</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Tan</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>FDA approved drug library screening identifies robenidine as a repositionable antifungal</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><pub-id pub-id-type="doi">10.3389/fmicb.2020.00996</pub-id></element-citation></ref><ref id="B168-antibiotics-09-00812"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Fu</surname><given-names>B.</given-names></name><name><surname>Green</surname><given-names>C.M.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Lang</surname><given-names>Y.</given-names></name><name><surname>Chaturvedi</surname><given-names>S.</given-names></name><name><surname>Belfort</surname><given-names>M.</given-names></name><name><surname>Liao</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>Cisplatin protects mice from challenge of <italic>Cryptococcus neoformans</italic> by targeting the Prp8 intein</article-title><source>Emerg. Microbes Infect.</source><year>2019</year><volume>8</volume><fpage>895</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1080/22221751.2019.1625727</pub-id><pub-id pub-id-type="pmid">31223062</pub-id></element-citation></ref><ref id="B169-antibiotics-09-00812"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>C.</given-names></name><name><surname>Burgain</surname><given-names>A.</given-names></name><name><surname>Chaillot</surname><given-names>J.</given-names></name><name><surname>Pic</surname><given-names>&#x000c9;.</given-names></name><name><surname>Khemiri</surname><given-names>I.</given-names></name><name><surname>Sellam</surname><given-names>A.</given-names></name></person-group><article-title>A phenotypic small-molecule screen identifies halogenated salicylanilides as inhibitors of fungal morphogenesis, biofilm formation and host cell invasion</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>11559</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-29973-8</pub-id><pub-id pub-id-type="pmid">30068935</pub-id></element-citation></ref><ref id="B170-antibiotics-09-00812"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehdashti</surname><given-names>S.J.</given-names></name><name><surname>Abbott</surname><given-names>J.</given-names></name><name><surname>Nguyen</surname><given-names>D.T.</given-names></name><name><surname>McKew</surname><given-names>J.C.</given-names></name><name><surname>Williamson</surname><given-names>P.R.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name></person-group><article-title>A high-throughput screening assay for assessing the viability of <italic>Cryptococcus neoformans</italic> under nutrient starvation conditions</article-title><source>Anal. Bioanl. Chem.</source><year>2013</year><volume>405</volume><fpage>6823</fpage><lpage>6829</lpage><pub-id pub-id-type="doi">10.1007/s00216-013-7134-4</pub-id></element-citation></ref><ref id="B171-antibiotics-09-00812"><label>171.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Clinical and Laboratory Standards Institute (CLSI)</collab></person-group><source>Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard</source><edition>2nd ed.</edition><publisher-name>CLSI document M27-A3; Clinical and Laboratory Standards Institute</publisher-name><publisher-loc>Wayne, PA, USA</publisher-loc><year>2008</year></element-citation></ref><ref id="B172-antibiotics-09-00812"><label>172.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>The European Committee on Antimicrobial Susceptibility Testing</collab></person-group><article-title>EUCAST Method for Susceptibility Testing of Yeasts (v 7.3.2 Valid from 22 April 2020)</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.eucast.org/astoffungi/methodsinantifungalsusceptibilitytesting/susceptibility_testing_of_yeasts/">https://www.eucast.org/astoffungi/methodsinantifungalsusceptibilitytesting/susceptibility_testing_of_yeasts/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-21">(accessed on 21 August 2020)</date-in-citation></element-citation></ref><ref id="B173-antibiotics-09-00812"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>G.L.</given-names></name><name><surname>Tisoncik-Go</surname><given-names>J.</given-names></name><name><surname>Korth</surname><given-names>M.J.</given-names></name><name><surname>Katze</surname><given-names>M.G.</given-names></name></person-group><article-title>Drug repurposing: A better approach for infectious disease drug discovery?</article-title><source>Curr. Opin. Immunol.</source><year>2013</year><volume>25</volume><fpage>588</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2013.08.004</pub-id><pub-id pub-id-type="pmid">24011665</pub-id></element-citation></ref><ref id="B174-antibiotics-09-00812"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abadio</surname><given-names>A.K.R.</given-names></name><name><surname>Kioshima</surname><given-names>E.S.</given-names></name><name><surname>Teixeira</surname><given-names>M.M.</given-names></name><name><surname>Martins</surname><given-names>N.F.</given-names></name><name><surname>Maigret</surname><given-names>B.</given-names></name><name><surname>Felipe</surname><given-names>M.S.S.</given-names></name></person-group><article-title>Comparative genomics allowed the identification of drug targets against human fungal pathogens</article-title><source>BMC Genom.</source><year>2011</year><volume>12</volume><elocation-id>75</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-12-75</pub-id></element-citation></ref><ref id="B175-antibiotics-09-00812"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gowri</surname><given-names>M.</given-names></name><name><surname>Sofi Beaula</surname><given-names>W.</given-names></name><name><surname>Biswal</surname><given-names>J.</given-names></name><name><surname>Dhamodharan</surname><given-names>P.</given-names></name><name><surname>Saiharish</surname><given-names>R.</given-names></name><name><surname>Rohan prasad</surname><given-names>S.</given-names></name><name><surname>Pitani</surname><given-names>R.</given-names></name><name><surname>Kandaswamy</surname><given-names>D.</given-names></name><name><surname>Raghunathan</surname><given-names>R.</given-names></name><name><surname>Jeyakanthan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>&#x003b2;-lactam substituted polycyclic fused pyrrolidine/pyrrolizidine derivatives eradicate <italic>C. albicans</italic> in an ex vivo human dentinal tubule model by inhibiting sterol 14-&#x003b1; demethylase and cAMP pathway</article-title><source>Biochim. Biophys. Acta</source><year>2016</year><volume>1860</volume><fpage>636</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2015.12.020</pub-id><?supplied-pmid 26723175?><pub-id pub-id-type="pmid">26723175</pub-id></element-citation></ref><ref id="B176-antibiotics-09-00812"><label>176.</label><element-citation publication-type="book"><source>OpenEye Scientific Software OMEGA</source><comment>v.2.5.1</comment><publisher-name>OpenEye Scientific Software</publisher-name><publisher-loc>Santa Fe, NM, USA</publisher-loc><year>2019</year></element-citation></ref><ref id="B177-antibiotics-09-00812"><label>177.</label><element-citation publication-type="book"><source>OpenEye Scientific Software QUACPAC</source><comment>v.1.6.3</comment><publisher-name>OpenEye Scientific Software</publisher-name><publisher-loc>Santa Fe, NM, USA</publisher-loc><year>2013</year></element-citation></ref><ref id="B178-antibiotics-09-00812"><label>178.</label><element-citation publication-type="book"><source>OpenEye Scientific Software OEDocking</source><comment>v3.2.0</comment><publisher-name>OpenEye Scientific Software</publisher-name><publisher-loc>Santa Fe, NM, USA</publisher-loc><year>2017</year></element-citation></ref><ref id="B179-antibiotics-09-00812"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anandakrishnan</surname><given-names>R.</given-names></name><name><surname>Aguilar</surname><given-names>B.</given-names></name><name><surname>Onufriev</surname><given-names>A.V.</given-names></name></person-group><article-title>H++ 3.0: Automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations</article-title><source>Nucleic Acids Res.</source><year>2012</year><volume>40</volume><fpage>W537</fpage><lpage>W541</lpage><pub-id pub-id-type="doi">10.1093/nar/gks375</pub-id><?supplied-pmid 22570416?><pub-id pub-id-type="pmid">22570416</pub-id></element-citation></ref><ref id="B180-antibiotics-09-00812"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biasini</surname><given-names>M.</given-names></name><name><surname>Bienert</surname><given-names>S.</given-names></name><name><surname>Waterhouse</surname><given-names>A.</given-names></name><name><surname>Arnold</surname><given-names>K.</given-names></name><name><surname>Studer</surname><given-names>G.</given-names></name><name><surname>Schmidt</surname><given-names>T.</given-names></name><name><surname>Kiefer</surname><given-names>F.</given-names></name><name><surname>Cassarino</surname><given-names>T.G.</given-names></name><name><surname>Bertoni</surname><given-names>M.</given-names></name><name><surname>Bordoli</surname><given-names>L.</given-names></name><etal/></person-group><article-title>SWISS-MODEL: Modelling protein tertiary and quaternary structure using evolutionary information</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>W252</fpage><lpage>W258</lpage><pub-id pub-id-type="doi">10.1093/nar/gku340</pub-id><?supplied-pmid 24782522?><pub-id pub-id-type="pmid">24782522</pub-id></element-citation></ref><ref id="B181-antibiotics-09-00812"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordoli</surname><given-names>L.</given-names></name><name><surname>Kiefer</surname><given-names>F.</given-names></name><name><surname>Arnold</surname><given-names>K.</given-names></name><name><surname>Benkert</surname><given-names>P.</given-names></name><name><surname>Battey</surname><given-names>J.</given-names></name><name><surname>Schwede</surname><given-names>T.</given-names></name></person-group><article-title>Protein structure homology modeling using SWISS-MODEL workspace</article-title><source>Nat. Protoc.</source><year>2009</year><volume>4</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.197</pub-id><pub-id pub-id-type="pmid">19131951</pub-id></element-citation></ref><ref id="B182-antibiotics-09-00812"><label>182.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Broad Institute</collab></person-group><article-title>Fungal Genomics</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.broadinstitute.org/fungal-genome-initiative">https://www.broadinstitute.org/fungal-genome-initiative</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-21">(accessed on 21 August 2020)</date-in-citation></element-citation></ref><ref id="B183-antibiotics-09-00812"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>V.B.</given-names></name><name><surname>Arendall</surname><given-names>W.B.</given-names><suffix>III</suffix></name><name><surname>Headd</surname><given-names>J.J.</given-names></name><name><surname>Keedy</surname><given-names>D.A.</given-names></name><name><surname>Immormino</surname><given-names>R.M.</given-names></name><name><surname>Kapral</surname><given-names>G.J.</given-names></name><name><surname>Murray</surname><given-names>L.W.</given-names></name><name><surname>Richardson</surname><given-names>J.S.</given-names></name><name><surname>Richardson</surname><given-names>D.C.</given-names></name></person-group><article-title>MolProbity: All-atom structure validation for macromolecular crystallography</article-title><source>Acta Crystallograph. Sect. D</source><year>2010</year><volume>66</volume><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1107/S0907444909042073</pub-id></element-citation></ref><ref id="B184-antibiotics-09-00812"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Paula e Silva</surname><given-names>A.C.A.</given-names></name><name><surname>Oliveira</surname><given-names>H.C.</given-names></name><name><surname>Silva</surname><given-names>J.F.</given-names></name><name><surname>Sangalli-Leite</surname><given-names>F.</given-names></name><name><surname>Scorzoni</surname><given-names>L.</given-names></name><name><surname>Fusco-Almeida</surname><given-names>A.M.</given-names></name><name><surname>Mendes-Giannini</surname><given-names>M.J.S.</given-names></name></person-group><article-title>Microplate alamarBlue assay for <italic>Paracoccidioides</italic> susceptibility testing</article-title><source>J. Clin. Microbiol.</source><year>2013</year><volume>51</volume><fpage>1250</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1128/JCM.02914-12</pub-id><?supplied-pmid 23345296?><pub-id pub-id-type="pmid">23345296</pub-id></element-citation></ref><ref id="B185-antibiotics-09-00812"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>V.</given-names></name><name><surname>Knox</surname><given-names>C.</given-names></name><name><surname>Djoumbou</surname><given-names>Y.</given-names></name><name><surname>Jewison</surname><given-names>T.</given-names></name><name><surname>Guo</surname><given-names>A.C.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Maciejewski</surname><given-names>A.</given-names></name><name><surname>Arndt</surname><given-names>D.</given-names></name><name><surname>Wilson</surname><given-names>M.</given-names></name><name><surname>Neveu</surname><given-names>V.</given-names></name><etal/></person-group><article-title>DrugBank 4.0: Shedding new light on drug metabolism</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>42</volume><fpage>D1091</fpage><lpage>D1097</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1068</pub-id><pub-id pub-id-type="pmid">24203711</pub-id></element-citation></ref><ref id="B186-antibiotics-09-00812"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.H.</given-names></name><name><surname>Yu</surname><given-names>C.Y.</given-names></name><name><surname>Li</surname><given-names>X.X.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Fu</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Tu</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Therapeutic target database update 2018: Enriched resource for facilitating bench-to-clinic research of targeted therapeutics</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>46</volume><fpage>D1121</fpage><lpage>D1127</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1076</pub-id></element-citation></ref><ref id="B187-antibiotics-09-00812"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGann</surname><given-names>M.</given-names></name></person-group><article-title>FRED and HYBRID docking performance on standardized datasets</article-title><source>J. Comput.-Aided Mol. Des.</source><year>2012</year><volume>26</volume><fpage>897</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1007/s10822-012-9584-8</pub-id><pub-id pub-id-type="pmid">22669221</pub-id></element-citation></ref><ref id="B188-antibiotics-09-00812"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>J.P.G.L.M.</given-names></name><name><surname>Levitt</surname><given-names>M.</given-names></name><name><surname>Chopra</surname><given-names>G.</given-names></name></person-group><article-title>KoBaMIN: A knowledge-based minimization web server for protein structure refinement</article-title><source>Nucleic Acids Res.</source><year>2012</year><volume>40</volume><fpage>W323</fpage><lpage>W328</lpage><pub-id pub-id-type="doi">10.1093/nar/gks376</pub-id><pub-id pub-id-type="pmid">22564897</pub-id></element-citation></ref><ref id="B189-antibiotics-09-00812"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>P.W.</given-names></name><name><surname>Prli&#x00107;</surname><given-names>A.</given-names></name><name><surname>Bi</surname><given-names>C.</given-names></name><name><surname>Bluhm</surname><given-names>W.F.</given-names></name><name><surname>Christie</surname><given-names>C.H.</given-names></name><name><surname>Dutta</surname><given-names>S.</given-names></name><name><surname>Green</surname><given-names>R.K.</given-names></name><name><surname>Goodsell</surname><given-names>D.S.</given-names></name><name><surname>Westbrook</surname><given-names>J.D.</given-names></name><name><surname>Woo</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The RCSB Protein Data Bank: Views of structural biology for basic and applied research and education</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>43</volume><fpage>D345</fpage><lpage>D356</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1214</pub-id><?supplied-pmid 25428375?><pub-id pub-id-type="pmid">25428375</pub-id></element-citation></ref><ref id="B190-antibiotics-09-00812"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Coleman-Derr</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Gu</surname><given-names>Y.Q.</given-names></name></person-group><article-title>OrthoVenn: A web server for genome wide comparison and annotation of orthologous clusters across multiple species</article-title><source>Nucleic Acids Res.</source><year>2015</year><volume>43</volume><fpage>W78</fpage><lpage>W84</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv487</pub-id><?supplied-pmid 25964301?><pub-id pub-id-type="pmid">25964301</pub-id></element-citation></ref><ref id="B191-antibiotics-09-00812"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name></person-group><article-title>DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes</article-title><source>Nucleic Acids Res.</source><year>2008</year><volume>37</volume><fpage>D455</fpage><lpage>D458</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn858</pub-id><?supplied-pmid 18974178?><pub-id pub-id-type="pmid">18974178</pub-id></element-citation></ref><ref id="B192-antibiotics-09-00812"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Ou</surname><given-names>H.Y.</given-names></name><name><surname>Zhang</surname><given-names>C.T.</given-names></name></person-group><article-title>DEG: A database of essential genes</article-title><source>Nucleic Acids Res.</source><year>2004</year><volume>32</volume><fpage>D271</fpage><lpage>D272</lpage><pub-id pub-id-type="doi">10.1093/nar/gkh024</pub-id><?supplied-pmid 14681410?><pub-id pub-id-type="pmid">14681410</pub-id></element-citation></ref><ref id="B193-antibiotics-09-00812"><label>193.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>European Bioinformatics Institute</collab></person-group><article-title>CLUSTALW</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/Tools/msa/">http://www.ebi.ac.uk/Tools/msa/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-21">(accessed on 21 August 2020)</date-in-citation></element-citation></ref><ref id="B194-antibiotics-09-00812"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>B.</given-names></name><name><surname>Kutzner</surname><given-names>C.</given-names></name><name><surname>van der Spoel</surname><given-names>D.</given-names></name><name><surname>Lindahl</surname><given-names>E.</given-names></name></person-group><article-title>GROMACS 4:&#x02009; Algorithms for highly efficient, load-balanced, and scalable molecular simulation</article-title><source>J. Chem. Theory Comput.</source><year>2008</year><volume>4</volume><fpage>435</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1021/ct700301q</pub-id><pub-id pub-id-type="pmid">26620784</pub-id></element-citation></ref><ref id="B195-antibiotics-09-00812"><label>195.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>National Center for Biotechnology Information</collab></person-group><article-title>BLAST</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/BLAST/">https://www.ncbi.nlm.nih.gov/BLAST/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-21">(accessed on 21 August 2020)</date-in-citation></element-citation></ref><ref id="B196-antibiotics-09-00812"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amiri</surname><given-names>S.</given-names></name><name><surname>Sansom</surname><given-names>M.S.P.</given-names></name><name><surname>Biggin</surname><given-names>P.C.</given-names></name></person-group><article-title>Molecular dynamics studies of AChBP with nicotine and carbamylcholine: The role of water in the binding pocket</article-title><source>Protein Eng. Des. Sel.</source><year>2007</year><volume>20</volume><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1093/protein/gzm029</pub-id><?supplied-pmid 17595341?><pub-id pub-id-type="pmid">17595341</pub-id></element-citation></ref><ref id="B197-antibiotics-09-00812"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clancy</surname><given-names>C.J.</given-names></name><name><surname>Nguyen</surname><given-names>M.H.</given-names></name></person-group><article-title>Comparison of a photometric method with standardized methods of antifungal susceptibility testing of yeasts</article-title><source>J. Clin. Microbiol.</source><year>1997</year><volume>35</volume><fpage>2878</fpage><lpage>2882</lpage><pub-id pub-id-type="doi">10.1128/JCM.35.11.2878-2882.1997</pub-id><pub-id pub-id-type="pmid">9350751</pub-id></element-citation></ref><ref id="B198-antibiotics-09-00812"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>W.</given-names></name><name><surname>Dalke</surname><given-names>A.</given-names></name><name><surname>Schulten</surname><given-names>K.</given-names></name></person-group><article-title>VMD: Visual molecular dynamics</article-title><source>J. Mol. Graph.</source><year>1996</year><volume>14</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/0263-7855(96)00018-5</pub-id><pub-id pub-id-type="pmid">8744570</pub-id></element-citation></ref><ref id="B199-antibiotics-09-00812"><label>199.</label><element-citation publication-type="book"><source>Molecular Operating Environment (MOE)</source><comment>v.2013.08</comment><publisher-name>Chemical Computing Group, Inc.</publisher-name><publisher-loc>Montreal, QC, Canada</publisher-loc><year>2014</year></element-citation></ref><ref id="B200-antibiotics-09-00812"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oostenbrink</surname><given-names>C.</given-names></name><name><surname>Villa</surname><given-names>A.</given-names></name><name><surname>Mark</surname><given-names>A.E.</given-names></name><name><surname>Van Gunsteren</surname><given-names>W.F.</given-names></name></person-group><article-title>A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force-field parameter sets 53A5 and 53A6</article-title><source>J. Comput. Chem.</source><year>2004</year><volume>25</volume><fpage>1656</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1002/jcc.20090</pub-id><pub-id pub-id-type="pmid">15264259</pub-id></element-citation></ref><ref id="B201-antibiotics-09-00812"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pronk</surname><given-names>S.</given-names></name><name><surname>P&#x000e1;ll</surname><given-names>S.</given-names></name><name><surname>Schulz</surname><given-names>R.</given-names></name><name><surname>Larsson</surname><given-names>P.</given-names></name><name><surname>Bjelkmar</surname><given-names>P.</given-names></name><name><surname>Apostolov</surname><given-names>R.</given-names></name><name><surname>Shirts</surname><given-names>M.R.</given-names></name><name><surname>Smith</surname><given-names>J.C.</given-names></name><name><surname>Kasson</surname><given-names>P.M.</given-names></name><name><surname>van der Spoel</surname><given-names>D.</given-names></name><etal/></person-group><article-title>GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit</article-title><source>Bioinformatics</source><year>2013</year><volume>29</volume><fpage>845</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt055</pub-id><pub-id pub-id-type="pmid">23407358</pub-id></element-citation></ref><ref id="B202-antibiotics-09-00812"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rarey</surname><given-names>M.</given-names></name><name><surname>Kramer</surname><given-names>B.</given-names></name><name><surname>Lengauer</surname><given-names>T.</given-names></name><name><surname>Klebe</surname><given-names>G.</given-names></name></person-group><article-title>A fast flexible docking method using an incremental construction algorithm</article-title><source>J. Mol. Biol.</source><year>1996</year><volume>261</volume><fpage>470</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1996.0477</pub-id><?supplied-pmid 8780787?><pub-id pub-id-type="pmid">8780787</pub-id></element-citation></ref><ref id="B203-antibiotics-09-00812"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000fc;ttelkopf</surname><given-names>A.W.</given-names></name><name><surname>van Aalten</surname><given-names>D.M.</given-names></name></person-group><article-title>PRODRG: A tool for high-throughput crystallography of protein-ligand complexes</article-title><source>Acta Crystallogr. D Biol. Crystallogr.</source><year>2004</year><volume>60</volume><fpage>1355</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1107/S0907444904011679</pub-id><?supplied-pmid 15272157?><pub-id pub-id-type="pmid">15272157</pub-id></element-citation></ref><ref id="B204-antibiotics-09-00812"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Dommert</surname><given-names>F.</given-names></name><name><surname>Holm</surname><given-names>C.</given-names></name></person-group><article-title>Optimizing working parameters of the smooth particle mesh Ewald algorithm in terms of accuracy and efficiency</article-title><source>J. Chem. Phys.</source><year>2010</year><volume>133</volume><fpage>034117</fpage><pub-id pub-id-type="doi">10.1063/1.3446812</pub-id><?supplied-pmid 20649318?><pub-id pub-id-type="pmid">20649318</pub-id></element-citation></ref><ref id="B205-antibiotics-09-00812"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dallakyan</surname><given-names>S.</given-names></name><name><surname>Olson</surname><given-names>A.J.</given-names></name></person-group><article-title>Small-molecule library screening by docking with PyRx</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>1263</volume><fpage>243</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2269-7_19</pub-id><pub-id pub-id-type="pmid">25618350</pub-id></element-citation></ref><ref id="B206-antibiotics-09-00812"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>G.M.</given-names></name><name><surname>Huey</surname><given-names>R.</given-names></name><name><surname>Lindstrom</surname><given-names>W.</given-names></name><name><surname>Sanner</surname><given-names>M.F.</given-names></name><name><surname>Belew</surname><given-names>R.K.</given-names></name><name><surname>Goodsell</surname><given-names>D.S.</given-names></name><name><surname>Olson</surname><given-names>A.J.</given-names></name></person-group><article-title>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</article-title><source>J. Comput. Chem.</source><year>2009</year><volume>30</volume><fpage>2785</fpage><lpage>2791</lpage><pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id><pub-id pub-id-type="pmid">19399780</pub-id></element-citation></ref><ref id="B207-antibiotics-09-00812"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasteiger</surname><given-names>J.</given-names></name><name><surname>Rudolph</surname><given-names>C.</given-names></name><name><surname>Sadowski</surname><given-names>J.</given-names></name></person-group><article-title>Automatic generation of 3D-atomic coordinates for organic molecules</article-title><source>Tetrahedron. Comput. Methodol.</source><year>1990</year><volume>3</volume><fpage>537</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1016/0898-5529(90)90156-3</pub-id></element-citation></ref><ref id="B208-antibiotics-09-00812"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>G.</given-names></name><name><surname>Willett</surname><given-names>P.</given-names></name><name><surname>Glen</surname><given-names>R.C.</given-names></name><name><surname>Leach</surname><given-names>A.R.</given-names></name><name><surname>Taylor</surname><given-names>R.</given-names></name></person-group><article-title>Development and validation of a genetic algorithm for flexible docking</article-title><source>J. Mol. Biol.</source><year>1997</year><volume>267</volume><fpage>727</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1996.0897</pub-id><pub-id pub-id-type="pmid">9126849</pub-id></element-citation></ref><ref id="B209-antibiotics-09-00812"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000e4;fer</surname><given-names>T.</given-names></name><name><surname>Kriege</surname><given-names>N.</given-names></name><name><surname>Humbeck</surname><given-names>L.</given-names></name><name><surname>Klein</surname><given-names>K.</given-names></name><name><surname>Koch</surname><given-names>O.</given-names></name><name><surname>Mutzel</surname><given-names>P.</given-names></name></person-group><article-title>Scaffold hunter: A comprehensive visual analytics framework for drug discovery</article-title><source>J. Cheminform.</source><year>2017</year><volume>9</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s13321-017-0213-3</pub-id><pub-id pub-id-type="pmid">29086162</pub-id></element-citation></ref><ref id="B210-antibiotics-09-00812"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>A.C.</given-names></name><name><surname>Laskowski</surname><given-names>R.A.</given-names></name><name><surname>Thornton</surname><given-names>J.M.</given-names></name></person-group><article-title>LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions</article-title><source>Protein Eng.</source><year>1995</year><volume>8</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1093/protein/8.2.127</pub-id><pub-id pub-id-type="pmid">7630882</pub-id></element-citation></ref><ref id="B211-antibiotics-09-00812"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meletiadis</surname><given-names>J.</given-names></name><name><surname>Antachopoulos</surname><given-names>C.</given-names></name><name><surname>Stergiopoulou</surname><given-names>T.</given-names></name><name><surname>Pournaras</surname><given-names>S.</given-names></name><name><surname>Roilides</surname><given-names>E.</given-names></name><name><surname>Walsh</surname><given-names>T.J.</given-names></name></person-group><article-title>Differential fungicidal activities of amphotericin B and voriconazole against <italic>Aspergillus</italic> species determined by microbroth methodology</article-title><source>Antimicrob. Agents Chemother.</source><year>2007</year><volume>51</volume><fpage>3329</fpage><lpage>3337</lpage><pub-id pub-id-type="doi">10.1128/AAC.00345-07</pub-id><pub-id pub-id-type="pmid">17576838</pub-id></element-citation></ref><ref id="B212-antibiotics-09-00812"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odds</surname><given-names>F.C.</given-names></name></person-group><article-title>Synergy, antagonism, and what the chequerboard puts between them</article-title><source>J. Antimicrob. Chemother.</source><year>2003</year><volume>52</volume><pub-id pub-id-type="doi">10.1093/jac/dkg301</pub-id><?supplied-pmid 12805255?><pub-id pub-id-type="pmid">12805255</pub-id></element-citation></ref><ref id="B213-antibiotics-09-00812"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alastruey-Izquierdo</surname><given-names>A.</given-names></name><name><surname>Melhem</surname><given-names>M.S.</given-names></name><name><surname>Bonfietti</surname><given-names>L.X.</given-names></name><name><surname>Rodriguez-Tudela</surname><given-names>J.L.</given-names></name></person-group><article-title>Susceptiblity test for fungi: Clinical and laboratorial correlations in medical mycology</article-title><source>Rev. Inst. Med. Trop S&#x000e3;o Paulo</source><year>2015</year><volume>57</volume><issue>Suppl. 19</issue><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1590/S0036-46652015000700011</pub-id><?supplied-pmid 26465371?><pub-id pub-id-type="pmid">26465371</pub-id></element-citation></ref><ref id="B214-antibiotics-09-00812"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Dong</surname><given-names>G.</given-names></name><name><surname>Sheng</surname><given-names>C.</given-names></name></person-group><article-title>Tackling fungal resistance by biofilm inhibitors</article-title><source>J. Med. Chem.</source><year>2017</year><volume>60</volume><fpage>2193</fpage><lpage>2211</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01203</pub-id><?supplied-pmid 28051303?><pub-id pub-id-type="pmid">28051303</pub-id></element-citation></ref><ref id="B215-antibiotics-09-00812"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherry</surname><given-names>L.</given-names></name><name><surname>Rajendran</surname><given-names>R.</given-names></name><name><surname>Lappin</surname><given-names>D.F.</given-names></name><name><surname>Borghi</surname><given-names>E.</given-names></name><name><surname>Perdoni</surname><given-names>F.</given-names></name><name><surname>Falleni</surname><given-names>M.</given-names></name><name><surname>Tosi</surname><given-names>D.</given-names></name><name><surname>Smith</surname><given-names>K.</given-names></name><name><surname>Williams</surname><given-names>C.</given-names></name><name><surname>Jones</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity</article-title><source>BMC Microbiol.</source><year>2014</year><volume>14</volume><elocation-id>182</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-14-182</pub-id><?supplied-pmid 24996549?><pub-id pub-id-type="pmid">24996549</pub-id></element-citation></ref><ref id="B216-antibiotics-09-00812"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>J.V.</given-names></name><name><surname>Mitchell</surname><given-names>A.P.</given-names></name><name><surname>Andes</surname><given-names>D.R.</given-names></name></person-group><article-title>Fungal biofilms, drug resistance, and recurrent infection</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2014</year><volume>4</volume><pub-id pub-id-type="doi">10.1101/cshperspect.a019729</pub-id></element-citation></ref><ref id="B217-antibiotics-09-00812"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulati</surname><given-names>M.</given-names></name><name><surname>Lohse</surname><given-names>M.B.</given-names></name><name><surname>Ennis</surname><given-names>C.L.</given-names></name><name><surname>Gonzalez</surname><given-names>R.E.</given-names></name><name><surname>Perry</surname><given-names>A.M.</given-names></name><name><surname>Bapat</surname><given-names>P.</given-names></name><name><surname>Arevalo</surname><given-names>A.V.</given-names></name><name><surname>Rodriguez</surname><given-names>D.L.</given-names></name><name><surname>Nobile</surname><given-names>C.J.</given-names></name></person-group><article-title>In Vitro culturing and screening of <italic>Candida albicans</italic> biofilms</article-title><source>Curr. Prot. Microbiol.</source><year>2018</year><volume>50</volume><fpage>e60</fpage><pub-id pub-id-type="doi">10.1002/cpmc.60</pub-id></element-citation></ref><ref id="B218-antibiotics-09-00812"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>C.G.</given-names></name><name><surname>Srinivasan</surname><given-names>A.</given-names></name><name><surname>Uppuluri</surname><given-names>P.</given-names></name><name><surname>Ramasubramanian</surname><given-names>A.K.</given-names></name><name><surname>L&#x000f3;pez-Ribot</surname><given-names>J.L.</given-names></name></person-group><article-title>Antifungal therapy with an emphasis on biofilms</article-title><source>Curr. Opin. Pharmacol.</source><year>2013</year><volume>13</volume><fpage>726</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2013.08.008</pub-id><pub-id pub-id-type="pmid">24011516</pub-id></element-citation></ref><ref id="B219-antibiotics-09-00812"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherry</surname><given-names>L.</given-names></name><name><surname>Ramage</surname><given-names>G.</given-names></name><name><surname>Kean</surname><given-names>R.</given-names></name><name><surname>Borman</surname><given-names>A.</given-names></name><name><surname>Johnson</surname><given-names>E.</given-names></name><name><surname>Richardson</surname><given-names>M.</given-names></name><name><surname>Rautemaa-Richardson</surname><given-names>R.</given-names></name></person-group><article-title>Biofilm-Forming capability of highly virulent, multidrug-resistant <italic>Candida auris</italic></article-title><source>Emerg. Infect. Dis.</source><year>2017</year><volume>23</volume><fpage>328</fpage><pub-id pub-id-type="doi">10.3201/eid2302.161320</pub-id><pub-id pub-id-type="pmid">28098553</pub-id></element-citation></ref><ref id="B220-antibiotics-09-00812"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>K.C.</given-names></name><name><surname>White</surname><given-names>T.C.</given-names></name></person-group><article-title>Effects of azole antifungal drugs on the transition from yeast cells to hyphae in susceptible and resistant isolates of the pathogenic yeast <italic>Candida albicans</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1999</year><volume>43</volume><fpage>763</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1128/AAC.43.4.763</pub-id><pub-id pub-id-type="pmid">10103178</pub-id></element-citation></ref><ref id="B221-antibiotics-09-00812"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heilman</surname><given-names>B.J.</given-names></name><name><surname>Tadle</surname><given-names>A.C.</given-names></name><name><surname>Pimentel</surname><given-names>L.R.</given-names></name><name><surname>Mascharak</surname><given-names>P.K.</given-names></name></person-group><article-title>Selective damage to hyphal form through light-induced delivery of nitric oxide to <italic>Candida albicans</italic> colonies</article-title><source>J. Inorg. Biochem.</source><year>2013</year><volume>123</volume><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2013.02.003</pub-id><pub-id pub-id-type="pmid">23501134</pub-id></element-citation></ref><ref id="B222-antibiotics-09-00812"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>J.</given-names></name><name><surname>Pinjon</surname><given-names>E.</given-names></name><name><surname>Oltean</surname><given-names>H.N.</given-names></name><name><surname>White</surname><given-names>T.C.</given-names></name><name><surname>Kelly</surname><given-names>S.L.</given-names></name><name><surname>Martel</surname><given-names>C.M.</given-names></name><name><surname>Sullivan</surname><given-names>D.J.</given-names></name><name><surname>Coleman</surname><given-names>D.C.</given-names></name><name><surname>Moran</surname><given-names>G.P.</given-names></name></person-group><article-title>Triclosan antagonizes fluconazole activity against <italic>Candida albicans</italic></article-title><source>J. Dent. Res.</source><year>2012</year><volume>91</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1177/0022034511425046</pub-id><?supplied-pmid 21972257?><pub-id pub-id-type="pmid">21972257</pub-id></element-citation></ref><ref id="B223-antibiotics-09-00812"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van de Sande</surname><given-names>W.W.J.</given-names></name><name><surname>Tavakol</surname><given-names>M.</given-names></name><name><surname>van Vianen</surname><given-names>W.</given-names></name><name><surname>Bakker-Woudenberg</surname><given-names>I.A.J.M.</given-names></name></person-group><article-title>The effects of antifungal agents to conidial and hyphal forms of <italic>Aspergillus fumigatus</italic></article-title><source>Med. Mycol.</source><year>2010</year><volume>48</volume><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.3109/13693780802713497</pub-id><?supplied-pmid 20055743?><pub-id pub-id-type="pmid">20055743</pub-id></element-citation></ref><ref id="B224-antibiotics-09-00812"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marin&#x000e9;</surname><given-names>M.</given-names></name><name><surname>Bom</surname><given-names>V.L.P.</given-names></name><name><surname>de Castro</surname><given-names>P.A.</given-names></name><name><surname>Winkelstroter</surname><given-names>L.K.</given-names></name><name><surname>Ramalho</surname><given-names>L.N.</given-names></name><name><surname>Brown</surname><given-names>N.A.</given-names></name><name><surname>Goldman</surname><given-names>G.H.</given-names></name></person-group><article-title>The development of animal infection models and antifungal efficacy assays against clinical isolates of <italic>Trichosporon asahii, T. asteroides and T. inkin</italic></article-title><source>Virulence</source><year>2015</year><volume>6</volume><fpage>476</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1080/21505594.2015.1020273</pub-id><pub-id pub-id-type="pmid">25751127</pub-id></element-citation></ref><ref id="B225-antibiotics-09-00812"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulussen</surname><given-names>C.</given-names></name><name><surname>Boulet</surname><given-names>G.A.V.</given-names></name><name><surname>Cos</surname><given-names>P.</given-names></name><name><surname>Delputte</surname><given-names>P.</given-names></name><name><surname>Maes</surname><given-names>L.J.R.M.</given-names></name></person-group><article-title>Animal models of invasive aspergillosis for drug discovery</article-title><source>Drug Discov. Today</source><year>2014</year><volume>19</volume><fpage>1380</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2014.06.006</pub-id><?supplied-pmid 24931219?><pub-id pub-id-type="pmid">24931219</pub-id></element-citation></ref><ref id="B226-antibiotics-09-00812"><label>226.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Research Council (US) Committee to Update Science, Medicine, and Animals</collab></person-group><article-title>Regulation of animal research</article-title><source>Science, Medicine, and Animals</source><publisher-name>National Academies Press</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2004</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK24650/">https://www.ncbi.nlm.nih.gov/books/NBK24650/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-11-14">(accessed on 14 November 2020)</date-in-citation></element-citation></ref><ref id="B227-antibiotics-09-00812"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvanitis</surname><given-names>M.</given-names></name><name><surname>Glavis-Bloom</surname><given-names>J.</given-names></name><name><surname>Mylonakis</surname><given-names>E.</given-names></name></person-group><article-title>Invertebrate models of fungal infection</article-title><source>Biochim. Biophys. Acta Mol. Basis Dis.</source><year>2013</year><volume>1832</volume><fpage>1378</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2013.03.008</pub-id></element-citation></ref><ref id="B228-antibiotics-09-00812"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Oliveira</surname><given-names>H.C.</given-names></name><name><surname>Monteiro</surname><given-names>M.C.</given-names></name><name><surname>Rossi</surname><given-names>S.A.</given-names></name><name><surname>Pem&#x000e1;n</surname><given-names>J.</given-names></name><name><surname>Ruiz-Gait&#x000e1;n</surname><given-names>A.</given-names></name><name><surname>Mendes-Giannini</surname><given-names>M.J.S.</given-names></name><name><surname>Mellado</surname><given-names>E.</given-names></name><name><surname>Zaragoza</surname><given-names>O.</given-names></name></person-group><article-title>Identification of off-patent compounds that present antifungal activity against the emerging fungal pathogen <italic>Candida auris</italic></article-title><source>Front. Cell. Infect. Microbiol.</source><year>2019</year><volume>9</volume><fpage>83</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2019.00083</pub-id><pub-id pub-id-type="pmid">31001487</pub-id></element-citation></ref><ref id="B229-antibiotics-09-00812"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamo</surname><given-names>F.-J.</given-names></name><name><surname>Sanz</surname><given-names>L.M.</given-names></name><name><surname>Vidal</surname><given-names>J.</given-names></name><name><surname>de Cozar</surname><given-names>C.</given-names></name><name><surname>Alvarez</surname><given-names>E.</given-names></name><name><surname>Lavandera</surname><given-names>J.-L.</given-names></name><name><surname>Vanderwall</surname><given-names>D.E.</given-names></name><name><surname>Green</surname><given-names>D.V.S.</given-names></name><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Hasan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Thousands of chemical starting points for antimalarial lead identification</article-title><source>Nature</source><year>2010</year><volume>465</volume><fpage>305</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1038/nature09107</pub-id><pub-id pub-id-type="pmid">20485427</pub-id></element-citation></ref><ref id="B230-antibiotics-09-00812"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>M.D.</given-names></name><name><surname>Perfect</surname><given-names>J.R.</given-names></name></person-group><article-title>Use of antifungal combination therapy: Agents, order, and timing</article-title><source>Curr. Fungal Infect. Rep.</source><year>2010</year><volume>4</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s12281-010-0018-6</pub-id><pub-id pub-id-type="pmid">20574543</pub-id></element-citation></ref><ref id="B231-antibiotics-09-00812"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrillo-Mu&#x000f1;oz</surname><given-names>A.J.</given-names></name><name><surname>Finquelievich</surname><given-names>J.</given-names></name><name><surname>Tur-Tur</surname><given-names>C.</given-names></name><name><surname>Eraso</surname><given-names>E.</given-names></name><name><surname>Jauregizar</surname><given-names>N.</given-names></name><name><surname>Quind&#x000f3;s</surname><given-names>G.</given-names></name><name><surname>Giusiano</surname><given-names>G.</given-names></name></person-group><article-title>Combination antifungal therapy: A strategy for the management of invasive fungal infections</article-title><source>Rev. Esp. Quim.</source><year>2014</year><volume>27</volume><fpage>141</fpage><lpage>158</lpage></element-citation></ref><ref id="B232-antibiotics-09-00812"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Haff</surname><given-names>R.P.</given-names></name><name><surname>Faria</surname><given-names>N.C.G.</given-names></name><name><surname>Martins</surname><given-names>M.D.L.</given-names></name><name><surname>Chan</surname><given-names>K.L.</given-names></name><name><surname>Campbell</surname><given-names>B.C.</given-names></name></person-group><article-title>Targeting the mitochondrial respiratory chain of <italic>Cryptococcus</italic> through antifungal chemosensitization: A model for control of non-fermentative pathogens</article-title><source>Molecules</source><year>2013</year><volume>18</volume><fpage>8873</fpage><lpage>8894</lpage><pub-id pub-id-type="doi">10.3390/molecules18088873</pub-id><pub-id pub-id-type="pmid">23892633</pub-id></element-citation></ref><ref id="B233-antibiotics-09-00812"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>B.C.</given-names></name><name><surname>Chan</surname><given-names>K.L.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name></person-group><article-title>Chemosensitization as a means to augment commercial antifungal agents</article-title><source>Front. Microbiol.</source><year>2012</year><volume>3</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2012.00079</pub-id><?supplied-pmid 22393330?><pub-id pub-id-type="pmid">22393330</pub-id></element-citation></ref><ref id="B234-antibiotics-09-00812"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Chan</surname><given-names>K.L.</given-names></name><name><surname>Cheng</surname><given-names>L.W.</given-names></name></person-group><article-title>Octyl gallate as an intervention catalyst to augment antifungal efficacy of caspofungin</article-title><source>J&#x02014;Multidiscip. Sci. J.</source><year>2018</year><volume>1</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.3390/j1010004</pub-id></element-citation></ref><ref id="B235-antibiotics-09-00812"><label>235.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>AHFS&#x000ae; Patient Medication Information&#x02122;</collab></person-group><article-title>Pioglitazone</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://medlineplus.gov/druginfo/meds/a699016.html#why">https://medlineplus.gov/druginfo/meds/a699016.html#why</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-09-03">(accessed on 3 September 2020)</date-in-citation></element-citation></ref><ref id="B236-antibiotics-09-00812"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>N.Q.</given-names></name><name><surname>Santos</surname><given-names>A.P.N.</given-names></name><name><surname>Em&#x000ed;dio</surname><given-names>E.C.P.</given-names></name><name><surname>Costa</surname><given-names>M.C.</given-names></name><name><surname>Freitas</surname><given-names>G.J.C.</given-names></name><name><surname>Carmo</surname><given-names>P.H.F.</given-names></name><name><surname>Silva</surname><given-names>M.F.</given-names></name><name><surname>de Brito</surname><given-names>C.B.</given-names></name><name><surname>de Souza</surname><given-names>D.G.</given-names></name><name><surname>Paix&#x000e3;o</surname><given-names>T.A.</given-names></name><etal/></person-group><article-title>Pioglitazone as an adjuvant of amphotericin B for the treatment of cryptococcosis</article-title><source>Int. J. Antimicrob. Agents</source><year>2019</year><volume>54</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2019.06.020</pub-id><?supplied-pmid 31279153?><pub-id pub-id-type="pmid">31279153</pub-id></element-citation></ref><ref id="B237-antibiotics-09-00812"><label>237.</label><element-citation publication-type="commun"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.H.</given-names></name><aff>Western Regional Research Center, USDA-ARS, Albany, CA, USA</aff><name><surname>Haranahalli</surname><given-names>K.</given-names></name><aff>Stony Brook University, Stony Brook, NY, USA</aff></person-group><source>Personal communication</source><year>2020</year></element-citation></ref><ref id="B238-antibiotics-09-00812"><label>238.</label><element-citation publication-type="web"><article-title><italic>Saccharomyces</italic> Genome Database</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="www.yeastgenome.org">www.yeastgenome.org</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-09-03">(accessed on 3 September 2020)</date-in-citation></element-citation></ref><ref id="B239-antibiotics-09-00812"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>A.B.</given-names></name><name><surname>Brost</surname><given-names>R.L.</given-names></name><name><surname>Ding</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Sheikh</surname><given-names>B.</given-names></name><name><surname>Brown</surname><given-names>G.W.</given-names></name><name><surname>Kane</surname><given-names>P.M.</given-names></name><name><surname>Hughes</surname><given-names>T.R.</given-names></name><name><surname>Boone</surname><given-names>C.</given-names></name></person-group><article-title>Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways</article-title><source>Nat. Biotechnol.</source><year>2004</year><volume>22</volume><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1038/nbt919</pub-id><?supplied-pmid 14661025?><pub-id pub-id-type="pmid">14661025</pub-id></element-citation></ref><ref id="B240-antibiotics-09-00812"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Campbell</surname><given-names>B.C.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Mahoney</surname><given-names>N.</given-names></name><name><surname>Chan</surname><given-names>K.L.</given-names></name><name><surname>Molyneux</surname><given-names>R.J.</given-names></name><name><surname>Bhatnagar</surname><given-names>D.</given-names></name><name><surname>Cleveland</surname><given-names>T.E.</given-names></name></person-group><article-title>Examination of fungal stress response genes using <italic>Saccharomyces cerevisiae</italic> as a model system: Targeting genes affecting aflatoxin biosynthesis by <italic>Aspergillus flavus</italic> Link</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2005</year><volume>67</volume><fpage>807</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1007/s00253-004-1821-1</pub-id><pub-id pub-id-type="pmid">15614562</pub-id></element-citation></ref><ref id="B241-antibiotics-09-00812"><label>241.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>Substances Added to Food</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/food/food-additives-petitions/substances-added-food-formerly-eafus">https://www.fda.gov/food/food-additives-petitions/substances-added-food-formerly-eafus</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-21">(accessed on 21 July 2020)</date-in-citation></element-citation></ref><ref id="B242-antibiotics-09-00812"><label>242.</label><element-citation publication-type="web"><article-title>Fungicide Resistance Action Committee</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.frac.info">https://www.frac.info</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-21">(accessed on 21 July 2020)</date-in-citation></element-citation></ref><ref id="B243-antibiotics-09-00812"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Chan</surname><given-names>K.L.</given-names></name><name><surname>Cheng</surname><given-names>L.W.</given-names></name></person-group><article-title>Cinnamic acid analogs as intervention catalysts for overcoming antifungal tolerance</article-title><source>Molecules</source><year>2017</year><volume>22</volume><fpage>1783</fpage></element-citation></ref><ref id="B244-antibiotics-09-00812"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C.-M.</given-names></name><name><surname>Abe</surname><given-names>T.</given-names></name><name><surname>Komiyama</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Hattori</surname><given-names>M.</given-names></name><name><surname>Daneshtalab</surname><given-names>M.</given-names></name></person-group><article-title>Synthesis, anti-fungal and 1,3-&#x003b2;-d-glucan synthase inhibitory activities of caffeic and quinic acid derivatives</article-title><source>Bioorg. Med. Chem.</source><year>2010</year><volume>18</volume><fpage>7009</fpage><lpage>7014</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2010.08.022</pub-id><pub-id pub-id-type="pmid">20813534</pub-id></element-citation></ref><ref id="B245-antibiotics-09-00812"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couto</surname><given-names>N.</given-names></name><name><surname>Wood</surname><given-names>J.</given-names></name><name><surname>Barber</surname><given-names>J.</given-names></name></person-group><article-title>The role of glutathione reductase and related enzymes on cellular redox homoeostasis network</article-title><source>Free Radic. Biol. Med.</source><year>2016</year><volume>95</volume><fpage>27</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.02.028</pub-id><pub-id pub-id-type="pmid">26923386</pub-id></element-citation></ref><ref id="B246-antibiotics-09-00812"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>T.</given-names></name><name><surname>Nguyen</surname><given-names>C.K.</given-names></name><name><surname>Romans</surname><given-names>A.</given-names></name><name><surname>May</surname><given-names>G.S.</given-names></name></person-group><article-title>A mitogen-activated protein kinase that senses nitrogen regulates conidial germination and growth in <italic>Aspergillus fumigatus</italic></article-title><source>Eukaryot. Cell</source><year>2004</year><volume>3</volume><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1128/EC.3.2.557-560.2004</pub-id><pub-id pub-id-type="pmid">15075285</pub-id></element-citation></ref><ref id="B247-antibiotics-09-00812"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes</surname><given-names>G.</given-names></name><name><surname>Romans</surname><given-names>A.</given-names></name><name><surname>Nguyen</surname><given-names>C.K.</given-names></name><name><surname>May</surname><given-names>G.S.</given-names></name></person-group><article-title>Novel mitogen-activated protein kinase MpkC of <italic>Aspergillus fumigatus</italic> is required for utilization of polyalcohol sugars</article-title><source>Eukaryot. Cell</source><year>2006</year><volume>5</volume><fpage>1934</fpage><lpage>1940</lpage><pub-id pub-id-type="doi">10.1128/EC.00178-06</pub-id><pub-id pub-id-type="pmid">16998074</pub-id></element-citation></ref><ref id="B248-antibiotics-09-00812"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>J.</given-names></name><name><surname>Krysan</surname><given-names>D.J.</given-names></name></person-group><article-title>Drug resistance and tolerance in fungi</article-title><source>Nat. Rev. Microbiol.</source><year>2020</year><volume>18</volume><fpage>319</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0322-2</pub-id><?supplied-pmid 32047294?><pub-id pub-id-type="pmid">32047294</pub-id></element-citation></ref><ref id="B249-antibiotics-09-00812"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beardsley</surname><given-names>J.</given-names></name><name><surname>Halliday</surname><given-names>C.L.</given-names></name><name><surname>Chen</surname><given-names>S.C.-A.</given-names></name><name><surname>Sorrell</surname><given-names>T.C.</given-names></name></person-group><article-title>Responding to the emergence of antifungal drug resistance: Perspectives from the bench and the bedside</article-title><source>Future Microbiol.</source><year>2018</year><volume>13</volume><fpage>1175</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.2217/fmb-2018-0059</pub-id><?supplied-pmid 30113223?><pub-id pub-id-type="pmid">30113223</pub-id></element-citation></ref><ref id="B250-antibiotics-09-00812"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernando-Amado</surname><given-names>S.</given-names></name><name><surname>Coque</surname><given-names>T.M.</given-names></name><name><surname>Baquero</surname><given-names>F.</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>J.L.</given-names></name></person-group><article-title>Defining and combating antibiotic resistance from One Health and Global Health perspectives</article-title><source>Nat. Microbiol.</source><year>2019</year><volume>4</volume><fpage>1432</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0503-9</pub-id><?supplied-pmid 31439928?><pub-id pub-id-type="pmid">31439928</pub-id></element-citation></ref><ref id="B251-antibiotics-09-00812"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>M.C.</given-names></name><name><surname>Hawkins</surname><given-names>N.J.</given-names></name><name><surname>Sanglard</surname><given-names>D.</given-names></name><name><surname>Gurr</surname><given-names>S.J.</given-names></name></person-group><article-title>Worldwide emergence of resistance to antifungal drugs challenges human health and food security</article-title><source>Science</source><year>2018</year><volume>360</volume><fpage>739</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1126/science.aap7999</pub-id><pub-id pub-id-type="pmid">29773744</pub-id></element-citation></ref><ref id="B252-antibiotics-09-00812"><label>252.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Translational Informatics Division at University of New Mexico</collab></person-group><article-title>DrugCentral</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://drugcentral.org">http://drugcentral.org</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-09-03">(accessed on 3 September 2020)</date-in-citation></element-citation></ref><ref id="B253-antibiotics-09-00812"><label>253.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Clinical Trials Transformation Initiative</collab></person-group><article-title>Aggregate Content of ClinicalTrials.gov (AACT)</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://aact.ctti-clinicaltrials.org/">https://aact.ctti-clinicaltrials.org/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-09-03">(accessed on 3 September 2020)</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig id="antibiotics-09-00812-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Yeast dilution bioassay showing differential susceptibility of <italic>S. cerevisiae slt2</italic>&#x00394;, <italic>bck1</italic>&#x00394;, and <italic>glr1</italic>&#x00394; mutants to cinnamic acid analogs (0.5 mM) (adapted from [<xref rid="B243-antibiotics-09-00812" ref-type="bibr">243</xref>]). Numbers 10<sup>0</sup>, 10<sup>&#x02212;1</sup>, 10<sup>&#x02212;2</sup>, 10<sup>&#x02212;3</sup>, 10<sup>&#x02212;4</sup>, and 10<sup>&#x02212;5</sup> indicate the cell dilution rate for yeast spotting; growth scores 10<sup>1</sup>, 10<sup>2</sup>, 10<sup>3</sup>, 10<sup>4</sup>, 10<sup>5</sup>, and 10<sup>6</sup> denote cell numbers which appeared following incubation. <italic>slt2</italic>&#x00394;, mitogen-activated protein kinase (MAPK) mutant; <italic>bck1</italic>&#x00394;, MAPK kinase kinase (MAPKKK) mutant; <italic>glr1</italic>&#x00394;, glutathione reductase mutant.</p></caption><graphic xlink:href="antibiotics-09-00812-g001"/></fig><fig id="antibiotics-09-00812-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>(<bold>a</bold>) <italic>A. fumigatus</italic> MAPK mutant showing tolerance to the repurposed benzoic ingredient (Kim et al., unpublished observation); (<bold>b</bold>) scheme describing structural modifications of cinnamates or benzoates that could overcome the tolerance of <italic>S. cerevisiae glr1</italic>&#x00394; or <italic>A. fumigatus</italic> MAPK mutants, respectively, to the repurposed compounds (see <xref ref-type="fig" rid="antibiotics-09-00812-f001">Figure 1</xref> and [<xref rid="B243-antibiotics-09-00812" ref-type="bibr">243</xref>] for cinnamates).</p></caption><graphic xlink:href="antibiotics-09-00812-g002"/></fig><table-wrap id="antibiotics-09-00812-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">antibiotics-09-00812-t001_Table 1</object-id><label>Table 1</label><caption><p>Tools and procedures applicable to the in silico/computational antifungal drug repurposing.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pathogens<break/>Steps</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>Paracoccidioides</italic> Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Candida albicans</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>Candida, Aspergillus</italic>, and <italic>Trychophyton</italic> Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Pythium insidiosum</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>Paracoccidioides</italic> Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Candida auris</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mining and compilation of pathogen genome data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broad Institute Fungal Genomics Database (<uri xlink:href="https://www.broadinstitute.org/fungal-genome-initiative">https://www.broadinstitute.org/fungal-genome-initiative</uri>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The Basic Local Alignment Search Tool (BLASTP), National Center for Biotechnology Information (<uri xlink:href="http://www.ncbi.nlm.nih.gov/BLAST/">http://www.ncbi.nlm.nih.gov/BLAST/</uri>);<break/>CLUSTALW, European<break/>Bioinformatics Institute (<uri xlink:href="http://www.ebi.ac.uk/Tools/msa/">http://www.ebi.ac.uk/Tools/msa/</uri>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MOE 2014.09 (PDB search module);<break/>Clustal Omega tool, UniProt server (<uri xlink:href="http://www.ebi.ac.uk/Tools/msa/clustalo/">http://www.ebi.ac.uk/Tools/msa/clustalo/</uri>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UniProt database (<uri xlink:href="https://www.uniprot.org">https://www.uniprot.org</uri>);<break/>Protein Data Bank (<uri xlink:href="https://www.rcsb.org">https://www.rcsb.org</uri>);<break/>BLASTP (blast 2.2.28_ program) (<uri xlink:href="https://www.ncbi.nlm.nih.gov">https://www.ncbi.nlm.nih.gov</uri>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Identification of orthologs in pathogen isolates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OrthoVenn server </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Identification of homologs in the drug&#x02013;target databases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DrugBank; Therapeutic targets database (TTD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDL Drug Data Report (MDDR) (BIOVIA and Thomson Reuters);<break/>DrugBank (<uri xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</uri>);<break/>TargetMol provider (<uri xlink:href="http://targetmol.com/">http://targetmol.com/</uri>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selection of essential targets in the <italic>Saccharomyces cerevisiae</italic> system</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Database of Essential Genes (DEG) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Homology modeling</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SWISS-MODEL server;<break/>Protein Data Bank<break/>(PDB); <break/>KoBaMIN server;<break/>HCC server; MolProbity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SWISS-MODEL server;<break/>Ramachandran plot, SAVES<break/>(<uri xlink:href="http://services.mbi.ucla.edu/PROCHECK">http://services.mbi.ucla.edu/PROCHECK</uri>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AMBER99 (with <italic>S. cerevisiae</italic> chorismate mutase; PDB entry code 4CSM) as a template</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PubChem server (<uri xlink:href="http://pubchem.ncbi.nlm.nih.gov/">http://pubchem.ncbi.nlm.nih.gov/</uri>) (3D structure);<break/>PreADMET server (<uri xlink:href="https://preadmet.bmdrc.kr/introduction/">https://preadmet.bmdrc.kr/introduction/</uri>) (3D structure)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Homology modeling for <italic>Candida albicans</italic> thioredoxin reductase [<xref rid="B174-antibiotics-09-00812" ref-type="bibr">174</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytochrome P450 51 (<italic>CYP51</italic>) modeling [<xref rid="B175-antibiotics-09-00812" ref-type="bibr">175</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ligand preparation and Molecular docking</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OMEGA v.3.0.0.1 software by OpenEye Scientific [<xref rid="B176-antibiotics-09-00812" ref-type="bibr">176</xref>];<break/>QUACPAC v.1.7.0.2 software by OpenEye Scientific [<xref rid="B177-antibiotics-09-00812" ref-type="bibr">177</xref>];<break/>OEDocking suite v.3.2.0 by OpenEye Scientific [<xref rid="B178-antibiotics-09-00812" ref-type="bibr">178</xref>];<break/>FRED program with the ChemGauss4 score function in the OEDocking suite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein Preparation Wizard of Schrodinger&#x02019;s suite 8.5 (Chimeric 1EA1);<break/>Docking between internal ligand (fluconazole) and 1EA1 in Schrodinger&#x02019;s suite 8.5;<break/>GROMACS 5.0 for molecular dynamics simulations with<break/>GROMOS9643a1 force field;<break/>LIGPREP and<break/>MAESTRO (fluvastatin 3D<break/>structure);<break/>MATLAB version R2015b (plotting and calculations);<break/>Dundee Prodrug 2.5;<break/>GLIDE 5.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MOE 2014.09 (Chemical<break/>Computing Group Inc., Sherbooke St, Montreal, QC, Canada) software;<break/>Leadit 2.1.2 (BioSolveIT GmbH, Germany) software;<break/>Gromacs 4.5.5 (Molecular dynamics);<break/>PRODRG2 and GROMOS 53A6 force field (Topology);<break/>Particle Mesh Ewald (PME) method and linear constraint solver (LINCS);<break/>Xmgrace and VMD software</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AutoDock Vina program; PyRx suite open-source software version 0.9.7;<break/>AutoDock Vina program;<break/>Discovery Studio Visualizer version 17.2.0 (Dassault Systemes Biovia Corp.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scaffold Hunter program (<uri xlink:href="http://scaffoldhunter.sourceforge.net/">http://scaffoldhunter.sourceforge.net/</uri>) (selection of top ten best compounds from each database);<break/>GOLD software (docking simulation against <italic>Candida albicans</italic> thioredoxin reductase);<break/>CORINA (three-dimensional models);<break/>Visual Molecular Dynamics (VMD) program (<uri xlink:href="http://www.ks.uiuc.edu/Research/vmd/">http://www.ks.uiuc.edu/Research/vmd/</uri>);<break/>LigPlot program (<uri xlink:href="https://www.ebi.ac.uk/thornton-srv/software/LIGPLOT/">https://www.ebi.ac.uk/thornton-srv/software/LIGPLOT/</uri>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein preparation wizard (<italic>C. albicans CYP51</italic>);<break/>LigPrep module of the Schrodinger suite (sertraline);<break/>Schrodinger suite (LLC, New York, NY) (induced fit molecular docking analysis);<break/>Glide module (extra precision feature for sertraline)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental validation in the target pathogen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modified Clinical and Laboratory Standards Institute (CLSI) protocol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microtiter bioassay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) microdilution assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Agar- and broth-based assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CLSI M27-A3 [<xref rid="B171-antibiotics-09-00812" ref-type="bibr">171</xref>]<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microdilution (killing kinetics)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">References </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B15-antibiotics-09-00812" ref-type="bibr">15</xref>,<xref rid="B176-antibiotics-09-00812" ref-type="bibr">176</xref>,<xref rid="B177-antibiotics-09-00812" ref-type="bibr">177</xref>,<xref rid="B178-antibiotics-09-00812" ref-type="bibr">178</xref>,<xref rid="B179-antibiotics-09-00812" ref-type="bibr">179</xref>,<xref rid="B180-antibiotics-09-00812" ref-type="bibr">180</xref>,<xref rid="B181-antibiotics-09-00812" ref-type="bibr">181</xref>,<xref rid="B182-antibiotics-09-00812" ref-type="bibr">182</xref>,<xref rid="B183-antibiotics-09-00812" ref-type="bibr">183</xref>,<xref rid="B184-antibiotics-09-00812" ref-type="bibr">184</xref>,<xref rid="B185-antibiotics-09-00812" ref-type="bibr">185</xref>,<xref rid="B186-antibiotics-09-00812" ref-type="bibr">186</xref>,<xref rid="B187-antibiotics-09-00812" ref-type="bibr">187</xref>,<xref rid="B188-antibiotics-09-00812" ref-type="bibr">188</xref>,<xref rid="B189-antibiotics-09-00812" ref-type="bibr">189</xref>,<xref rid="B190-antibiotics-09-00812" ref-type="bibr">190</xref>,<xref rid="B191-antibiotics-09-00812" ref-type="bibr">191</xref>,<xref rid="B192-antibiotics-09-00812" ref-type="bibr">192</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B18-antibiotics-09-00812" ref-type="bibr">18</xref>,<xref rid="B193-antibiotics-09-00812" ref-type="bibr">193</xref>,<xref rid="B194-antibiotics-09-00812" ref-type="bibr">194</xref>,<xref rid="B195-antibiotics-09-00812" ref-type="bibr">195</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B16-antibiotics-09-00812" ref-type="bibr">16</xref>,<xref rid="B196-antibiotics-09-00812" ref-type="bibr">196</xref>,<xref rid="B197-antibiotics-09-00812" ref-type="bibr">197</xref>,<xref rid="B198-antibiotics-09-00812" ref-type="bibr">198</xref>,<xref rid="B199-antibiotics-09-00812" ref-type="bibr">199</xref>,<xref rid="B200-antibiotics-09-00812" ref-type="bibr">200</xref>,<xref rid="B201-antibiotics-09-00812" ref-type="bibr">201</xref>,<xref rid="B202-antibiotics-09-00812" ref-type="bibr">202</xref>,<xref rid="B203-antibiotics-09-00812" ref-type="bibr">203</xref>,<xref rid="B204-antibiotics-09-00812" ref-type="bibr">204</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B17-antibiotics-09-00812" ref-type="bibr">17</xref>,<xref rid="B205-antibiotics-09-00812" ref-type="bibr">205</xref>,<xref rid="B206-antibiotics-09-00812" ref-type="bibr">206</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-antibiotics-09-00812" ref-type="bibr">20</xref>,<xref rid="B171-antibiotics-09-00812" ref-type="bibr">171</xref>,<xref rid="B174-antibiotics-09-00812" ref-type="bibr">174</xref>,<xref rid="B207-antibiotics-09-00812" ref-type="bibr">207</xref>,<xref rid="B208-antibiotics-09-00812" ref-type="bibr">208</xref>,<xref rid="B209-antibiotics-09-00812" ref-type="bibr">209</xref>,<xref rid="B210-antibiotics-09-00812" ref-type="bibr">210</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-antibiotics-09-00812" ref-type="bibr">21</xref>,<xref rid="B175-antibiotics-09-00812" ref-type="bibr">175</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="antibiotics-09-00812-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">antibiotics-09-00812-t002_Table 2</object-id><label>Table 2</label><caption><p>Examples of repurposed drugs negatively affecting biofilm formation, hyphal filamentation, or yeast growth in fungi.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compounds</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fungi</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Haloperidol or<break/>benzocyclane<break/>derivative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans,</italic>
<break/>
<italic>C. glabrata,</italic>
<break/>
<italic>C. neoformans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of filamentation, melanin production, and<break/>biofilm formation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B78-antibiotics-09-00812" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aripiprazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of biofilm formation and hyphal filamentation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B152-antibiotics-09-00812" ref-type="bibr">152</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alexidine dihydrochloride</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. albicans</italic>, <break/><italic>C. auris</italic>, <break/><italic>A. fumigatus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiofilm activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-antibiotics-09-00812" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mefloquine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans,</italic>
<break/>
<italic>C. neoformans,</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of the expression of virulence traits: filamentation in <italic>C. albicans</italic> and capsule formation/melanization in <italic>C. neoformans</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B155-antibiotics-09-00812" ref-type="bibr">155</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pentamidine, bifonazole,<break/>econazole, alexidine,<break/>cetylpyridinium chloride, <break/>otilonium bromide,<break/>benzethonium chloride, <break/>niclosamide, disulfiram,<break/>temsirolimus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. neoformans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of spore germination and yeast growth</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-antibiotics-09-00812" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sulfonamide drugs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of biofilm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B113-antibiotics-09-00812" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Miltefosine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. albicans</italic>,<break/><italic>C. auris,</italic><break/><italic>C. dubliniensis</italic>,<break/><italic>C. glabrata,</italic><break/><italic>C. krusei</italic>,<break/><italic>C. parapsilosis</italic>, <italic>C. tropicalis,</italic><break/><italic>Sporothrix schenckii</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of both planktonic growth and biofilm formation; inhibition of <italic>Coccidioides posadasii</italic> filamentous phase and <italic>Histoplasma capsulatum</italic> filamentous/yeast phases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-antibiotics-09-00812" ref-type="bibr">116</xref>,<xref rid="B117-antibiotics-09-00812" ref-type="bibr">117</xref>,<xref rid="B119-antibiotics-09-00812" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mebendazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. neoformans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal activity against phagocytized <italic>C. neoformans</italic>: affected biofilms and reduced capsular dimensions</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B157-antibiotics-09-00812" ref-type="bibr">157</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quinacrine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of biofilm and<break/>inhibition of planktonic growth (alkaline pH) and filamentation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B123-antibiotics-09-00812" ref-type="bibr">123</xref>]<break/></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Auranofin,<break/>pyrvinium pamoate, benzbromarone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of biofilm formation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B124-antibiotics-09-00812" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Finasteride</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of urinary biofilm formation and filamentation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-antibiotics-09-00812" ref-type="bibr">164</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Auranofin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. albicans</italic>,<break/><italic>Staphylococcus aureus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of <italic>C. albicans</italic> and <italic>S. aureus</italic> (bacterium) mono- and dual biofilm formation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B161-antibiotics-09-00812" ref-type="bibr">161</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Panobinostat</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of biofilm, hyphal, and planktonic growth<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-antibiotics-09-00812" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Robenidine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>A. fumigatus,</italic>
<break/>
<italic>C. albicans,</italic>
<break/>
<italic>C. neoformans,</italic>
<break/>
<italic>S. cerevisiae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of yeast cell growth, filamentation, and biofilm formation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B167-antibiotics-09-00812" ref-type="bibr">167</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>bis</italic>-Biguanide alexidine dihydrochloride</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal and antibiofilm activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-antibiotics-09-00812" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Halogenated salicylanilide,<break/>niclosamide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans,</italic>
<break/>
<italic>C. auris</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifilamentation and antibiofilm activities </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B169-antibiotics-09-00812" ref-type="bibr">169</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arachidonic acid </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. albicans</italic>, <break/><italic>C. parapsilosis,</italic><break/><italic>C. glabrata,</italic><break/><italic>C. tropicalis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiofilm activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-antibiotics-09-00812" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aspirin, ibuprofen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans,</italic>
<break/>
<italic>Trichosporon asahii</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiofilm and antiplanktonic activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-antibiotics-09-00812" ref-type="bibr">60</xref>,<xref rid="B62-antibiotics-09-00812" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nortriptyline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. utilis</italic>, <break/><italic>C. krusei</italic>,<break/><italic>C. glabrata</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antihyphal and antibiofilm activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-antibiotics-09-00812" ref-type="bibr">74</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quinine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal synergy with bicarbonate or hygromycin against biofilm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B125-antibiotics-09-00812" ref-type="bibr">125</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="antibiotics-09-00812-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">antibiotics-09-00812-t003_Table 3</object-id><label>Table 3</label><caption><p>Examples of animal models used in drug repurposing (see also <xref ref-type="app" rid="app1-antibiotics-09-00812">Table S1</xref>, <xref ref-type="app" rid="app1-antibiotics-09-00812">Supplementary Materials</xref>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug/Compound Repurposed</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Animal Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fungi</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effect</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Raltegravir</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice,<break/>male, 6 weeks old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Paracoccidioides</italic> species</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction of the fungal burden, decreased alterations in the lung structure of mice (1 mg/kg of raltegravir)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-antibiotics-09-00812" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thioridazine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine J774 phagocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. neoformans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased the intracellular burden of <italic>C. neoformans</italic> (2.7-fold at a concentration 16-fold below the MIC (2 &#x003bc;g/mL))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-antibiotics-09-00812" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beauvericin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Specific pathogen-free female ICR (Crl: CD-1) mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C.&#x02009;albicans</italic> or <italic>C.&#x02009;parapsilosis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction in tissue damage and inflammatory cell infiltration in<break/>kidneys (0.5&#x02009;mg/kg beauvericin and KET <sup>1</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-antibiotics-09-00812" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beauvericin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c (inbred) mice, female, 7 weeks old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beauvericin (4 mg/kg) and FLU <sup>1</sup> (0.5 mg/kg) combination exhibited a therapeutic benefit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-antibiotics-09-00812" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pentamidine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6J, female, 8 to 10 weeks old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. neoformans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice treated prophylactically with pentamidine (for 3 days prior to infection) resulted in a 2-fold-lower fungal burden than the control;<break/>minimized lung fungal burden in spore-mediated infections of mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-antibiotics-09-00812" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deferasirox</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, female, 4 to 6 weeks old;<break/>immunosuppression model of murine oropharyngeal candidiasis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preventive deferasirox treatment significantly reduced the fungal burden in tongue tissue </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B137-antibiotics-09-00812" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>N</italic>-Acetylcysteine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57/BL6 mice, female, 6 to 8 weeks old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. gattii</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>N</italic>-Acetylcysteine + AMB <sup>1</sup> achieved higher survival than the control and reduced morbidity in murine-induced cryptococcosis; reduced fungal burden in lungs/brain and lower concentrations of proinflammatory cytokines in the lungs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-antibiotics-09-00812" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisplatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, female, 4 to 6 weeks old<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. neoformans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisplatin significantly inhibited <italic>C. neoformans</italic> growth in a mouse model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B168-antibiotics-09-00812" ref-type="bibr">168</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Panobinostat</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Galleria mellonella</italic> larvae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Panobinostat and FLU combination enhanced<break/>survival rate of <italic>G. mellonella</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-antibiotics-09-00812" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pilocarpine hydrochloride</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>G. mellonella</italic> larvae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pilocarpine hydrochloride<break/>protects <italic>G. mellonella</italic> larvae from <italic>C. albicans-</italic>induced mortality in a dose-dependent manner</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B154-antibiotics-09-00812" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pitavastatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Caenorhabditis elegans</italic> animal model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pitavastatin&#x02013;FLU combination reduced the biofilm formation of<break/><italic>Candida</italic> species and the fungal burdens in a <italic>C. elegans</italic> infection model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-antibiotics-09-00812" ref-type="bibr">77</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Drug abbreviations: amphotericin B (AMB), fluconazole (FLU), and ketoconazole (KET).</p></fn></table-wrap-foot></table-wrap><table-wrap id="antibiotics-09-00812-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">antibiotics-09-00812-t004_Table 4</object-id><label>Table 4</label><caption><p>Summary of the drug/compound libraries used in the antifungal drug repurposing (see also <xref ref-type="app" rid="app1-antibiotics-09-00812">Table S1, Supplementary Materials</xref>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug, Compound Libraries </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sources</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fungi Tested</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDL Drug Data Report (MDDR), <break/>DrugBank, TargetMol databases or library (L4200)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BIOVIA and Thomson Reuters <uri xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</uri>, <uri xlink:href="http://targetmol.com/">http://targetmol.com/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. albicans,</italic><break/><italic>Paracoccidioides</italic> species</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-antibiotics-09-00812" ref-type="bibr">20</xref>,<xref rid="B167-antibiotics-09-00812" ref-type="bibr">167</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prestwick Chemical <break/>Library</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prestwick Chemical (Illkirch, France) <uri xlink:href="http://www.prestwickchemical.com/">http://www.prestwickchemical.com/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Candida</italic> species,<break/><italic>Cryptococcus</italic> species,<break/><italic>Saccharomyces cerevisiae,</italic><break/><italic>Aspergillus fumigatus,</italic><break/><italic>Fusarium oxysporum,</italic><break/><italic>Fusarium solani,</italic><break/><italic>Lichtheimia</italic> species,<break/><italic>Lomentospora prolificans,</italic><break/><italic>Paecilomyces variotii,</italic><break/><italic>Rhizopus arrhizus,</italic><break/><italic>Scedosporium apiospermum</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-antibiotics-09-00812" ref-type="bibr">23</xref>,<xref rid="B25-antibiotics-09-00812" ref-type="bibr">25</xref>,<xref rid="B66-antibiotics-09-00812" ref-type="bibr">66</xref>,<xref rid="B75-antibiotics-09-00812" ref-type="bibr">75</xref>,<xref rid="B83-antibiotics-09-00812" ref-type="bibr">83</xref>,<xref rid="B94-antibiotics-09-00812" ref-type="bibr">94</xref>,<xref rid="B96-antibiotics-09-00812" ref-type="bibr">96</xref>,<xref rid="B124-antibiotics-09-00812" ref-type="bibr">124</xref>,<xref rid="B165-antibiotics-09-00812" ref-type="bibr">165</xref>,<xref rid="B228-antibiotics-09-00812" ref-type="bibr">228</xref>]<break/></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmakon1600 drug library</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MicroSource Discovery Systems (Gaylordsville, CT, USA)<break/><uri xlink:href="http://www.msdiscovery.com/">http://www.msdiscovery.com/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans,</italic>
<break/>
<italic>C. glabrata</italic>
<break/>
<italic>C. auris</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-antibiotics-09-00812" ref-type="bibr">68</xref>,<xref rid="B77-antibiotics-09-00812" ref-type="bibr">77</xref>,<xref rid="B162-antibiotics-09-00812" ref-type="bibr">162</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Library of Pharmacologically Active Compounds (LOPAC<sup>1280</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sigma-Aldrich <break/>(St. Louis, MO, USA)<break/><uri xlink:href="https://www.sigmaaldrich.com/">https://www.sigmaaldrich.com/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Exserohilum rostratum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-antibiotics-09-00812" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medicines for Malaria Venture (MMV) Malaria Box </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medicines for Malaria Venture <break/>(Geneva, Switzerland) <break/><uri xlink:href="https://www.mmv.org/">https://www.mmv.org/</uri><break/>[<xref rid="B229-antibiotics-09-00812" ref-type="bibr">229</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. albicans</italic>,<break/><italic>C. gatti,</italic><break/><italic>C. neoformans</italic>,<break/><italic>L. prolificans,</italic><break/><italic>Fonsecaea pedrosoi,</italic><break/><italic>Fonsecaea monophora</italic>,<break/><italic>Fonsecaea nubica</italic>,<break/><italic>Cladophialophora carrionii</italic>,<break/><italic>Phialophora verrucosa</italic>,<break/><italic>Rhinocladiela similis</italic>,<break/><italic>Exophiala jeanselmei</italic> var. <italic>heteromorpha</italic>,<break/><italic>Exophiala dermatitidis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-antibiotics-09-00812" ref-type="bibr">91</xref>,<xref rid="B148-antibiotics-09-00812" ref-type="bibr">148</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Screen-Well Enzo library <break/>of 640 compounds</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enzo Life Sciences (Farmingdale, NY, USA)<break/><uri xlink:href="https://www.enzolifesciences.com/">https://www.enzolifesciences.com/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Aspergillus</italic> species,<break/><italic>Candida,</italic>
<break/><italic>Cryptococcus deuterogattii,</italic><break/><italic>Saccharomyces</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-antibiotics-09-00812" ref-type="bibr">110</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L1300 Selleck library, <break/>1018 United States Food and Drug Administration (FDA)-approved Selleck library</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selleck Chemicals<break/><uri xlink:href="https://www.selleckchem.com/">https://www.selleckchem.com/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>A. fumigatus,</italic>
<break/>
<italic>C. gattii,</italic>
<break/>
<italic>C. glabrata,</italic>
<break/>
<italic>C. neoformans,</italic>
<break/>
<italic>Trichophyton rubrum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-antibiotics-09-00812" ref-type="bibr">73</xref>,<xref rid="B100-antibiotics-09-00812" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathogen Box<sup>&#x000ae;</sup> chemical library</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medicines for Malaria Venture <break/>(Geneva, Switzerland) <break/><uri xlink:href="https://www.mmv.org/">https://www.mmv.org/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. auris</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-antibiotics-09-00812" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">United States National Institutes of Health/National Cancer Institute (NIH/NCI) compound <break/>library</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developmental Therapeutics Program of the NIH/NCI (Rockville, MD, USA)<break/><uri xlink:href="https://dtp.cancer.gov/">https://dtp.cancer.gov/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>A. fumigatus,</italic><break/><italic>Candida</italic> species, <break/><italic>C. neoformans</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B127-antibiotics-09-00812" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1547 or 1581 FDA-approved <break/>drug library</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Johns Hopkins, USA<break/>Johns Hopkins Clinical Compound Library (JHCCL) version 1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans,</italic>
<break/>
<italic>C. auris,</italic>
<break/>
<italic>C. krusei,</italic>
<break/>
<italic>C. parapsilosis,</italic>
<break/>
<italic>C. tropicalis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B133-antibiotics-09-00812" ref-type="bibr">133</xref>,<xref rid="B163-antibiotics-09-00812" ref-type="bibr">163</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">678 Maybridge collection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thermo Fisher Scientific (Waltham, MA, USA)<break/><uri xlink:href="https://www.thermofisher.com/us/en/home/chemicals/maybridge.html">https://www.thermofisher.com/us/en/home/chemicals/maybridge.html</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>C. albicans,</italic>
<break/>
<italic>C. auris</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B169-antibiotics-09-00812" ref-type="bibr">169</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="antibiotics-09-00812-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">antibiotics-09-00812-t005_Table 5</object-id><label>Table 5</label><caption><p>Summary of the drugs and compounds exerting synergism during co-application (see also <xref ref-type="app" rid="app1-antibiotics-09-00812">Table S1, Supplementary Materials</xref>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Repurposed Drugs/Compounds Co-Applied.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conventional Antifungal Drugs with Synergism </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>N</italic>-Acetylcysteine, alexidine dihydrochloride, amiodarone, arachidonic acid, aspirin, beauvericin, bis-biguanide alexidine dihydrochloride, benzocyclane, bromperidol derivative, chenodiol, chlorcyclizine, clomiphene, cloperastine, colistin, <sc>l</sc>-cycloserine, deferasirox, drospirenon, ebselen, erythromycin, glimepiride, ibuprofen, idoxifene, lovastatin, methylene-idoxifene, miltefosine<break/>nisoldipine, nortriptyline, panobinostat, perhexiline, pitavastatin, polymyxin b, promazine, pyrvinium pamoate, quinacrine, quinine,<break/>ribavirin, riluzole, sertraline, suloctidil, tamoxifen, thioridazine, thiosemicarbazone, toremifene, trifluoperazine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Azoles<break/>(clotrimazole, fluconazole, isavuconazole, itraconazole, ketoconazole, miconazole, posaconazole, voriconazole),<break/>echinocandins<break/>(caspofungin, anidulafungin, micafungin),<break/>polyene (AMB),<break/>allylamine (terbinafine)</td></tr></tbody></table></table-wrap></floats-group></article>